

ACCESSION:AX742306
ACCESSION:AJ529196
ACCESSION:CQ766241
ACCESSION:AX394466
ACCESSION:AX394494
ACCESSION:AX394494
ACCESSION:A40583
ACCESSION:A89107
ACCESSION:AR232863
ACCESSION:AX030158
ACCESSION:AX316479
ACCESSION:AX525338
ACCESSION:AX525386
ACCESSION:AX572590
ACCESSION:AX572591
ACCESSION:AX572642
ACCESSION:BD066620
ACCESSION:AR132205
ACCESSION:AR132206
ACCESSION:AR132207
ACCESSION:AR132208
ACCESSION:AR132209
ACCESSION:AR133631
ACCESSION:AR133905
ACCESSION:AX572585
ACCESSION:AX572593
ACCESSION:AX572638
ACCESSION:AX572640
ACCESSION:AX587034

ALIGNMENTS

RESULT 1
AR475597/c 20 bp DNA linear PAT 20-FEB-2004
LOCUS AR475597 Sequence 52 from patent US 6692959.
DEFINITION AR475597
ACCESSION AR475597.1 GI:42715080
VERSION AR475597.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
expression
JOURNAL Patent: US 6692959-A 52 17-FEB-2004;
FEATURES Location/Qualifiers
source 1..20
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1548 GACAGTGGTTATTAAAGCAT 1567
|||||
Db 20 GACAGTGGTTATTAAAGCAT 1

RESULT 2
AR475598/c 20 bp DNA linear PAT 20-FEB-2004
LOCUS AR475598 Sequence 53 from patent US 6692959.
DEFINITION AR475598
ACCESSION AR475598.1 GI:42715081
VERSION AR475598.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
expression
JOURNAL Patent: US 6692959-A 53 17-FEB-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1560 TAAAGCATGGTTGAACCTTC 1579
|||||
Db 20 TAAAGCATGGTTGAACCTTC 1

RESULT 3
AR475599/c 20 bp DNA linear PAT 20-FEB-2004
LOCUS AR475599 Sequence 54 from patent US 6692959.
DEFINITION AR475599
ACCESSION AR475599.1 GI:42715082
VERSION AR475599.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
expression
JOURNAL Patent: US 6692959-A 54 17-FEB-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1646 TACAGTAATCCCTGAGAAAT 1665
|||||
Db 20 TACAGTAATCCCTGAGAAAT 1

RESULT 4
AR475600/c 20 bp DNA linear PAT 20-FEB-2004
LOCUS AR475600 Sequence 55 from patent US 6692959.
DEFINITION AR475600
ACCESSION AR475600.1 GI:42715083
VERSION AR475600.1
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
expression
JOURNAL Patent: US 6692959-A 55 17-FEB-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1674 AGCATCAACCAACACAGTTT 1693
|||||

Db 20 AGCATCACCAACACAGTTT 1

RESULT 5
AR475601/c
LOCUS AR475601 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 56 from patent US 6692959.
ACCESSION AR475601
VERSION AR475601.1 GI:42715084
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 CAAAAGAGCGCTGGCTGTA 1730
|||||
Db 20 CAAAAGAGCGCTGGCTGTA 1

RESULT 6
AR475602/c
LOCUS AR475602 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 57 from patent US 6692959.
ACCESSION AR475602
VERSION AR475602.1 GI:42715085
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 CAAAAGAGCGCTGGCTGTA 1730
|||||
Db 20 CAAAAGAGCGCTGGCTGTA 1

RESULT 7
AR475603/c
LOCUS AR475603 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 58 from patent US 6692959.
ACCESSION AR475603
VERSION AR475603.1 GI:42715086
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.

QY 1720 CCTGGGCTGTATGAGGGTG 1739
|||||
Db 20 CCTGGGCTGTATGAGGGTG 1

RESULT 8
AR475604/c
LOCUS AR475604 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 59 from patent US 6692959.
ACCESSION AR475604
VERSION AR475604.1 GI:42715087
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1737 GTGGAACACTCTGATCTGA 1756
|||||
Db 20 GTGGAACACTCTGATCTGA 1

RESULT 9
AR475605/c
LOCUS AR475605 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 60 from patent US 6692959.
ACCESSION AR475605
VERSION AR475605.1 GI:42715088
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1756 AAGCCAGCTGACTCCTCA 1775
|||||
Db 20 AAGCCAGCTGACTCCTCA 1

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1810 CTGCTGTGAGCCACTAATAA 1829
|||||
Db 20 CTGCTGTGAGCCACTAATAA 1

RESULT 10
AR475606/c
LOCUS AR475606 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 61 from patent US 6692959.
ACCESSION AR475606
VERSION AR475606.1 GI:42715089
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1829 ACATTGGCTTAATATCTGCT 1848
Db 20 ACATTGGCTTAATATCTGCT 1

RESULT 11
AR475607/c
LOCUS AR475607 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 62 from patent US 6692959.
ACCESSION AR475607
VERSION AR475607.1 GI:42715090
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1846 GCTGTGCTTCTCTGACAGGT 1865
Db 20 GCTGTGCTTCTCTGACAGGT 1

RESULT 12
AR475608/c
LOCUS AR475608 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 63 from patent US 6692959.
ACCESSION AR475608
VERSION AR475608.1 GI:42715091
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4

expression
JOURNAL Patent: US 6692959-A 63 17-FEB-2004;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1854 TCTCTGACAGGTAGTCATGA 1873
Db 20 TCTCTGACAGGTAGTCATGA 1

RESULT 13
AR475609/c
LOCUS AR475609 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 64 from patent US 6692959.
ACCESSION AR475609
VERSION AR475609.1 GI:42715092
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1894 TATACAGCAGCTTTGTAAAT 1913
Db 20 TATACAGCAGCTTTGTAAAT 1

RESULT 14
AR475610/c
LOCUS AR475610 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 65 from patent US 6692959.
ACCESSION AR475610
VERSION AR475610.1 GI:42715093
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Freier,S.M.
TITLE Antisense modulation of IL-1 receptor-associated kinase-4
JOURNAL
FEATURES
source
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1951 TTACAAAATCCTATTAGTCA 1970
Db 20 TTACAAAATCCTATTAGTCA 1

RESULT 15	AR475611/c	20 bp	DNA	linear	PAT 20-FEB-2004
LOCUS	Sequence 66 from patent US 6692959.				
DEFINITION	AR475611				
ACCESSION	AR475611				
VERSION	AR475611.1	GI:42715094			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
TITLE	Bennett,C.F. and Freier,S.M.				
	Antisense modulation of IL-1 receptor-associated kinase-4				
JOURNAL	expression				
FEATURES	Patent: US 6692959-A 66 17-FEB-2004;				
source	Location/Qualifiers				
	1..20				
	/organism="unknown"				
	/mol_type="genomic DNA"				
Query Match	2.2%; Score 20; DB 1; Length 20;				
Best Local Similarity	100.0%; Pred. No. 3.1;				
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
QY	1985 GTGTTACACGCAATCATTTA 2004				
Db	20 GTGTTACACGCAATCATTTA 1				
RESULT 16	AR475612/c	20 bp	DNA	linear	PAT 20-FEB-2004
LOCUS	Sequence 67 from patent US 6692959.				
DEFINITION	AR475612				
ACCESSION	AR475612				
VERSION	AR475612.1	GI:42715095			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
TITLE	Bennett,C.F. and Freier,S.M.				
	Antisense modulation of IL-1 receptor-associated kinase-4				
JOURNAL	expression				
FEATURES	Patent: US 6692959-A 67 17-FEB-2004;				
source	Location/Qualifiers				
	1..20				
	/organism="unknown"				
	/mol_type="genomic DNA"				
Query Match	2.2%; Score 20; DB 1; Length 20;				
Best Local Similarity	100.0%; Pred. No. 3.1;				
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
QY	2066 TTACATGACAAAGTTGAAGG 2085				
Db	20 TTACATGACAAAGTTGAAGG 1				
RESULT 17	AR475613/c	20 bp	DNA	linear	PAT 20-FEB-2004
LOCUS	Sequence 68 from patent US 6692959.				
DEFINITION	AR475613				
ACCESSION	AR475613				
VERSION	AR475613.1	GI:42715096			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
TITLE	Bennett,C.F. and Freier,S.M.				
	Antisense modulation of IL-1 receptor-associated kinase-4				
JOURNAL	expression				

```
RESULT 20
AR475616/c      AR475616      20 bp      DNA      linear      PAT 20-FEB-2004
LOCUS           Sequence 71 from patent US 6692959.
DEFINITION      AR475616
ACCESSION       AR475616
VERSION         AR475616.1 GI:42715099
KEYWORDS        Unknown.
SOURCE          Unclassified.
ORGANISM        1 (bases 1 to 20)
REFERENCE       Bennett,C.F. and Freier,S.M.
AUTHORS         Antisense modulation of IL-1 receptor-associated kinase-4
TITLE           expression
JOURNAL         Patent: US 6692959-A 71 17-FEB-2004;
FEATURES        Location/Qualifiers
source          1..20
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match     2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 21
AR475617/c      AR475617      20 bp      DNA      linear      PAT 20-FEB-2004
LOCUS           Sequence 72 from patent US 6692959.
DEFINITION      AR475617
ACCESSION       AR475617
VERSION         AR475617.1 GI:42715100
KEYWORDS        Unknown.
SOURCE          Unclassified.
ORGANISM        1 (bases 1 to 20)
REFERENCE       Bennett,C.F. and Freier,S.M.
AUTHORS         Antisense modulation of IL-1 receptor-associated kinase-4
TITLE           expression
JOURNAL         Patent: US 6692959-A 72 17-FEB-2004;
FEATURES        Location/Qualifiers
source          1..20
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match     2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 22
AR475618/c      AR475618      20 bp      DNA      linear      PAT 20-FEB-2004
LOCUS           Sequence 73 from patent US 6692959.
DEFINITION      AR475618
ACCESSION       AR475618
VERSION         AR475618.1 GI:42715101
KEYWORDS        Unknown.
SOURCE          Unclassified.
ORGANISM        1 (bases 1 to 20)
REFERENCE       Bennett,C.F. and Freier,S.M.
AUTHORS         Antisense modulation of IL-1 receptor-associated kinase-4
TITLE           expression
JOURNAL         Patent: US 6692959-A 73 17-FEB-2004;
```

```
FEATURES        Location/Qualifiers
source          1..20
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match     2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 23
AR475619/c      AR475619      20 bp      DNA      linear      PAT 20-FEB-2004
LOCUS           Sequence 74 from patent US 6692959.
DEFINITION      AR475619
ACCESSION       AR475619
VERSION         AR475619.1 GI:42715102
KEYWORDS        Unknown.
SOURCE          Unclassified.
ORGANISM        1 (bases 1 to 20)
REFERENCE       Bennett,C.F. and Freier,S.M.
AUTHORS         Antisense modulation of IL-1 receptor-associated kinase-4
TITLE           expression
JOURNAL         Patent: US 6692959-A 74 17-FEB-2004;
FEATURES        Location/Qualifiers
source          1..20
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match     2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 24
AR475620/c      AR475620      20 bp      DNA      linear      PAT 20-FEB-2004
LOCUS           Sequence 75 from patent US 6692959.
DEFINITION      AR475620
ACCESSION       AR475620
VERSION         AR475620.1 GI:42715103
KEYWORDS        Unknown.
SOURCE          Unclassified.
ORGANISM        1 (bases 1 to 20)
REFERENCE       Bennett,C.F. and Freier,S.M.
AUTHORS         Antisense modulation of IL-1 receptor-associated kinase-4
TITLE           expression
JOURNAL         Patent: US 6692959-A 75 17-FEB-2004;
FEATURES        Location/Qualifiers
source          1..20
                /organism="unknown"
                /mol_type="genomic DNA"

Query Match     2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 25
AR475621/c      AR475621      20 bp      DNA      linear      PAT 20-FEB-2004
LOCUS           Sequence 76 from patent US 6692959.
DEFINITION      AR475621
ACCESSION       AR475621
VERSION         AR475621.1 GI:42715104
KEYWORDS        Unknown.
SOURCE          Unclassified.
ORGANISM        1 (bases 1 to 20)
REFERENCE       Bennett,C.F. and Freier,S.M.
AUTHORS         Antisense modulation of IL-1 receptor-associated kinase-4
TITLE           expression
JOURNAL         Patent: US 6692959-A 76 17-FEB-2004;
```


Thu Apr 7 06:02:11 2005

```
DEFINITION Sequence 3774 from Patent WO03040369.
ACCESSION AX760453
VERSION AX760453.1 GI:32255069
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Telerman,A., Anson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 3774 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.8%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 8;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1750 GATCTGAAGCCGAGCTG 1766
|||||
DB 1 GATCTGAAGCCGAGCTG 17
RESULT 31
AX649705/c
LOCUS AX649705 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1545 from Patent EP1273660.
ACCESSION AX649705
VERSION AX649705.1 GI:29152523
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1545 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1745 ACTCTGATCTGAAGCC 1760
|||||
DB 17 ACTCTGATCTGAAGCC 2
RESULT 32
AX649706/c
LOCUS AX649706 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1546 from Patent EP1273660.
ACCESSION AX649706
VERSION AX649706.1 GI:29152524
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1543 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1745 ACTCTGATCTGAAGCC 1760
|||||
DB 17 ACTCTGATCTGAAGCC 2
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1546 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 19;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2146 GACCTAATCCAGTGAACC 2164
|||||
DB 1 GAACAAATCCAGTGAACC 19
RESULT 34
AX649703/c
LOCUS AX649703 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1543 from Patent EP1273660.
ACCESSION AX649703
VERSION AX649703.1 GI:29152521
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu,Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1543 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1745 ACTCTGATCTGAAGCC 1760
|||||
DB 17 ACTCTGATCTGAAGCC 2
```

```

QY 1747 TCTGATCTGAAGCCCAAG 1763
Db 17 TCTGATCTGAAGCCCAAG 1

RESULT 35
AX649704/c
LOCUS AX649704 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1544 from Patent EP1273660.
ACCESSION AX649704
VERSION AX649704.1 GI:29152522
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Gu, Y.
TITLE Human sodium-hydrogen exchanger like protein 1
JOURNAL Patent: EP 1273660-A 1544 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1745 ACTCTGATCTGAAGC 1759
Db 15 ACTCTGATCTGAAGC 1

RESULT 38
BD176280
LOCUS BD176280 18 bp DNA linear PAT 18-MAR-2003
DEFINITION A method of arraying genome clone.
ACCESSION BD176280
VERSION BD176280.1 GI:29121986
KEYWORDS WO 02072815-A/80.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 18)
AUTHORS Soeda, E.
TITLE A method of arraying genome clone
JOURNAL Patent: WO 02072815-A 80 19-SEP-2002;
Eiichi Soeda, Takeshi KUKITA
COMMENT OS Artificial Sequence
PN WO 02072815-A/80
PD 19-SEP-2002
PF 17-MAY-2001 WO 2001JP004139
PR 12-MAR-2001 JP 01P 68285
PI Eiichi Soeda
PC C12N15/09, C12Q1/68
CC Description of Artificial Sequence: Synthetic DNA FH Key
FT source 1..18
FT Location/Qualifiers
source 1..18
/organism="Artificial Sequence"
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.6%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1955 AAAATCCTATTAGTC 1969
Db 4 AAAATCCTATTAGTC 18

RESULT 39
BD090202
LOCUS BD090202 18 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.
ACCESSION BD090202
VERSION BD090202.1 GI:22635812
KEYWORDS JP 2001321190-A/2446.
SOURCE synthetic construct

```

ORGANISM synthetic construct
 other sequences; artificial sequences.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Soeda,E
 TITLE A method of arraying genome clone
 JOURNAL Patent: JP 2001321190-A 2446 20-NOV-2001;
 THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
 GENOTECHS
 COMMENT OS Artificial Sequence
 PN JP 2001321190-A/2446
 PD 20-NOV-2001
 PF 12-MAR-2001 JP 2001068285
 PI EIICHI SOEDA
 PC C12N15/09:C12N15/09,C12M1/00,C12Q1/69,G01N33/53,G01N33/566, PC
 C12N15/00,
 PC C12N15/00
 CC Description of Artificial Sequence:Synthetic DNA FH Key
 FT source Location/Qualifiers
 FT 1..18 /organism='Artificial Sequence'.
 FEATURES
 source Location/Qualifiers
 1..18 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 Query Match 1..6%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 24;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1955 AAAATCCTATTAGTC 1969
 Db 4 AAAATCCTATTAGTC 18
 RESULT 40
 AX649702/c
 LOCUS AX649702 17 bp DNA linear PAT 22-MAR-2003
 DEFINITION Sequence 1542 from Patent EP1273660.
 ACCESSION AX649702
 VERSION AX649702.1 GI:29152520
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Gu,Y.
 TITLE Human sodium-hydrogen exchanger like protein 1
 JOURNAL Patent: EP 1273660-A 1542 08-JAN-2003;
 Neomica, Inc. (US)
 FEATURES
 source Location/Qualifiers
 1..17 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 1..6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 27;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1748 CTGATCTGAAGCCAG 1763
 Db 17 CTGATCTGAAGCCAG 2
 RESULT 41
 AX734430/c
 LOCUS AX734430 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 20 from Patent WO03025177.
 ACCESSION AX734430
 VERSION AX734430.1 GI:30513707
 KEYWORDS

SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversion, apoptosis and/or resistance to viruses and the use
 thereof as medicaments
 JOURNAL Patent: WO 03025177-A 20 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source Location/Qualifiers
 1..17 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 1..6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 27;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1583 AATATAAAATAGAC 1598
 Db 16 AATATAAAATAGATC 1
 RESULT 42
 AX734488/c
 LOCUS AX734488 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 78 from Patent WO03025177.
 ACCESSION AX734488
 VERSION AX734488.1 GI:30513765
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour
 reversion, apoptosis and/or resistance to viruses and the use
 thereof as medicaments
 JOURNAL Patent: WO 03025177-A 78 27-MAR-2003;
 Molecular Engines Laboratories (FR)
 FEATURES
 source Location/Qualifiers
 1..17 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 1..6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 27;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2016 AATATCCCTTGATGAT 2031
 Db 17 AATATCCATTGATGAT 2
 RESULT 43
 AX760843
 LOCUS AX760843 17 bp DNA linear PAT 25-JUN-2003
 DEFINITION Sequence 4164 from Patent WO03040369.
 ACCESSION AX760843
 VERSION AX760843.1 GI:32255459
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Telerman,A., Anson,R. and Tuijnder,M.
 TITLE Sequences involved in tumoral suppression, tumoral reversion,

apoptosis and/or viral resistance phenomena and their use as medicines
Patent: WO 03040369-A 4164 15-MAY-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 27;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1750 GATCTGAAGCCGAGCT 1765
|||||
Db 1 GATCTGAAGCCGAGT 16

RESULT 44
AX761964
LOCUS AX761964 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 5285 from Patent WO03040369.
ACCESSION AX761964
VERSION AX761964.1 GI:32256580
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Telerman, A., Anson, R. and Tuijnder, M.
Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
Patent: WO 03040369-A 5285 15-MAY-2003;
Molecular Engines Laboratories (FR)
Location/Qualifiers
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 27;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1750 GATCTGAAGCCGAGCT 1765
|||||
Db 1 GATCTTAAGCCGAGT 16

RESULT 45
AR188899/c
LOCUS AR188899 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4387 from patent US 6346398.
ACCESSION AR188899
VERSION AR188899.1 GI:20234864
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 4387 12-FEB-2002;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 33;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAAATG 1883
|||||
Db 14 ATGAAATCAAAATG 1

RESULT 46
AR190454/c
LOCUS AR190454 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5942 from patent US 6346398.
ACCESSION AR190454
VERSION AR190454.1 GI:20236419
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J., Stinchcomb, D. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5942 12-FEB-2002;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAAATG 1883
|||||
Db 14 ATGAAATCAAAATG 1

RESULT 47
AR324752/c
LOCUS AR324752 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2154 from patent US 6566127.
ACCESSION AR324752
VERSION AR324752.1 GI:33710560
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2154 20-MAY-2003;
FEATURES Location/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="unassigned RNA"

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAAATG 1883
|||||
Db 14 ATGAAATCAAAATG 1

RESULT 48
AR325377/c
LOCUS AR325377 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2779 from patent US 6566127.
ACCESSION AR325377
VERSION AR325377.1 GI:33711185
KEYWORDS

Db 17 AAATGATAAACATTTA 1

RESULT 53
A90567/c 17 bp DNA linear PAT 22-JAN-2000

LOCUS A90567 Sequence 748 from Patent EP0858579.
DEFINITION A90567
ACCESSION A90567.1 GI:6739081
VERSION
KEYWORDS
SOURCE unidentified
ORGANISM unclassified.

REFERENCE 1 (bases 1 to 17)
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 748 05-AUG-1998;
BIOLOGISTIK GES (DE)
FEATURES Location/Qualifiers
source 1..17
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 AAATGATACAAATTTA 1934
|||||
Db 17 AAATGATAAACATTTA 1

RESULT 54
AR034270 17 bp DNA linear PAT 29-SEP-1999

LOCUS AR034270 Sequence 2 from patent US 5869336.
DEFINITION AR034270
ACCESSION AR034270
VERSION AR034270.1 GI:5949875
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Meyer,S.L., Scott,R.W. and Siman,R.
TITLE Recombinant enzymatically active calpain expressed in a baculovirus system
JOURNAL Patent: US 5869336-A 2 09-FEB-1999;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 CACTCTGATCTGAAGCC 1760
|||||
Db 1 CACCTTGATCTGAAGAC 17

RESULT 55
AR046375/c 17 bp DNA linear PAT 29-SEP-1999

LOCUS AR046375 Sequence 1168 from patent US 5817796.
DEFINITION AR046375
ACCESSION AR046375
VERSION AR046375.1 GI:5967840
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)

AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 1168 06-OCT-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1574 AACTTCCAAAATATAA 1590
|||||
Db 17 AACTCCCAATATATAA 1

RESULT 56
AR046377/c 17 bp DNA linear PAT 29-SEP-1999

LOCUS AR046377 Sequence 1170 from patent US 5817796.
DEFINITION AR046377
ACCESSION AR046377
VERSION AR046377.1 GI:5967842
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb ribozymes having 2'-5'-linked adenylate residues
JOURNAL Patent: US 5817796-A 1170 06-OCT-1998;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1573 GAACCTCCAAAATATAA 1589
|||||
Db 17 GAACCTCCCAATATATAA 1

RESULT 57
AR083059/c 17 bp DNA linear PAT 01-SEP-2000

LOCUS AR083059 Sequence 3 from patent US 5976799.
DEFINITION AR083059
ACCESSION AR083059
VERSION AR083059.1 GI:10009849
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS O'Brien,T.J. and Shigemasa,K.
TITLE Early detection of ovarian carcinoma using p16 gene products
JOURNAL Patent: US 5976799-A 3 02-NOV-1999;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 AAGGAAGTGAATTCGTC 2331
|||||
Db 17 AAGGAAGTGAATTCGTC 1

```
RESULT 58
AR167916/c
LOCUS AR167916 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 3 from patent US 6287775.
ACCESSION AR167916
VERSION AR167916.1 GI:17903728
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS O'Brien,T.J. and Shigemasa,K.
TITLE Early detection of ovarian carcinoma using p16 gene products
JOURNAL
JOURNAL Patent: US 6287775-A 3 11-SEP-2001;
FEATURES
source
1. .17
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 AAGGAAGTGAATCTGC 2331
Db 17 AAGGAAGTGAATCTGC 1

RESULT 59
CQ618041
LOCUS CQ618041 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2781 from Patent WO0192524.
ACCESSION CQ618041
VERSION CQ618041.1 GI:41668259
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
REFERENCE
1 (bases 1 to 17)
AUTHORS Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE
JOURNAL
JOURNAL Patent: WO 0192524-A 2781 06-DEC-2001;
FEATURES
source
1. .17
Location/Qualifiers
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CTCCTTCAAGCACC 1682
Db 1 CACCTTCAAGCACC 17

RESULT 60
I53427/c
LOCUS I53427 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1168 from patent US 5646042.
ACCESSION I53427
VERSION I53427.1 GI:2474630
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL
JOURNAL Patent: US 5646042-A 1168 08-JUL-1997;
FEATURES
source
1. .17
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1574 AACTTCCAAATATATAA 1590
Db 17 AACTTCCAAATATATAA 1

RESULT 61
I53429/c
LOCUS I53429 17 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 1170 from patent US 5646042.
ACCESSION I53429
VERSION I53429.1 GI:2474632
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Stinchcomb,D.T., Draper,K., McSwiggen,J. and Jarvis,T.
TITLE C-myb targeted ribozymes
JOURNAL
JOURNAL Patent: US 5646042-A 1170 08-JUL-1997;
FEATURES
source
1. .17
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1573 GAACCTCCAAATATATAA 1589
Db 17 GAACCTCCAAATATATAA 1

RESULT 62
AR188898/c
LOCUS AR188898 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4386 from patent US 6346398.
ACCESSION AR188898
VERSION AR188898.1 GI:20234863
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Eacobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL
JOURNAL Patent: US 6346398-A 4386 12-FEB-2002;
FEATURES
source
1. .17
Location/Qualifiers
/mol_type="unassigned DNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATCAATCAATGTC 1887
Db 17 TGAATCAATCAATGTC 1

RESULT 63
```

```
AR190453/c
LOCUS AR190453 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5941 from patent US 6346398.
ACCESSION AR190453
VERSION AR190453.1 GI:20236418
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 5941 12-FEB-2002;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1871 TGAATAATCAATGATGC 1887
Db 17 TGAATAATCAATGATGC 1
RESULT 64
AR324751/c
LOCUS AR324751 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2153 from patent US 6566127.
ACCESSION AR324751
VERSION AR324751.1 GI:33710559
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2153 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1871 TGAATAATCAATGATGC 1887
Db 17 TGAATAATCAATGATGC 1
RESULT 65
AR325376/c
LOCUS AR325376 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 2778 from patent US 6566127.
ACCESSION AR325376
VERSION AR325376.1 GI:33711184
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 2778 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1871 TGAATAATCAATGATGC 1887
Db 17 TGAATAATCAATGCGC 1
```

```
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1871 TGAATAATCAATGATGC 1887
Db 17 TGAATAATCAATGATGC 1
RESULT 66
AR328081/c
LOCUS AR328081 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 5483 from patent US 6566127.
ACCESSION AR328081
VERSION AR328081.1 GI:33713889
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions
related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 5483 20-MAY-2003;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1899 AAGCACTTTGTAATG 1915
Db 17 AAGCACTTTGTAATG 1
RESULT 67
AR459104
LOCUS AR459104 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2781 from patent US 6686188.
ACCESSION AR459104
VERSION AR459104.1 GI:42694161
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 2781 03-FEB-2004;
FEATURES
source
1. .17
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1666 CTCCTTCAAGCATCACC 1682
Db 1 CACCTTCAAGCATCACC 17
RESULT 68
```

AX531188/c
LOCUS AX531188 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 697 from Patent EP1239051.
ACCESSION AX531188
VERSION AX531188.1 GI:25254169
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 697 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2042 TGATATGTCCTATTATTA 2058
Db 17 TGATATCTCCCTATTATTA 1
RESULT 69
AX531189/c
LOCUS AX531189 17 bp DNA linear PAT 22-NOV-2002
DEFINITION Sequence 698 from Patent EP1239051.
ACCESSION AX531189
VERSION AX531189.1 GI:25254171
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Shannon,M.
TITLE Human posh-like protein 1
JOURNAL Patent: EP 1239051-A 698 11-SEP-2002;
Aeomica, Inc. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2042 TGATATGTCCTATTATTA 2058
Db 17 TGATATCTCCCTATTATTA 1
RESULT 70
AX649193/c
LOCUS AX649193 17 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 1033 from Patent EP1273660.
ACCESSION AX649193
VERSION AX649193.1 GI:29152011
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 2716 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Gu,Y.
Human sodium-hydrogen exchanger like protein 1
Patent: EP 1273660-A 1033 08-JAN-2003;
Aeomica, Inc. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2274 AGCAAGCAGGAAAAAA 2290
Db 17 AGAAAGCAGGAAAAACA 1
RESULT 71
AX745290
LOCUS AX745290 17 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 1255 from Patent WO03031621.
ACCESSION AX745290
VERSION AX745290.1 GI:30723957
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Zhang,J.
TITLE A human G protein coupled receptor
JOURNAL Patent: WO 03031621-A 1255 17-APR-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1655 CCCTGAGAAATCTCCTT 1671
Db 1 CCCTGAGAAATCTCCTT 17
RESULT 72
AX759395
LOCUS AX759395 17 bp DNA linear PAT 25-JUN-2003
DEFINITION Sequence 2716 from Patent WO03040369.
ACCESSION AX759395
VERSION AX759395.1 GI:32254011
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS Telerman,A., Amson,R. and Tuijinder,M.
TITLE Sequences involved in tumoral suppression, tumoral reversion,
apoptosis and/or viral resistance phenomena and their use as
medicines
JOURNAL Patent: WO 03040369-A 2716 15-MAY-2003;
Molecular Engines Laboratories (FR)
FEATURES
source 1..17
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```
Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2095 GATCCAGTTAAGGTTCC 2111
    ||| ||| ||| ||| ||| ||| |||
DB 1 GATCCAGTTAAGGTTCC 17

RESULT 73
LOCUS BD066113/c 17 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066113
VERSION BD066113.1 GI:22611716
KEYWORDS JP 2001511000-A/748.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 17)
AUTHORS Schlengensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 748 07-AUG-2001;
COMMENT BIOLOGISCHES INSTITUT FÜR MOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/748
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH key
Location/Qualifiers
FT source 1..17
FEATURES
    source Location/Qualifiers
        1..17 /organism="Unknown".

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 36;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 AAATGATACAAATTTA 1934
    ||| ||| ||| ||| ||| ||| |||
DB 17 AAATGATACAAATTTA 1

RESULT 74
LOCUS CQ828930/c 16 bp DNA linear PAT 05-JUL-2004
DEFINITION Sequence 648 from Patent WO2004053120.
ACCESSION CQ828930
VERSION CQ828930.1 GI:49732413
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL Weihe,E., Bieller,A. and Schaefer,M.K.
Regulatory elements in the 5' region of the vrl gene
Patent: WO 2004053120-A 648 24-JUN-2004;
Gruenthal GmbH (DE)
Location/Qualifiers
    source 1..16
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
        /note="V$FREAC7 01"

Query Match      1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1970 ATATATTTATATGATT 1984
    ||| ||| ||| ||| ||| ||| |||
DB 15 ATATATTTATATGATT 1

RESULT 75
LOCUS I38662/c 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 22 from patent US 5614617.
ACCESSION I38662
VERSION I38662.1 GI:2084716
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Cook,P.D. and Sanghvi,Y.S.
TITLE Nuclease resistant, pyrimidine modified oligonucleotides that
detect and modulate gene expression
JOURNAL Patent: US 5614617-A 22 25-MAR-1997;
FEATURES
    source Location/Qualifiers
        1..16 /organism="unknown"
        /mol_type="unassigned DNA"

Query Match      1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2389 GGGCTGACACCTGGA 2403
    ||| ||| ||| ||| ||| ||| |||
DB 15 GGGCTGACACCTGGA 1

RESULT 76
LOCUS I38663/c 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 23 from patent US 5614617.
ACCESSION I38663
VERSION I38663.1 GI:2084717
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Cook,P.D. and Sanghvi,Y.S.
TITLE Nuclease resistant, pyrimidine modified oligonucleotides that
detect and modulate gene expression
JOURNAL Patent: US 5614617-A 23 25-MAR-1997;
FEATURES
    source Location/Qualifiers
        1..16 /organism="unknown"
        /mol_type="unassigned DNA"

Query Match      1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2389 GGGCTGACACCTGGA 2403
    ||| ||| ||| ||| ||| ||| |||
DB 15 GGGCTGACACCTGGA 1

RESULT 77
LOCUS I38692/c 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 52 from patent US 5614617.
ACCESSION I38692
```

```

VERSION I38692.1 GI:2084746
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Cook,P.D. and Sanghvi,Y.S.
TITLE Nuclease resistant, pyrimidine modified oligonucleotides that
detect and modulate gene expression
JOURNAL Patent: US 5614617-A 52 25-MAR-1997;
FEATURES
    Location/Qualifiers
    source
        1..16
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2389 GGGCTGACACCTGGA 2403
Db 15 GGGCGGACACCTGGA 1

RESULT 78
I38698/c
LOCUS I38698 16 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 58 from patent US 5614617.
ACCESSION I38698
VERSION I38698.1 GI:2084752
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Cook,P.D. and Sanghvi,Y.S.
TITLE Nuclease resistant, pyrimidine modified oligonucleotides that
detect and modulate gene expression
JOURNAL Patent: US 5614617-A 58 25-MAR-1997;
FEATURES
    Location/Qualifiers
    source
        1..16
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2389 GGGCTGACACCTGGA 2403
Db 15 GGGCGGACACCTGGA 1

RESULT 79
AX572137/c
LOCUS AX572137 16 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 177 from Patent WO02055741.
ACCESSION AX572137
VERSION AX572137.1 GI:26004227
KEYWORDS Human immunodeficiency virus
SOURCE Human immunodeficiency virus
ORGANISM Human immunodeficiency virus
REFERENCE 1
AUTHORS de Smet,K. and Stuyver,L.
TITLE Method for detection of drug-induced mutations in the hiv reverse
transcriptase gene
JOURNAL Patent: WO 02055741-A 177 18-JUL-2002;
INNOCENETICS N.V. (BE)
FEATURES
    Location/Qualifiers
    source
        1..16
        /organism="Human immunodeficiency virus"

/mol_type="unassigned DNA"
/db_xref="taxon:12721"

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1969 CATATATTATAGAT 1983
Db 16 CATATATTATAGAT 2

RESULT 80
ATH523894/c
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone
064A08.
DEFINITION Arabidopsis thaliana T-DNA flanking sequence.
ACCESSION AJ523894.1 GI:26792130
VERSION AJ523894
KEYWORDS left border; T-DNA flanking sequence.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE 1
AUTHORS Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,
Lepiniec,L., Caboche,M. and Lecharny,A.
TITLE T-DNA integration into the Arabidopsis genome depends on sequences
of pre-insertion sites
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
MEDLINE 22363535
PubMed 12446565
REFERENCE 2 (bases 1 to 16)
AUTHORS Balzergue,S.
TITLE Direct Submission
JOURNAL Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue
Gaston Cremieux, 91057 Evry cedex, FRANCE
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana
plants from INRA (Versailles). The DNA fragment(s) resulting from
the PCR were directly sequenced from the left or the right border
to determine the genomic sequence flanking the insertion. T-DNA
derived sequences were removed. Information to order the
corresponding mutant line and a link to a database providing a
graphical display of the insertion site are available at
http://dbgap.versailles.inra.fr/publiclines/. This sequence has
been generated in the framework of the French plant genomics
program 'Genoplante' (http://www.genoplante.com and
http://genoplante-info.infobiogen.fr).
FEATURES
    Location/Qualifiers
    source
        1..16
        /organism="Arabidopsis thaliana"
        /mol_type="genomic DNA"
        /cultivar="Wassiliewskija"
        /db_xref="taxon:3702"
        /clone="064A08"
        /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
    misc_feature
        1..16
        /note="T-DNA flanking sequence
        left border"

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 36;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1927 AAAATTAAAGTTTA 1941
Db 16 AAAATGTAAGTTTA 2

RESULT 81
AR041231/c

```

LOCUS AR041231 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5811300.
ACCESSION AR041231
VERSION AR041231.1 GI:5961727
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.
TITLE TNF- α ribozymes
JOURNAL Patent: US 5811300-A 21 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2201 AGTATGTGAGAGG 2213
|||||
Db 15 AGTATGTGAGAGG 3
RESULT 82
LOCUS AX636694/c
DEFINITION Sequence 3833 from Patent EP1260586.
ACCESSION AX636694
VERSION AX636694.1 GI:28472308
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Direnzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 3833 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source 1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2201 AGTATGTGAGAGG 2213
|||||
Db 15 AGTATGTGAGAGG 3
RESULT 83
LOCUS AR435811/c
DEFINITION Sequence 70 from patent US 6656731.
ACCESSION AR435811
VERSION AR435811.1 GI:40198895
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Eckstein, F., Ludwig, J. and Beigelman, L.

LOCUS AR041231 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5811300.
ACCESSION AR041231
VERSION AR041231.1 GI:5961727
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Sullivan, S., Draper, K., Kisich, K., Stinchcomb, D.T. and McSwiggen, J.
TITLE TNF- α ribozymes
JOURNAL Patent: US 5811300-A 21 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2201 AGTATGTGAGAGG 2213
|||||
Db 15 AGTATGTGAGAGG 3
RESULT 82
LOCUS AX636694/c
DEFINITION Sequence 3833 from Patent EP1260586.
ACCESSION AX636694
VERSION AX636694.1 GI:28472308
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Direnzo, A.,
Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J.,
McSwiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M.,
Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and
Woolf, T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 3833 27-NOV-2002;
FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)
source 1..15
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"
Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 36;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2201 AGTATGTGAGAGG 2213
|||||
Db 15 AGTATGTGAGAGG 3
RESULT 83
LOCUS AR435811/c
DEFINITION Sequence 70 from patent US 6656731.
ACCESSION AR435811
VERSION AR435811.1 GI:40198895
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Eckstein, F., Ludwig, J. and Beigelman, L.

TITLE Nucleic acid catalysts with endonuclease activity
JOURNAL Patent: US 6656731-A 70 02-DEC-2003;
FEATURES Location/Qualifiers
source 1..16
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2278 AGCAGGAAAAAA 2290
|||||
Db 13 AGCAGGAAAAAA 1
RESULT 84
LOCUS A88599/c
DEFINITION Sequence 747 from Patent WO9833904.
ACCESSION A88599
VERSION A88599.1 GI:6737169
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch, W. and Schlingensiefen, K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 747 06-AUG-1998;
FEATURES BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
source 1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1918 AAATGATACAAATTT 1933
|||||
Db 16 AAATGATACAAATTT 1
RESULT 85
LOCUS A90566/c
DEFINITION Sequence 747 from Patent EP0856579.
ACCESSION A90566
VERSION A90566.1 GI:6739080
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 16)
AUTHORS Brysch, W.D. and Schlingensiefen, K.D.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: EP 0856579-A 747 05-AUG-1998;
FEATURES BIOGNOSTIK GES (DE)
source 1..16
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1918 AAATGATACAAATTT 1933
|||||

```
Db 16 AATGATATAAACATTT 1

RESULT 86
LOCUS AR033128/c
DEFINITION Sequence 15 from patent US 5869248.
ACCESSION AR033128
VERSION AR033128.1 GI:5948733
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Yuan,Y., Guerrier-Takada,C., Altman,S. and Liu,F.
TITLE Targeted cleavage of RNA using ribonuclease P targeting and
JOURNAL cleavage sequences
COMMENT Patent: US 5869248-A 15 09-FEB-1999;
FEATURES
    Location/Qualifiers
    source 1..16
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred.No.47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CCTTCAAGCATCACCA 1683
Db 16 CCTTCATGCCTCACCA 1

RESULT 87
LOCUS BD226644
DEFINITION Use of antiprolactin agent for remedy of hypercytosis.
ACCESSION BD226644
VERSION BD226644.1 GI:33036414
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Chen,W.Y. and Wagner,T.E.
TITLE Use of antiprolactin agent for remedy of hypercytosis
JOURNAL Patent: JP 2002515404-A 2 28-MAY-2002;
COMMENT WEN Y CHEN,THOMAS E WAGNER
OS Artificial Sequence
PN JP 2002515404-A/2
PD 28-MAY-2002
PF 11-MAY-1999 JP 2000547993
PR 12-MAY-1998 US 60/085128,05-FEB-1999 US 09/246041 PI
PC A61K38/22,A61K31/138,A61P35/00,C07K14/575,C07K14/72// PC
(A61K38/22,A61K31:133),A61K37/24,(A61K37/24,A61K31:133) CC
Artificially synthesized primer sequence
FH Key Location/Qualifiers
FT source 1..16
/organism='Artificial Sequence'.

FEATURES
    source 1..16
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred.No.47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1870 ATGAAAATCAAAATGAT 1885
Db 1 ATGAACATCAAGGAT 16

RESULT 88
LOCUS BD226649
DEFINITION Use of antiprolactin agent for remedy of hypercytosis.
ACCESSION BD226649
VERSION BD226649.1 GI:33036419
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 16)
AUTHORS Chen,W.Y. and Wagner,T.E.
TITLE Use of antiprolactin agent for remedy of hypercytosis
JOURNAL Patent: JP 2002515404-A 7 28-MAY-2002;
COMMENT WEN Y CHEN,THOMAS E WAGNER
OS Artificial Sequence
PN JP 2002515404-A/7
PD 28-MAY-2002
PF 11-MAY-1999 JP 2000547993
PR 12-MAY-1998 US 60/085128,05-FEB-1999 US 09/246041 PI
PC A61K38/22,A61K31/138,A61P35/00,C07K14/575,C07K14/72// PC
(A61K38/22,A61K31:133),A61K37/24,(A61K37/24,A61K31:133) CC
Artificially synthesized primer sequence
FH Key Location/Qualifiers
FT source 1..16
/organism='Artificial Sequence'.

FEATURES
    source 1..16
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred.No.47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1870 ATGAAAATCAAAATGAT 1885
Db 1 ATGAACATCAAGGAT 16

RESULT 89
LOCUS I41208/c
DEFINITION Sequence 15 from patent US 5624824.
ACCESSION I41208
VERSION I41208.1 GI:2081798
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Yuan,Y., Guerrier-Takada,C., Altman,S. and Liu,F.
TITLE Targeted cleavage of RNA using eukaryotic ribonuclease P and
JOURNAL external guide sequence
COMMENT Patent: US 5624824-A 15 29-APR-1997;
FEATURES
    Location/Qualifiers
    source 1..16
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred.No.47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CCTTCAAGCATCACCA 1683
Db 16 CCTTCATGCCTCACCA 1

RESULT 90
```

192440/c
LOCUS 192440 16 bp DNA linear PAT 01-DEC-1998
DEFINITION Sequence 15 from patent US 5728521.
ACCESSION 192440
VERSION 192440.1 GI:3936910
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Yuan,Y., Guerrier-Takada,C., Altman,S. and Liu,F.
TITLE Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
JOURNAL Patent: US 5728521-A 15 17-MAR-1998;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1668 CCTCAGCAGCATCACA 1683
Db 16 CCTTCATGCCCTCACA 1
RESULT 91
AR328635/c
LOCUS AR328635 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 6037 from patent US 6566127.
ACCESSION AR328635
VERSION AR328635.1 GI:33714443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 6037 20-MAY-2003;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1893 ATATACAGCAGCATTTG 1908
Db 16 ATGACAGCAGCATTTG 1
RESULT 92
AR329711
LOCUS AR329711 16 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 7113 from patent US 6566127.
ACCESSION AR329711
VERSION AR329711.1 GI:33715519
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 7113 20-MAY-2003;
FEATURES
Location/Qualifiers

source 1. .16
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1661 GAAATCTCTCTCAAGC 1676
Db 1 GAAATCTCTCTCAAGC 16
RESULT 93
AR435950/c
LOCUS AR435950 16 bp RNA linear PAT 18-DEC-2003
DEFINITION Sequence 209 from patent US 6566731.
ACCESSION AR435950
VERSION AR435950.1 GI:40199034
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 16)
AUTHORS Eckstein,F., Ludwig,J. and Beigelman,L.
TITLE Nucleic acid catalysts with endonuclease activity
JOURNAL Patent: US 6566731-A 209 02-DEC-2003;
FEATURES
source
1. .16
/organism="unknown"
/mol_type="unassigned RNA"
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1974 ATTTATAGATTGTGTT 1989
Db 16 ATTACAGATTGTGCT 1
RESULT 94
AX255763/c
LOCUS AX255763 16 bp DNA linear PAT 10-OCT-2001
DEFINITION Sequence 184 from Patent WO0170982.
ACCESSION AX255763
VERSION AX255763.1 GI:16074818
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Beger,C., Barber,J. and Wong-Staal,F.
TITLE Brca-1 regulators and methods of use
JOURNAL Patent: WO 0170982-A 184 27-SEP-2001;
Immunol Incorporated (US); Beger, Carmela (DE)
FEATURES
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2289 AAAATTGGGACCTCAG 2304
Db 16 AAAATTAGGACCCACAG 1
RESULT 95

BD066112/c
LOCUS BD066112 16 bp DNA linear PAT 27-AUG-2002
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION BD066112
KEYWORDS BD066112.1 GI:22611715
SOURCE JP 2001511000-A/747.
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlingensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 747 07-AUG-2001;
BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
COMMENT OS Unknown
PN JP 2001511000-A/747
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
Location/Qualifiers
FT source 1..16
Location/Qualifiers
FEATURES
source
1..16
/organism="Unknown".
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1..4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 47;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1918 AATGATACAAATTT 1933
Db 16 AATGATACAAATTT 1
|||||
RESULT 96
A33037
LOCUS A33037 15 bp DNA linear PAT 11-DEC-1996
DEFINITION Synthetic gene III fdtDeltaTabst construct.
ACCESSION A33037
VERSION A33037.1 GI:1926674
KEYWORDS synthetic construct
SOURCE synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS
JOURNAL Patent: WO 9201047-A 160 23-JAN-1992;
FEATURES
source
1..15
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 1..3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2127 GAGACTGTTGAAG 2140
Db 1 GAAACTGTTGAAG 14
|||||
RESULT 97
AR033322/c
LOCUS AR033322 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 88 from patent US 5869253.

ACCESSION .. AR033322
VERSION AR033322.1 GI:5948927
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Draper,K.G.
TITLE Method and reagent for inhibiting hepatitis C virus replication
JOURNAL Patent: US 5869253-A 88 09-FEB-1999;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1..3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1597 GCACCATATCAAC 1610
Db 15 GCACCATATCCAC 2
|||||
RESULT 98
AR056010
LOCUS AR056010 15 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 214 from patent US 5837542.
ACCESSION AR056010
VERSION AR056010.1 GI:5981587
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and
TITLE Intercellular adhesion molecule-1 (ICAM-1) ribozymes
JOURNAL Patent: US 5837542-A 214 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1..3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2019 ATCCCTTGATGATA 2032
Db 2 AACCTTGATGATA 15
|||||
RESULT 99
AR113144/c
LOCUS AR113144 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 88 from patent US 6132966.
ACCESSION AR113144
VERSION AR113144.1 GI:14093466
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Draper,K.G.
TITLE Method and reagent for inhibiting hepatitis C virus replication
JOURNAL Patent: US 6132966-A 88 17-OCT-2000;
FEATURES Location/Qualifiers
source 1..15
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1..3%; Score 12.4; DB 1; Length 15;

```

Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1597 GCCACCATATCAAC 1610
DB 15 GCCACCATATCCAC 2

RESULT 100
AR113768
LOCUS AR113768 15 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 214 from patent US 6132967.
ACCESSION AR113768
VERSION AR113768.1 GI:14094090
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Grimm,S., Stinchcomb,D.T., McSwiggen,J., Sullivan,S. and Draper,K.G.
TITLE Ribozyme treatment of diseases or conditions related to levels of intercellular adhesion molecule-1 (ICAM-1)
JOURNAL Patent: US 6132967-A 214 17-OCT-2000;
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 1.3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2019 ATCCCTTGATGATA 2032
DB 2 AACCTTGATGATA 15

RESULT 101
BD184130/c
LOCUS BD184130 15 bp DNA linear PAT 17-JUN-2003
DEFINITION Method and detector for identifying subtypes of human papilloma viruses.
ACCESSION BD184130
VERSION BD184130.1 GI:31876330
KEYWORDS JP 2002360271-A/109.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 15)
AUTHORS Ling,C., Lin,R., Yoo,Z., Huang,X., Lee,B., Lee,S., Lin,Y., Huang,C., Hsu,H., Shi,C., Yeh,C., Cao,Y. and Pan,C.
TITLE Method and detector for identifying subtypes of human papilloma
JOURNAL Patent: JP 2002360271-A 109 17-DEC-2002;
COMMENT KING CAR FOOD INDUSTRIAL CO LTD
OS Artificial Sequence
PN JP 2002360271-A/109
PD 17-DEC-2002
PF 28-NOV-2001 JP 2001362595
PR 04-MAY-2001 TW 90110785
PI CHING-YEE LING, RUEY-WEN LIN, ZHOU-MENG YOO, XIN-HSUAN HUANG, BOW-HAENG LEE,
PI SHENG-HSIUNG LEE, YI-JU LIN, CI-CHUNG HUANG, HAN-CHANG HSU, CHA-WEN SHI,
PI CHIH-XIN YEH, YI-FENG CAO, CHIH-LONG PAN
PC C12N15/09, C12N15/05, C12M1/34, C12Q1/04, C12Q1/42, C12Q1/68 PC
, C12Q1/70, G01N21/64,
PC G01N33/53, G01N33/574, G01N33/58, G01N37/00// (C12M1/34, C12R1:93),
PC C12Q1/70, C12R1:93, C12N15/00, C12N15/00
CC Oligonucleotide M3203 for identifying HPV 32. FH Key
LOCUS/Qualifiers
    source
        Location/Qualifiers
            1..15
                /organism="Artificial Sequence".

Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1597 GCCACCATATCAAC 1610
DB 15 GCCACCATATCCAC 2

RESULT 103
BD208985/c
LOCUS BD208985
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION BD208985
VERSION BD208985.1 GI:33018755
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="synthetic construct"
                /mol_type="genomic DNA"
                /db_xref="taxon:32630"
Query Match 1.3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1639 CAGTTCCTTACAGTA 1652
DB 14 CAGTGTGTACAGTA 1

RESULT 102
BD207055/c
LOCUS BD207055 15 bp RNA linear PAT 17-JUL-2003
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION BD207055
VERSION BD207055.1 GI:33016825
KEYWORDS JP 2002512791-A/645.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Blatt,L., McSwiggen,J.A., Roberts,E., Pavco,P.A. and Macejak,D.
TITLE Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
JOURNAL Patent: JP 2002512791-A 645 08-MAY-2002;
COMMENT RIBOZYME PHARMACEUTICALS INC
OS Hepatitis virus (hepatitis C virus)
PN JP 2002512791-A/645
PD 08-MAY-2002
PF 28-APR-1999 JP 2000545991
PR 27-APR-1998 US 60/083217, 18-SEP-1998 US 60/100842 PR
25-FEB-1999 US 09/257608, 23-MAR-1999 US 09/274553 PI
LAWRENCE BLATT, JAMES A MCSWIGGEN, ELISABETH ROBERTS, PAMELA A PI
PAVCO,
PI DENNIS MACEJAK
PC C12N9/00, A61K31/7105, A61K38/21, A61K48/00, A61P31/12, C12N15/09,
PC A61K37/66,
PC C12N15/00
CC Enzymatic nucleic acid treatment of diseases or conditions
CC related to
CC hepatitis C virus infection.
CC Key
FH Key
FT source
    Location/Qualifiers
        1..15
            /organism="Hepatitis virus (hepatitis C virus)".
FEATURES
    source
        Location/Qualifiers
            1..15
                /organism="unidentified"
                /mol_type="genomic RNA"
                /db_xref="taxon:32644"
Query Match 1.3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 48;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1597 GCCACCATATCAAC 1610
DB 15 GCCACCATATCCAC 2

RESULT 103
BD208985/c
LOCUS BD208985
DEFINITION Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection.
ACCESSION BD208985
VERSION BD208985.1 GI:33018755

```

AX572592	LOCUS	AX572592	15 bp	DNA	linear	PAT 29-NOV-2000
	DEFINITION	Sequence 632 from Patent WO02055741.				
	ACCESSION	AX572592				
	VERSION	AX572592.1	GI:26004682			
	KEYWORDS	Human immunodeficiency virus				
	SOURCE	Human immunodeficiency virus				
	ORGANISM	Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate lentivirus group.				
	REFERENCE	1				
	AUTHORS	de Smet, K. and Struyver, L.				
	TITLE	Method for detection of drug-induced mutations in the hiv reverse transcriptase gene				
	JOURNAL	Patent: WO 02055741-A 632 18-JUL-2002;				
	INNOGENETICS	N.V. (BE)				
	FEATURES	Location/Qualifiers				
	source	1..15				
		/organism="Human immunodeficiency virus"				
		/mol_type="unassigned DNA"				
		/db_xref="taxon:12721"				
	Query Match	1.3%;	Score 12.4;	DB 1;	Length 15;	
	Best Local Similarity	92.9%;	Pred. No. 48;			
	Matches	13;	Conservative	0;	Mismatches	1;
						Indels 0;
						Gaps 0;
QY		1727 TGTATGTTAGGTGG	1740			
		2 TGTATGTTAGGTGCG	15			
Db						
RESULT 106						
AX633098	LOCUS	AX633098	15 bp	RNA	linear	PAT 21-FEB-2003
	DEFINITION	Sequence 237 from Patent EP1260586.				
	ACCESSION	AX633098				
	VERSION	AX633098.1	GI:28468712			
	KEYWORDS	unidentified				
	SOURCE	unidentified				
	ORGANISM	unclassified.				
	REFERENCE	1				
	AUTHORS	Stinchcomb, D.T., Dudycz, L.W., Chowrira, B., Grimm, S., Direnzo, A., Karpeisky, A., Draper, K.G., Kisich, K., Matulic-Adamic, J., Mcswiggen, J.A., Modak, A., Pavco, P., Beigelman, L., Sullivan, S.M., Sweedler, D., Thompson, J.D., Tracz, D., Usman, N., Wincott, F.E. and Woolf, T.				
	TITLE	Method and reagent for inhibiting the expression of disease related genes				
	JOURNAL	Patent: EP 1260586-A 237 27-NOV-2002;				
	INNOGENETICS	RIBOZYME PHARMACEUTICALS, INC. (US)				
	FEATURES	Location/Qualifiers				
	source	1..15				
		/organism="unidentified"				
		/mol_type="unassigned RNA"				
		/db_xref="taxon:32644"				
	Query Match	1.3%;	Score 12.4;	DB 1;	Length 15;	
	Best Local Similarity	92.9%;	Pred. No. 48;			
	Matches	13;	Conservative	0;	Mismatches	1;
						Indels 0;
						Gaps 0;
QY		2019 ATCCCTTGATGATA	2032			
		2 AACCTTGATGATA	15			
Db						
RESULT 107						
AX742306/c	LOCUS	AX742306	15 bp	DNA	linear	PAT 12-MAY-2003
	DEFINITION	Sequence 109 from Patent EP1302550.				
	ACCESSION	AX742306				
	VERSION	AX742306.1	GI:30576274			
	KEYWORDS					

	synthetic construct synthetic construct other sequences; artificial sequences.	misc_feature 1..15 /note="T-DNA flanking sequence left border"
REFERENCE	1	
AUTHORS	Lin,C.Y., Lin,R.W., You,C.M., Huang,H.H., Lee,B.H., Lee,H.H., Lin,Y.J., Fan,C.C., Hsu,H.C., Shih,C.W., Yeh,C.H., Kao,Y.F., Fan,C.L. and Chan,P.	Query Match 1.3%; Score 12.4; DB 1; Length 15; Best Local Similarity 92.9%; Pred.No.48; Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
TITLE	Method and detector for identifying subtypes of human papilloma viruses	
JOURNAL	Patent: EP 1302550-A 109 16-APR-2003; King Car Food Industrial Co., Ltd. (TW)	
FEATURES	Location/Qualifiers 1..15 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630" /note="Oligonucleotide for Identifying HPV 32"	QY 2045 TATGTCCTATTATA 2058 Db 2 TATGTCCTATTATA 15
source		RESULT 109 CQ766241 LOCUS CQ766241 12 bp DNA linear PAT 03-MAR-2004 DEFINITION Sequence 202 from Patent WO2004005547. ACCESSION CQ766241 VERSION CQ766241.1 GI:44908501 KEYWORDS synthetic construct SOURCE synthetic construct ORGANISM other sequences; artificial sequences.
Query Match	1.3%; Score 12.4; DB 1; Length 15;	
Best Local Similarity	92.9%; Pred.No.48;	
Matches	13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1639 CAGTTCTTACAGTA 1652 Db 14 CAGTTCTTACAGTA 1	
RESULT 108		
ATH529196		
LOCUS ATH529196 15 bp DNA linear PLN 29-MAR-2003		
DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 180D01.		
ACCESSION AJ529196		
VERSION AJ529196.1 GI:26797456		
KEYWORDS left border; T-DNA flanking sequence.		
SOURCE Arabidopsis thaliana (Chale cress)		
ORGANISM Arabidopsis thaliana		
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi.		
REFERENCE	1	
AUTHORS Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F., Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G., Lepiniec,L., Caboche,M. and Lecharny,A.		
TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites		
JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)		
MEDLINE 22363535		
PUBMED 12446565		
REFERENCE	2 (bases 1 to 15)	
AUTHORS Balzergue,S.		
TITLE Direct Submission		
JOURNAL Submitted (21-NOV-2002) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE		
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at http://dbsgap.versailles.inra.fr/publiclines/. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (http://www.genoplante.com and http://genoplante-info.infobiogen.fr/). Location/Qualifiers 1..15 /organism="Arabidopsis thaliana" /mol_type="genomic DNA" /cultivar="waslilewskija" /db_xrefs="taxon:3702" /clone="180D01" /clone_lib="Arabidopsis thaliana T-DNA insertion lines"		
FEATURES		
source		
Query Match	1.3%; Score 12; DB 1; Length 13;	
Best Local Similarity	100.0%; Pred.No.39;	
Matches	12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1581 AAAAATATAAAA 1592 Db 1 AAAAATATAAAA 12	
RESULT 110		
AX394466		
LOCUS AX394466 13 bp DNA linear PAT 18-MAY-2002		
DEFINITION Sequence 11 from Patent WO0218638.		
ACCESSION AX394466		
VERSION AX394466.1 GI:21065604		
KEYWORDS synthetic construct		
SOURCE synthetic construct		
ORGANISM other sequences; artificial sequences.		
REFERENCE	1	
AUTHORS Risinger,C., Andersson,M.K., Lewander,T. and Oliasson,E.		
TITLE Detection of cyp2d6 polymorphisms		
JOURNAL Patent: WO 0218638-A 11 07-MAR-2002; Gemini Genomics PLC (GB)		
FEATURES		
source		
Query Match	1.3%; Score 12; DB 1; Length 13;	
Best Local Similarity	100.0%; Pred.No.39;	
Matches	12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1581 AAAAATATAAAA 1592 Db 1 AAAAATATAAAA 12	

```
RESULT 111
AX394494/c
LOCUS AX394494 13 bp DNA linear PAT 18-MAY-2002
DEFINITION Sequence 39 from Patent WO218638.
ACCESSION AX394494
VERSION AX394494.1 GI:21065632
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE
1
AUTHORS Risinger,C., Andersson,M.K., Lewander,T. and Oliasson,E.
TITLE Detection of cyp2d6 polymorphisms
JOURNAL Patent: WO 0218638-A 39 07-MAR-2002;
GEMINI Genomics PLC (GB)
FEATURES
source
1. .13
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Synthetic oligonucleotide"
Query Match 1.3%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1581 AAAAAATAAAAA 1592
DB 13 AAAAAATAAAAA 2
RESULT 112
A40583/c
LOCUS A40583 14 bp DNA linear ~ PAT 05-MAR-1997
DEFINITION Sequence 120 from Patent WO9425578.
ACCESSION A40583
VERSION A40583.1 GI:2296618
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE
1 (bases 1 to 14)
AUTHORS
TITLE ANTISENSE-OLIGONUCLEOTIDES FOR THE TREATMENT OF IMMUNOSUPPRESSIVE
EFFECTS OF TRANSFORMING GROWTH FACTOR--g(b) (TGF--g(b))
JOURNAL Patent: WO 9425578-A 120 10-NOV-1994;
BIOGNOSTIK GES (DE)
FEATURES
source
1. .14
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 1.3%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2443 TTCTGTGCTGGA 2454
DB 12 TTCTGTGCTGGA 1
RESULT 113
A89107/c
LOCUS A89107 14 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 1255 from Patent WO9833904.
ACCESSION A89107
VERSION A89107.1 GI:6737677
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unidentified
```

```
unclassified.
REFERENCE
1 (bases 1 to 14)
AUTHORS Brysch,W. and Schlingensiepen,K.
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
JOURNAL Patent: WO 9833904-A 1255 06-AUG-1998;
BIOGNOSTIK GES (DE); BRYSCH WOLFGANG (DE)
FEATURES
source
1. .14
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 1.3%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2443 TTCTGTGCTGGA 2454
DB 12 TTCTGTGCTGGA 1
RESULT 114
AR232863/c
LOCUS AR232863 14 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 120 from patent US 6455689.
ACCESSION AR232863
VERSION AR232863.1 GI:27275201
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
1 (bases 1 to 14)
AUTHORS Schlingensiepen,G.-F., Brysch,W., Schlingensiepen,K.-H.,
Schlingensiepen,R. and Bogdahn,U.
TITLE Antisense-oligonucleotides for transforming growth factor-.beta.
(JGF-.beta.)
JOURNAL Patent: US 6455689-A 120 24-SEP-2002;
FEATURES
source
1. .14
Location/Qualifiers
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.3%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2443 TTCTGTGCTGGA 2454
DB 12 TTCTGTGCTGGA 1
RESULT 115
AX030158/c
LOCUS AX030158 14 bp DNA linear PAT 16-SEP-2000
DEFINITION Sequence 120 from Patent EP1008649.
ACCESSION AX030158
VERSION AX030158.1 GI:10190375
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
1
AUTHORS Bogdahn,U., Brysch,W., Schlingensiepen,G.-F., Schlingensiepen,K.H.
and Schlingensiepen,R.
TITLE Antisense-oligonucleotides for the treatment of immuno-suppressive
effects of transforming growth factor-b2(tgf-b2)
JOURNAL Patent: EP 1008649-A 120 14-JUN-2000;
BIOGNOSTIK GES (DE)
FEATURES
source
1. .14
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
```

```
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.3%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2443 TTCTGTGCTGGA 2454
|||||
Db 12 TTCTGTGCTGGA 1

RESULT 116
AX316479/c
LOCUS AX316479 14 bp DNA linear PAT 14-DEC-2001
DEFINITION Sequence 120 from Patent EP1160319.
ACCESSION AX316479
VERSION AX316479.1 GI:17899652
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
AUTHORS Schlingensiepen,G.F., Brysch,W., Schlingensiepen,K.H.,
Schlingensiepen,R. and Bogdahn,U.
TITLE Antisense-oligonucleotides for the treatment of immunosuppressive
effects of transforming growth factor-beta (tgf-beta)
JOURNAL Patent: EP 1160319-A 120 05-DEC-2001;
BIOGNOSTIK GESSELLSCHAFT FUER BIOMOLEKULARE DIAGNOSTIK mbH (DE)
FEATURES
source
1. .14
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/notes="Description of unknown: unknown"

Query Match
Best Local Similarity 1.3%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2443 TTCTGTGCTGGA 2454
|||||
Db 12 TTCTGTGCTGGA 1

RESULT 117
AX525338
LOCUS AX525338 14 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 25 from Patent WO2066676.
ACCESSION AX525338
VERSION AX525338.1 GI:25170227
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Pugniere,D., Marti,J., Manchon,L. and Piquemal,D.
TITLE Method for qualitative and quantitative analysis of a population of
nucleic acids contained in a sample
JOURNAL Patent: WO 02066676-A 25 29-AUG-2002;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES
source
1. .14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="TAG"

Query Match
Best Local Similarity 1.3%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2272 TCAGCAAGCAGG 2283
|||||
Db 12 TCAGCAAGCAGG 14

RESULT 118
AX525386
LOCUS AX525386 14 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 73 from Patent WO02066676.
ACCESSION AX525386
VERSION AX525386.1 GI:25170275
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
AUTHORS Pugniere,D., Marti,J., Manchon,L. and Piquemal,D.
TITLE Method for qualitative and quantitative analysis of a population of
nucleic acids contained in a sample
JOURNAL Patent: WO 02066676-A 73 29-AUG-2002;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR)
FEATURES
source
1. .14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="TAG"

Query Match
Best Local Similarity 1.3%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2272 TCAGCAAGCAGG 2283
|||||
Db 3 TCAGCAAGCAGG 14

RESULT 119
AX572590
LOCUS AX572590 14 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 630 from Patent WO02055741.
ACCESSION AX572590
VERSION AX572590.1 GI:26004680
KEYWORDS
SOURCE Human immunodeficiency virus
ORGANISM Human immunodeficiency virus
REFERENCE
AUTHORS de Smet,K. and Stuyver,L.
TITLE Method for detection of drug-induced mutations in the hiv reverse
transcriptase gene
JOURNAL Patent: WO 02055741-A 630 18-JUL-2002;
INNOGENETICS N.V. (BE)
FEATURES
source
1. .14
/organism="Human immunodeficiency virus"
/mol_type="unassigned DNA"
/db_xref="taxon:12721"

Query Match
Best Local Similarity 1.3%; Score 12; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1727 TGTATGTAGGGT 1738
|||||
Db 1 TGTATGTAGGGT 12

RESULT 120
AX572591
LOCUS AX572591 14 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 631 from Patent WO02055741.
ACCESSION AX572591
VERSION AX572591.1 GI:26004681
```

```
KEYWORDS
SOURCE      Human immunodeficiency virus
ORGANISM    Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
            lentivirus group.
REFERENCE 1
AUTHORS     de Smet,K. and Stuyver,L.
TITLE       Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
JOURNAL     Patent: WO 02055741-A 631 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES
source      1. .14
            Location/Qualifiers
            /organism="Human immunodeficiency virus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:12721"

Query Match      1.3%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1727 TGTATGTAGGGT 1738
DB 1 TGTATGTAGGGT 12

RESULT 121
AX572642      14 bp DNA linear PAT 29-NOV-2002
LOCUS         Sequence 682 from Patent WO02055741.
DEFINITION    AX572642
ACCESSION     AX572642
VERSION       AX572642.1 GI:26004732
KEYWORDS      Human immunodeficiency virus
SOURCE        Human immunodeficiency virus
              Viruses; Retroid viruses; Retroviridae; Lentivirus; Primate
              lentivirus group.
REFERENCE 1
AUTHORS       de Smet,K. and Stuyver,L.
TITLE         Method for detection of drug-induced mutations in the hiv reverse
              transcriptase gene
JOURNAL       Patent: WO 02055741-A 682 18-JUL-2002;
              INNOGENETICS N.V. (BE)
FEATURES
source        1. .14
              Location/Qualifiers
              /organism="Human immunodeficiency virus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:12721"

Query Match      1.3%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1727 TGTATGTAGGGT 1738
DB 1 TGTATGTAGGGT 12

RESULT 122
BD066620/c    14 bp DNA linear PAT 27-AUG-2002
LOCUS         An antisense oligonucleotide preparation method.
DEFINITION    BD066620
ACCESSION     BD066620
VERSION       BD066620.1 GI:22612223
KEYWORDS      JP 2001511000-A/1255.
SOURCE        unidentified
ORGANISM       unclassified.
REFERENCE 1 (bases 1 to 14)
AUTHORS       Schlingensiepen,K.H. and Brysch,W.
TITLE         An antisense oligonucleotide preparation method
JOURNAL       Patent: JP 2001511000-A 1255 07-AUG-2001;
              BIOGNOSTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH

KEYWORDS
SOURCE      Unknown
ORGANISM    OS JP 2001511000-A/1255
            PN 07-AUG-2001
            PF 30-JAN-1998 JP 1998532533
            PR 31-JAN-1997 EP 97101531.8
            PI KARL HERMANN SCHLINGENSIEPEN, WOLFGANG BRYSCH
            PC C12N15/11,C07H21/04,A61K31/70
            CC An antisense oligonucleotide preparation method FH Key
            Location/Qualifiers
            FT source 1. .14
            FT /organism='Unknown'.
            FEATURES
            source      1. .14
            Location/Qualifiers
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match      1.3%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2443 TTCTGTGCTGGA 2454
DB 12 TTCTGTGCTGGA 1

RESULT 123
AR132205/c    15 bp DNA linear PAT 16-MAY-2001
LOCUS         Sequence 630 from patent US 6194150.
DEFINITION    AR132205
ACCESSION     AR132205
VERSION       AR132205.1 GI:14121110
KEYWORDS      Unknown.
SOURCE        Unknown.
              Unclassified.
              1 (bases 1 to 15)
              AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
              TITLE   Nucleic acid based inhibition of CD40
              JOURNAL   Patent: US 6194150-A 630 27-FEB-2001;
              FEATURES Location/Qualifiers
              source      1. .15
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
DB 15 ATCCTATTAGTC 4

RESULT 124
AR132206/c    15 bp DNA linear PAT 16-MAY-2001
LOCUS         Sequence 631 from patent US 6194150.
DEFINITION    AR132206
ACCESSION     AR132206
VERSION       AR132206.1 GI:14121111
KEYWORDS      Unknown.
SOURCE        Unknown.
              Unclassified.
              1 (bases 1 to 15)
              AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
              TITLE   Nucleic acid based inhibition of CD40
              JOURNAL   Patent: US 6194150-A 631 27-FEB-2001;
              FEATURES Location/Qualifiers
              source      1. .15
              /organism="unknown"
              /mol_type="unassigned DNA"
```

```
Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 15 ATCCTATTAGTC 4

RESULT 125
AR132207/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      Sequence 632 from patent US 6194150.
DEFINITION AR132207
ACCESSION AR132207
VERSION AR132207.1 GI:14121112
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 632 27-FEB-2001;
FEATURES Location/Qualifiers
source 1..15
/mol_type="unassigned DNA"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 12 ATCCTATTAGTC 1

RESULT 128
AR133631/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      Sequence 2056 from patent US 6194150.
DEFINITION AR133631
ACCESSION AR133631
VERSION AR133631.1 GI:14122536
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2056 27-FEB-2001;
FEATURES Location/Qualifiers
source 1..15
/mol_type="unassigned DNA"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 15 ATCCTATTAGTC 4

RESULT 126
AR132208/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      Sequence 633 from patent US 6194150.
DEFINITION AR132208
ACCESSION AR132208
VERSION AR132208.1 GI:14121113
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 633 27-FEB-2001;
FEATURES Location/Qualifiers
source 1..15
/mol_type="unassigned DNA"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 12 ATCCTATTAGTC 1

RESULT 127
AR132209/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      Sequence 634 from patent US 6194150.
DEFINITION AR132209
ACCESSION AR132209
VERSION AR132209.1 GI:14121114
KEYWORDS
SOURCE
ORGANISM Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 634 27-FEB-2001;
FEATURES Location/Qualifiers
source 1..15
/mol_type="unassigned DNA"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 12 ATCCTATTAGTC 1

RESULT 129
AR133905/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      Sequence 2330 from patent US 6194150.
DEFINITION AR133905
ACCESSION AR133905
VERSION AR133905.1 GI:14122810
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2330 27-FEB-2001;
FEATURES Location/Qualifiers
source 1..15
/mol_type="unassigned DNA"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2271 GTCAGCAAGCAG 2282
Db 14 GTCAGCAAGCAG 3

RESULT 129
AR133905/c      15 bp DNA linear PAT 16-MAY-2001
LOCUS      Sequence 2330 from patent US 6194150.
DEFINITION AR133905
ACCESSION AR133905
VERSION AR133905.1 GI:14122810
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 15)
AUTHORS Stinchcomb,D.T., Jarvis,T. and McSwiggen,J.
TITLE Nucleic acid based inhibition of CD40
JOURNAL Patent: US 6194150-A 2330 27-FEB-2001;
FEATURES Location/Qualifiers
source 1..15
/mol_type="unassigned DNA"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2271 GTCAGCAAGCAG 2282
Db 14 GTCAGCAAGCAG 3
```

```

Db      14  GTCAGCAAGCAG 3

RESULT 130
AX572585
LOCUS      15 bp      DNA      linear      PAT 29-NOV-2002
DEFINITION Sequence 625 from Patent WO02055741.
ACCESSION  AX572585
VERSION     AX572585.1 GI:26004675
KEYWORDS
SOURCE      Human immunodeficiency virus
ORGANISM    Human immunodeficiency virus
            Viruses; Retrovirdae; Retroviridae; Lentivirus; Primate

REFERENCE   1
AUTHORS     de Smet,K. and Stuyver,L.
TITLE       Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
JOURNAL     Patent: WO 02055741-A 625 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES
source      Location/Qualifiers
            1..15
            /organism="Human immunodeficiency virus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:12721"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1727 TGTATGTAGGGT 1738
Db      2 TGTATGTAGGGT 13

RESULT 131
AX572593
LOCUS      15 bp      DNA      linear      PAT 29-NOV-2002
DEFINITION Sequence 633 from Patent WO02055741.
ACCESSION  AX572593
VERSION     AX572593.1 GI:26004683
KEYWORDS
SOURCE      Human immunodeficiency virus
ORGANISM    Human immunodeficiency virus
            Viruses; Retrovirdae; Retroviridae; Lentivirus; Primate

REFERENCE   1
AUTHORS     de Smet,K. and Stuyver,L.
TITLE       Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
JOURNAL     Patent: WO 02055741-A 633 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES
source      Location/Qualifiers
            1..15
            /organism="Human immunodeficiency virus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:12721"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1727 TGTATGTAGGGT 1738
Db      2 TGTATGTAGGGT 13

RESULT 132
AX572638
LOCUS      15 bp      DNA      linear      PAT 29-NOV-2002
DEFINITION Sequence 678 from Patent WO02055741.
ACCESSION  AX572638
VERSION     AX572638.1 GI:26004728
KEYWORDS
SOURCE      Human immunodeficiency virus
ORGANISM    Human immunodeficiency virus
            Viruses; Retrovirdae; Retroviridae; Lentivirus; Primate

REFERENCE   1
AUTHORS     de Smet,K. and Stuyver,L.
TITLE       Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
JOURNAL     Patent: WO 02055741-A 678 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES
source      Location/Qualifiers
            1..15
            /organism="Human immunodeficiency virus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:12721"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1727 TGTATGTAGGGT 1738
Db      4 TGTATGTAGGGT 15

RESULT 133
AX572640
LOCUS      15 bp      DNA      linear      PAT 29-NOV-2002
DEFINITION Sequence 680 from Patent WO02055741.
ACCESSION  AX572640
VERSION     AX572640.1 GI:26004730
KEYWORDS
SOURCE      Human immunodeficiency virus
ORGANISM    Human immunodeficiency virus
            Viruses; Retrovirdae; Retroviridae; Lentivirus; Primate

REFERENCE   1
AUTHORS     de Smet,K. and Stuyver,L.
TITLE       Method for detection of drug-induced mutations in the hiv reverse
            transcriptase gene
JOURNAL     Patent: WO 02055741-A 680 18-JUL-2002;
            INNOGENETICS N.V. (BE)
FEATURES
source      Location/Qualifiers
            1..15
            /organism="Human immunodeficiency virus"
            /mol_type="unassigned DNA"
            /db_xref="taxon:12721"

Query Match      1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1727 TGTATGTAGGGT 1738
Db      2 TGTATGTAGGGT 13

RESULT 134
AX587034
LOCUS      15 bp      DNA      linear      PAT 10-JAN-2003
DEFINITION Sequence 56 from Patent WO02072883.
ACCESSION  AX587034
VERSION     AX587034.1 GI:27655909
KEYWORDS
SOURCE      Pantoea agglomerans
ORGANISM    Pantoea agglomerans
            Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
            Enterobacteriaceae; Pantoea.

REFERENCE   1
AUTHORS     Roetger, A.
TITLE       Nucleotide carrier for diagnosing and treating oral diseases
            Patent: WO 02072883-A 56 19-SEP-2002;
            INNOGENETICS N.V. (BE)

```

```

FEATURES      ROETGER, Antje (DE)
source        Location/Qualifiers
              1..15
              /organism="Pantoea agglomerans"
              /mol_type="unassigned DNA"
              /db_xref="taxon:543"

Query Match   1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2085 GAATTGGCAGA 2096
    |||||
Db 1 GAATTGGCAGA 12

Search completed: April 6, 2005, 15:52:15
Job time : 2 secs

```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 6, 2005, 15:54:25 ; Search time 1 Seconds
(without alignments)
4.568 Million cell updates/sec

Title: US-10-630-399-3

Perfect score: 922

Sequence: 1 gacagtgttataaagcat.....ctggacttctaataatagata 922

Scoring table: IDENTITY NUC

Gapop 10_0 , Gapext 0.5

Searched: 148 segs, 2477 residues

Total number of hits satisfying chosen parameters: 296

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 149 summaries

Database : rng3.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	5.4	50	1	ABZ03275 Human leukocyte ge
2	20	2.2	20	1	ACCS8943 Human IL-1 recepto
3	20	2.2	20	1	ACCS8950 Human IL-1 recepto
4	20	2.2	20	1	ACCS8957 Human IL-1 recepto
5	20	2.2	20	1	ACCS8942 Human IL-1 recepto
6	20	2.2	20	1	ACCS8949 Human IL-1 recepto
7	20	2.2	20	1	ACCS8968 Human IL-1 recepto
8	20	2.2	20	1	ACCS8948 Human IL-1 recepto
9	20	2.2	20	1	ACCS8951 Human IL-1 recepto
10	20	2.2	20	1	ACCS8954 Human IL-1 recepto
11	20	2.2	20	1	ACCS8963 Human IL-1 recepto
12	20	2.2	20	1	ACCS8961 Human IL-1 recepto
13	20	2.2	20	1	ACCS8967 Human IL-1 recepto
14	20	2.2	20	1	ACCS8969 Human IL-1 recepto
15	20	2.2	20	1	ACCS8959 Human IL-1 recepto
16	20	2.2	20	1	ACCS8954 Human IL-1 recepto
17	20	2.2	20	1	ACCS8944 Human IL-1 recepto
18	20	2.2	20	1	ACCS8944 Human IL-1 recepto
19	20	2.2	20	1	ACCS8962 Human IL-1 recepto
20	20	2.2	20	1	ACCS8946 Human IL-1 recepto
21	20	2.2	20	1	ACCS8955 Human IL-1 recepto
22	20	2.2	20	1	ACCS8953 Human IL-1 recepto
23	20	2.2	20	1	ACCS8965 Human IL-1 recepto
24	20	2.2	20	1	ACCS8945 Human IL-1 recepto
25	20	2.2	20	1	ACCS8956 Human IL-1 recepto
26	20	2.2	20	1	ACCS8960 Human IL-1 recepto
27	20	2.2	20	1	ACCS8966 Human IL-1 recepto
28	20	2.2	20	1	ACCS8952 Human IL-1 recepto
29	20	2.2	20	1	ACCS8958 Human IL-1 recepto
30	18	2.0	20	1	ACCS1214 Human bcl-6 phosph
31	17.8	1.9	22	1	ADFL1662 Vascular endotheli
32	17	1.8	17	1	ADB43451 Tumour suppression
33	16.8	1.8	21	1	AB598265 Human lactoferrin

C 34	16	1.7	17	1	ADC05059 Human Na/H exchang
C 35	16	1.7	17	1	ADC05058 Human Na/H exchang
C 36	15.8	1.7	19	1	AAZ77372 Human biallelic ma
C 37	15.8	1.7	19	1	ADF36507 Human VEGFR1 short
C 38	15.8	1.7	19	1	ADP36080 Human VEGFR1 short
C 39	15.8	1.7	19	1	ADP36080 Human apolipoprote
C 40	15.8	1.7	19	1	ADP36080 Human apolipoprote
C 41	15.8	1.7	19	1	ADP36080 Human apolipoprote
C 42	15.8	1.7	19	1	ADP36080 Human apolipoprote
C 43	15.4	1.7	17	1	ADC05056 Human Na/H exchang
C 44	15.4	1.7	17	1	ADC05057 Human Na/H exchang
C 45	15.4	1.7	17	1	ADC05057 Human PDGFR-target
C 46	15.4	1.7	17	1	ADC05057 Human PDGFR-target
C 47	15	1.6	17	1	ADC05060 Human Na/H exchang
C 48	15	1.6	18	1	ABL45402 Human chromosome 2
C 49	14.8	1.6	17	1	ADH36295 Human purinergic r
C 50	14.4	1.6	17	1	ADH36295 Tumour suppression
C 51	14.4	1.6	17	1	ADH36295 Human Na/H exchang
C 52	14.4	1.6	17	1	ADC05055 Tumour suppression
C 53	14.4	1.6	17	1	ADH44962 Human tumour suppr
C 54	14.4	1.6	17	1	ADH44962 Human tumour suppr
C 55	14	1.5	17	1	ADH44962 Mouse flk-1 VEGF r
C 56	14	1.5	17	1	ADH44962 Human KDR VEGF r
C 57	14	1.5	17	1	ADH44962 Murine oligonucleo
C 58	14	1.5	17	1	ADH44962 Human Na/H exchang
C 59	14	1.5	17	1	ADH44962 Human tumour suppr
C 60	14	1.5	17	1	ADH44962 Human PKR substrat
C 61	14	1.5	17	1	ADH44962 Human PKR substrat
C 62	13.8	1.5	15	1	AAO05540 Probe to sequence
C 63	13.8	1.5	17	1	AAO05540 Human Calpain I ge
C 64	13.8	1.5	17	1	AAO05540 Human c-myb hamme
C 65	13.8	1.5	17	1	AAO05540 Human c-myb hamme
C 66	13.8	1.5	17	1	AAO05540 Human c-myb hamme
C 67	13.8	1.5	17	1	AAO05540 Human KDR VEGF r
C 68	13.8	1.5	17	1	AAO05540 Mouse flk-1 VEGF r
C 69	13.8	1.5	17	1	AAO05540 rb gene antisense
C 70	13.8	1.5	17	1	AAO05540 Human C-raf target
C 71	13.8	1.5	17	1	AAO05540 Human C-raf target
C 72	13.8	1.5	17	1	AAO05540 Oestrogen receptor
C 73	13.8	1.5	17	1	AAO05540 Human GMPLP-1 17-m
C 74	13.8	1.5	17	1	AAO05540 Human p21 sense PC
C 75	13.8	1.5	17	1	AAO05540 Human POSH1 scann
C 76	13.8	1.5	17	1	AAO05540 Human POSH1 scann
C 77	13.8	1.5	17	1	AAO05540 G-protein coupled
C 78	13.8	1.5	17	1	AAO05540 Human K-Ras DNazym
C 79	13.8	1.5	17	1	AAO05540 HBV DNazyme substr
C 80	13.8	1.5	17	1	AAO05540 HBV hammerhead rib
C 81	13.8	1.5	17	1	AAO05540 Tumour suppression
C 82	13.8	1.5	17	1	AAO05540 Human Na/H exchang
C 83	13.8	1.5	17	1	AAO05540 Human NOGO recepto
C 84	13.8	1.5	17	1	AAO05540 Human PKR substrat
C 85	13.8	1.5	17	1	AAO05540 Hepatitis B virus
C 86	13.8	1.5	17	1	AAO05540 Hepatitis B virus
C 87	13.8	1.5	17	1	AAO05540 Human GMPLP-1 prob
C 88	13.6	1.5	15	1	AAO05540 Human ADDB gene a
C 89	13.4	1.5	15	1	AAO05540 IGFBP3 oligonucleo
C 90	13.4	1.5	15	1	AAO05540 IGFBP3 oligonucleo
C 91	13.4	1.5	16	1	AAO05540 HIV-1 reverse tran
C 92	13.4	1.5	16	1	AAO05540 Human VRI exon id
C 93	13.2	1.4	50	1	AAO05540 Human leukocyte ge
C 94	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 95	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 96	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 97	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 98	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 99	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 100	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 101	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 102	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 103	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 104	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 105	13	1.4	13	1	AAO05540 Oligonucleotide SE
C 106	13	1.4	13	1	AAO05540 Oligonucleotide SE

107 1.4 13 1 ABR32140
 108 1.4 13 1 ABC50480
 109 1.4 13 1 ABC52298
 110 1.4 13 1 ABC52299
 111 1.4 13 1 ABH47034
 112 1.4 13 1 ABC23755
 113 1.4 13 1 ABR32141
 114 1.4 13 1 ABR93762
 115 1.4 13 1 ABR53075
 116 1.4 13 1 ABR93763
 117 1.4 13 1 ABR62301
 118 1.4 13 1 ABR00804
 119 1.4 13 1 ABR15318
 120 1.4 14 1 ADR61903
 121 1.4 15 1 AAT55633
 122 1.4 15 1 ABR51921
 123 1.4 15 1 ABR199114
 124 1.4 16 1 ADR74580
 125 1.4 16 1 ADR74581
 126 12.8 1.4 15 1 AAO05541
 127 12.8 1.4 16 1 AAO05518
 128 12.8 1.4 16 1 AAO98791
 129 12.8 1.4 16 1 AAV49158
 130 12.8 1.4 16 1 AA223160
 131 12.8 1.4 16 1 AA248622
 132 12.8 1.4 16 1 AA248617
 133 12.8 1.4 16 1 AAL46073
 134 12.8 1.4 16 1 AAS56909
 135 12.8 1.4 16 1 ACA60933
 136 12.6 1.4 13 1 ABR11493
 137 12.6 1.4 13 1 ABR11492
 138 12.6 1.4 13 1 ABR11491
 139 12.6 1.4 13 1 ABR11490
 140 12.6 1.4 13 1 ABR11489
 141 12.6 1.4 13 1 ABR11488
 142 12.6 1.4 13 1 ABR59749
 143 12.6 1.4 13 1 ABR59748
 144 12.6 1.4 13 1 ABR59747
 145 12.6 1.4 13 1 ABR38162
 146 12.6 1.4 13 1 ABR38161
 147 12.6 1.4 13 1 ABR38160
 148 12.6 1.4 15 1 AAO05538
 149 12.6 1.4 15 1 ABL01281

ALIGNMENTS

RESULT 1
 ABZ03275
 ID ABZ03275 standard; DNA; 50 BP.

XX
 AC ABZ03275;
 DT 09-JAN-2003 (first entry)
 DE Human leukocyte gene expression profiling probe SEQ ID NO 3266.
 XX
 KW T7; leukocyte; gene expression profiling; allograft rejection;
 KW atherosclerosis; congestive heart failure; systemic lupus erythematosus;
 KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200257414-A2.
 PD 25-JUL-2002.
 XX
 PF 22-OCT-2001; 2001WO-US047856.
 XX
 PR 20-OCT-2000; 2000US-0241994P.
 PR 08-JUN-2001; 2001US-0296764P.

XX (BIOC-) BIOCARDIA INC.
 PA Wohlgemuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
 XX Ly N, Woodward R, Quertermous T, Johnson F;
 PI WPI; 2002-636525/68.
 XX
 DR New system for leukocyte expression profiling, diagnosing a disease, or
 XX monitoring (the rate of) progression of a disease, e.g. atherosclerosis
 PT or congestive heart failure, comprises diagnostic oligonucleotides.
 PT
 XX Claim 1; Page 431; Opp; English.
 PS
 XX The invention relates to a system for detecting gene expression, which
 CC comprises one or two isolated DNA molecules that detect expression of a
 CC gene, where the gene corresponds to any of 8143 oligonucleotides
 CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
 CC for leukocyte expression profiling, it is particularly useful for
 CC diagnosing a disease, monitoring (rate of) progression of a disease,
 CC predicting therapeutic outcome, determining prognosis for a patient,
 CC predicting disease complications in an individual or monitoring response
 CC to treatment in an individual. The diseases include cardiac allograft
 CC rejection, kidney allograft rejection, liver allograft rejection,
 CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
 CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
 XX
 SQ Sequence 50 BP; 12 A; 11 C; 11 G; 16 T; 0 U; 0 Other;
 Query Match 5.4%; Score 50; DB 1; Length 50;
 Best Local Similarity 100.0%; Pred. No. 0.0022;
 Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1819 GCCATAATACATTGGGCTAATATCTGCTGCTTCTCTGACAGGTAGT 1868
 Db 1 GCCATAATACATTGGGCTAATATCTGCTGCTTCTCTGACAGGTAGT 50
 RESULT 2
 ACC58943/c
 ID ACC58943 standard; DNA; 20 BP.
 XX
 AC ACC58943;
 XX
 DT 11-JUL-2003 (first entry)
 XX
 DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156496.
 XX
 KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
 KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
 KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 EH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages. All cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003028636-A2.
 XX
 PD 10-APR-2003.

XX 26-SEP-2002; 2002WO-US030574.
 XX 28-SEP-2001; 2001US-00966451.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett FC, Freier SM;
 XX WPI; 2003-363256/34.
 XX New antisense oligonucleotides for modulating IL-1 receptor-associated
 PT kinase-4 gene expression, particularly useful for preventing, delaying or
 PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
 PT infection.
 XX Claim 3; Page 75; 119pp; English.
 XX The invention relates to a compound of 8-50 nucleobases which is targeted
 CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
 CC kinase-4, specifically hybridizing with the nucleic acid and inhibiting
 CC the expression of the encoded product. Also disclosed is the compound
 CC hybridizing with an 8-nucleobase portion of an active site on a nucleic
 CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
 CC oligonucleotide is useful for treating an animal having a disease or
 CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
 CC (particularly renal cancer), inflammatory disease or an infection. The
 CC antisense compounds are useful for diagnostics, therapeutics,
 CC prophylaxis, or as research reagents or kits. The current sequence
 CC represents a human IL-1 receptor-associated kinase-4 expression antisense
 CC inhibitor oligonucleotide
 XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 SQ Query Match 2.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1560 TAAAGCATGGTGAACCTTC 1579
 DB 20 TAAAGCATGGTGAACCTTC 1

RESULT 3
 ACC58950/c
 ID ACC58950 standard; DNA; 20 BP.
 XX ACC58950;
 XX 11-JUL-2003 (first entry)
 DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156510.
 KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
 KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
 KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
 KW ss.
 XX Homo sapiens.
 OS Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages. All cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 WO2003028636-A2.
 XX 10-APR-2003.
 XX 26-SEP-2002; 2002WO-US030574.
 XX 28-SEP-2001; 2001US-00966451.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett FC, Freier SM;
 XX WPI; 2003-363256/34.
 XX New antisense oligonucleotides for modulating IL-1 receptor-associated
 PT kinase-4 gene expression, particularly useful for preventing, delaying or
 PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
 PT infection.
 XX Claim 3; Page 75; 119pp; English.
 XX The invention relates to a compound of 8-50 nucleobases which is targeted
 CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
 CC kinase-4, specifically hybridizing with the nucleic acid and inhibiting
 CC the expression of the encoded product. Also disclosed is the compound
 CC hybridizing with an 8-nucleobase portion of an active site on a nucleic
 CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
 CC oligonucleotide is useful for treating an animal having a disease or
 CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
 CC (particularly renal cancer), inflammatory disease or an infection. The
 CC antisense compounds are useful for diagnostics, therapeutics,
 CC prophylaxis, or as research reagents or kits. The current sequence
 CC represents a human IL-1 receptor-associated kinase-4 expression antisense
 CC inhibitor oligonucleotide
 XX Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 SQ Query Match 2.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1810 CTGCTGTGAGCCACTAATAA 1829
 DB 20 CTGCTGTGAGCCACTAATAA 1

RESULT 4
 ACC58957/c
 ID ACC58957 standard; DNA; 20 BP.
 XX ACC58957;
 XX 11-JUL-2003 (first entry)
 DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156524.
 KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
 KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
 KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
 KW ss.
 XX Homo sapiens.
 OS Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages. All cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= b

```

FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /tag= C
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003028636-A2.
XX 10-APR-2003.
XX 26-SEP-2002; 2002WO-US030574.
XX 28-SEP-2001; 2001US-00966451.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Freier SM;
XX WPI; 2003-363256/34.
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
XX kinase-4 gene expression, particularly useful for preventing, delaying or
XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX infection.
XX Claim 3; Page 75; 119pp; English.
XX The invention relates to a compound of 8-50 nucleobases which is targeted
XX to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX the expression of the encoded product. Also disclosed is the compound
XX hybridising with an 8-nucleobase portion of an active site on a nucleic
XX acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX oligonucleotide is useful for treating an animal having a disease or
XX conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX (particularly renal cancer), inflammatory disease or an infection. The
XX antisense compounds are useful for diagnostics, therapeutics,
XX prophylaxis, or as research reagents or kits. The current sequence
XX represents a human IL-1 receptor-associated kinase-4 expression antisense
XX inhibitor oligonucleotide
XX Sequence 20 BP; 5 A; 5 C; 2 G; 8 T; 0 U; 0 Other;
SQ
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2066 TTACATGACAAAGTTGAAGG 2085
Db 20 TTACATGACAAAGTTGAAGG 1
RESULT 5
ACC58942/c
ID ACC58942 standard; DNA; 20 BP.
XX ACC58942;
XX 11-JUL-2003 (first entry)
XX Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156494.
XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX inflammatory disease; infection; diagnostic; prophylaxis;
XX ss.
XX Homo sapiens.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a

```

```

FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylycytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX modified_base 16..20
XX /tag= C
XX /mod_base= OTHER
XX /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003028636-A2.
XX 10-APR-2003.
XX 26-SEP-2002; 2002WO-US030574.
XX 28-SEP-2001; 2001US-00966451.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Freier SM;
XX WPI; 2003-363256/34.
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
XX kinase-4 gene expression, particularly useful for preventing, delaying or
XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX infection.
XX Claim 3; Page 75; 119pp; English.
XX The invention relates to a compound of 8-50 nucleobases which is targeted
XX to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX the expression of the encoded product. Also disclosed is the compound
XX hybridising with an 8-nucleobase portion of an active site on a nucleic
XX acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX oligonucleotide is useful for treating an animal having a disease or
XX conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX (particularly renal cancer), inflammatory disease or an infection. The
XX antisense compounds are useful for diagnostics, therapeutics,
XX prophylaxis, or as research reagents or kits. The current sequence
XX represents a human IL-1 receptor-associated kinase-4 expression antisense
XX inhibitor oligonucleotide
XX Sequence 20 BP; 6 A; 5 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1548 GACAGTGGTTATTAAAGCAT 1567
Db 20 GACAGTGGTTATTAAAGCAT 1
RESULT 6
ACC58949/c
ID ACC58949 standard; DNA; 20 BP.
XX ACC58949;
XX 11-JUL-2003 (first entry)
XX Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156508.
XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX inflammatory disease; infection; diagnostic; prophylaxis;
XX ss.
XX

```

OS Homo sapiens.
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages. All cytosines are 5-methylcytosine"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003028636-A2.
 PN 10-APR-2003.
 XX 26-SEP-2002; 2002WO-US030574.
 XX 28-SEP-2001; 2001US-00966451.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett FC, Freier SM;
 XX WPI; 2003-363256/34.
 XX New antisense oligonucleotides for modulating IL-1 receptor-associated kinase-4 gene expression, particularly useful for preventing, delaying or treating e.g. cancer (e.g. renal cancer), inflammatory disease or an infection.
 XX Claim 3; Page 75; 119pp; English.
 XX The invention relates to a compound of 8-50 nucleobases which is targeted to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated kinase-4, specifically hybridizing with the nucleic acid and inhibiting the expression of the encoded product. Also disclosed is the compound hybridizing with an 8-nucleobase portion of an active site on a nucleic acid molecule encoding IL-1 receptor-associated kinase-4. The antisense oligonucleotide is useful for treating an animal having a disease or conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer (particularly renal cancer), inflammatory disease or an infection. The antisense compounds are useful for diagnostics, therapeutics, prophylaxis, or as research reagents or kits. The current sequence represents a human IL-1 receptor-associated kinase-4 expression antisense inhibitor oligonucleotide
 XX Sequence 20 BP; 3 A; 3 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 2.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1756 AAGCCGAGCTGACTCCACTA 1775
 DB 20 AAGCCGAGCTGACTCCACTA 1
 RESULT 7
 ACC58968/c
 ID ACC58968 standard; DNA; 20 BP.
 XX ACC58968;
 AC ACC58968;
 XX 11-JUL-2003 (first entry)
 DT Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156546.
 DE
 XX

KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
 KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
 KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
 KW ss.
 XX Homo sapiens.
 OS Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages. All cytosines are 5-methylcytosine"
 FT modified_base 1..5
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX WO2003028636-A2.
 PN 10-APR-2003.
 XX 26-SEP-2002; 2002WO-US030574.
 XX 28-SEP-2001; 2001US-00966451.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett FC, Freier SM;
 XX WPI; 2003-363256/34.
 XX New antisense oligonucleotides for modulating IL-1 receptor-associated kinase-4 gene expression, particularly useful for preventing, delaying or treating e.g. cancer (e.g. renal cancer), inflammatory disease or an infection.
 XX Claim 3; Page 76; 119pp; English.
 XX The invention relates to a compound of 8-50 nucleobases which is targeted to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated kinase-4, specifically hybridizing with the nucleic acid and inhibiting the expression of the encoded product. Also disclosed is the compound hybridizing with an 8-nucleobase portion of an active site on a nucleic acid molecule encoding IL-1 receptor-associated kinase-4. The antisense oligonucleotide is useful for treating an animal having a disease or conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer (particularly renal cancer), inflammatory disease or an infection. The antisense compounds are useful for diagnostics, therapeutics, prophylaxis, or as research reagents or kits. The current sequence represents a human IL-1 receptor-associated kinase-4 expression antisense inhibitor oligonucleotide
 XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 2.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2377 TAACCACAGCTGGGCTGAC 2396
 DB 20 TAACCACAGCTGGGCTGAC 1
 RESULT 8
 ACC58948/c
 ID ACC58948 standard; DNA; 20 BP.
 XX ACC58948;
 AC ACC58948;


```
QY 1829 ACATTGGGCTAATATCTGCT 1848
Db 20 ACATTGGGCTAATATCTGCT 1

RESULT 10
ID ACCS8954/c
AC ACCS8954;
XX
XX
DT 11-JUL-2003 (first entry)
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156518.
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003028636-A2.
XX
XX 10-APR-2003.
XX
XX 26-SEP-2002; 2002WO-US030574.
XX
XX 28-SEP-2001; 2001US-00966451.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
XX kinase-4 gene expression, particularly useful for preventing, delaying or
XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX infection.
XX
XX Claim 3; Page 75; 119pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases which is targeted
XX to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX kinase-4, specifically hybridizing with the nucleic acid and inhibiting
XX the expression of the encoded product. Also disclosed is the compound
XX hybridizing with an 8-nucleobase portion of an active site on a nucleic
XX acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX oligonucleotide is useful for treating an animal having a disease or
XX conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX (particularly renal cancer), inflammatory disease or an infection. The
XX antisense compounds are useful for diagnostics, therapeutics,
XX prophylaxis, or as research reagents or kits. The current sequence
XX represents a human IL-1 receptor-associated kinase-4 expression antisense
XX inhibitor oligonucleotide
XX
XX Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1894 TATACAAGCAGCTTTGTAAT 1913
Db 20 TATACAAGCAGCTTTGTAAT 1

RESULT 11
ID ACCS8963/c
AC ACCS8963;
XX
XX
DT 11-JUL-2003 (first entry)
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156536.
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX
PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003028636-A2.
XX
XX 10-APR-2003.
XX
XX 26-SEP-2002; 2002WO-US030574.
XX
XX 28-SEP-2001; 2001US-00966451.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
XX kinase-4 gene expression, particularly useful for preventing, delaying or
XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX infection.
XX
XX Claim 3; Page 75; 119pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases which is targeted
XX to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX kinase-4, specifically hybridizing with the nucleic acid and inhibiting
XX the expression of the encoded product. Also disclosed is the compound
XX hybridizing with an 8-nucleobase portion of an active site on a nucleic
XX acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX oligonucleotide is useful for treating an animal having a disease or
XX conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX (particularly renal cancer), inflammatory disease or an infection. The
XX antisense compounds are useful for diagnostics, therapeutics,
XX prophylaxis, or as research reagents or kits. The current sequence
XX represents a human IL-1 receptor-associated kinase-4 expression antisense
XX inhibitor oligonucleotide
XX
XX Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
```

CC prophylaxis, or as research reagents or kits. The current sequence
CC represents a human IL-1 receptor-associated kinase-4 expression antisense
CC inhibitor oligonucleotide
XX
SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2223 GCTAAACCTAAGGTGGCC 2242
DB 20 GCTAAACCTAAGGTGGCC 1
RESULT 12
ACC58961/c
ID ACC58961 standard; DNA; 20 BP.
XX
AC ACC58961;
XX
DT 11-JUL-2003 (first entry)
XX
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156532.
XX
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003028636-A2.
XX
PD 10-APR-2003.
XX
PF 26-SEP-2002; 2002WO-US030574.
XX
PR 28-SEP-2001; 2001US-00966451.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
PT kinase-4 gene expression, particularly useful for preventing, delaying or
PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT infection.
XX
PS Claim 3; Page 75; 119pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases which is targeted
CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
CC the expression of the encoded product. Also disclosed is the compound
CC hybridising with an 8-nucleobase portion of an active site on a nucleic

CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC oligonucleotide is useful for treating an animal having a disease or
CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC (particularly renal cancer), inflammatory disease or an infection. The
CC antisense compounds are useful for diagnostics, therapeutics,
CC prophylaxis, or as research reagents or kits. The current sequence
CC represents a human IL-1 receptor-associated kinase-4 expression antisense
CC inhibitor oligonucleotide
XX
SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2211 AGGGCCACATTGGCTAAAC 2230
DB 20 AGGGCCACATTGGCTAAAC 1
RESULT 13
ACC58967/c
ID ACC58967 standard; DNA; 20 BP.
XX
AC ACC58967;
XX
DT 11-JUL-2003 (first entry)
XX
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156544.
XX
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003028636-A2.
XX
PD 10-APR-2003.
XX
PF 26-SEP-2002; 2002WO-US030574.
XX
PR 28-SEP-2001; 2001US-00966451.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
PT kinase-4 gene expression, particularly useful for preventing, delaying or
PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT infection.
XX
PS Example 15; Page 75; 119pp; English.
XX

PT	treating e.g. cancer (e.g. renal cancer), inflammatory disease or an infection.
XX	
XX	
PS	Claim 3; Page 76; 119pp; English.
XX	
CC	The invention relates to a compound of 8-50 nucleobases which is targeted to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated kinase-4, specifically hybridising with the nucleic acid and inhibiting the expression of the encoded product. Also disclosed is the compound hybridising with an 8-nucleobase portion of an active site on a nucleic acid molecule encoding IL-1 receptor-associated kinase-4. The antisense oligonucleotide is useful for treating an animal having a disease or conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer (particularly renal cancer), inflammatory disease or an infection. The antisense compounds are useful for diagnostics, therapeutics, prophylaxis, or as research reagents or kits. The current sequence represents a human IL-1 receptor-associated kinase-4 expression antisense inhibitor oligonucleotide
CC	
XX	
XX	Sequence 20 BP; 6 A; 3 C; 4 G; 7 T; 0 U; 0 Other;
XX	
XX	Query Match 2.2%; Score 20; DB 1; Length 20;
XX	Best Local Similarity 100.0%; Pred. No. 12;
XX	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY	2419 ATCCTCAGTATGAGAATCTA 2438
DB	20 ATCCTCAGTATGAGAATCTA 1
XX	
RESULT 15	
ACC58959/c	
ID	ACC58959 standard; DNA; 20 BP.
XX	
AC	ACC58959;
XX	
DT	11-JUL-2003 (first entry)
XX	
DE	Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156528.
XX	
KW	Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW	interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW	inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
SS	ss.
XX	
OS	Homo sapiens.
XX	
FH	Key Location/Qualifiers
FT	modified_base 1..20
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "phosphorothioate linkages. All cytosines are 5-methylcytosine"
FT	modified_base 1..5
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT	modified_base 16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX	
XX	WO2003028636-A2.
PN	
PD	10-APR-2003.
XX	
XX	26-SEP-2002; 2002WO-US030574.
PF	
XX	
PR	28-SEP-2001; 2001US-00966451.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Bennett FC, Freier SM;

```
XX DR WPI; 2003-363256/34.
XX PT New antisense oligonucleotides for modulating IL-1 receptor-associated
XX PT kinase-4 gene expression, particularly useful for preventing, delaying or
XX PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX PT infection.
XX PS Claim 3; Page 75; 119pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
XX CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX CC kinase-4, specifically hybridizing with the nucleic acid and inhibiting
XX CC the expression of the encoded product. Also disclosed is the compound
XX CC hybridizing with an 8-nucleobase portion of an active site on a nucleic
XX CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX CC oligonucleotide is useful for treating an animal having a disease or
XX CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX CC (particularly renal cancer), inflammatory disease or an infection. The
XX CC antisense compounds are useful for diagnostics, therapeutics,
XX CC prophylaxis, or as research reagents or kits. The current sequence
XX CC represents a human IL-1 receptor-associated kinase-4 expression antisense
XX CC inhibitor oligonucleotide
XX SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2137 AAAGGCGCTGACCTAATCCA 2156
DB 20 AAAGGCGCTGACCTAATCCA 1
|||||
|||||

RESULT 16
ACC58964/c
ID ACC58964 standard; DNA; 20 BP.
XX AC ACC58964;
XX DT 11-JUL-2003 (first entry)
XX DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156538.
XX KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
XX KW ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003028636-A2.
XX PD 10-APR-2003.
XX PF 26-SEP-2002; 2002WO-US030574.
XX XX
```

```
PR 28-SEP-2001; 2001US-00966451.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett FC, Freier SM;
XX XX WPI; 2003-363256/34.
XX PT New antisense oligonucleotides for modulating IL-1 receptor-associated
XX PT kinase-4 gene expression, particularly useful for preventing, delaying or
XX PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX PT infection.
XX PS Claim 3; Page 75; 119pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
XX CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX CC kinase-4, specifically hybridizing with the nucleic acid and inhibiting
XX CC the expression of the encoded product. Also disclosed is the compound
XX CC hybridizing with an 8-nucleobase portion of an active site on a nucleic
XX CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX CC oligonucleotide is useful for treating an animal having a disease or
XX CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX CC (particularly renal cancer), inflammatory disease or an infection. The
XX CC antisense compounds are useful for diagnostics, therapeutics,
XX CC prophylaxis, or as research reagents or kits. The current sequence
XX CC represents a human IL-1 receptor-associated kinase-4 expression antisense
XX CC inhibitor oligonucleotide
XX SQ Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2236 GGTGGCCTCTAGGAGATGAG 2255
DB 20 GGTGGCCTCTAGGAGATGAG 1
|||||
|||||

RESULT 17
ACC58947/c
ID ACC58947 standard; DNA; 20 BP.
XX AC ACC58947;
XX DT 11-JUL-2003 (first entry)
XX DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156504.
XX KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
XX KW ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003028636-A2.
```

```

XX PD 10-APR-2003.
XX PF 26-SEP-2002; 2002WO-US030574.
XX PR 28-SEP-2001; 2001US-00966451.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett FC, Freier SM;
XX DR WPI; 2003-363256/34.
XX PT New antisense oligonucleotides for modulating IL-1 receptor-associated
XX PT kinase-4 gene expression, particularly useful for preventing, delaying or
XX PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX PT infection.
XX PS Claim 3; Page 75; 119pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
XX CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX CC the expression of the encoded product. Also disclosed is the compound
XX CC hybridising with an 8-nucleobase portion of an active site on a nucleic
XX CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX CC oligonucleotide is useful for treating an animal having a disease or
XX CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX CC (particularly renal cancer), inflammatory disease or an infection. The
XX CC antisense compounds are useful for diagnostics, therapeutics,
XX CC prophylaxis, or as research reagents or kits. The current sequence
XX CC represents a human IL-1 receptor-associated kinase-4 expression antisense
XX CC inhibitor oligonucleotide
XX CC Sequence 20 BP; 6 A; 9 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1720 CCTGGGCTGTATAGGGTG 1739
DB 20 CCTGGGCTGTATAGGGTG 1

RESULT 18
ACC58944/c
ID ACC58944 standard; DNA; 20 BP.
XX AC ACC58944;
XX AC ACC58944;
XX DT 11-JUL-2003 (first entry)
XX DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156498.
XX KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
XX KW ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20

```

```

FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003028636-A2.
XX PD 10-APR-2003.
XX PF 26-SEP-2002; 2002WO-US030574.
XX PR 28-SEP-2001; 2001US-00966451.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett FC, Freier SM;
XX DR WPI; 2003-363256/34.
XX PT New antisense oligonucleotides for modulating IL-1 receptor-associated
XX PT kinase-4 gene expression, particularly useful for preventing, delaying or
XX PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX PT infection.
XX PS Claim 3; Page 75; 119pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
XX CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX CC the expression of the encoded product. Also disclosed is the compound
XX CC hybridising with an 8-nucleobase portion of an active site on a nucleic
XX CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX CC oligonucleotide is useful for treating an animal having a disease or
XX CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX CC (particularly renal cancer), inflammatory disease or an infection. The
XX CC antisense compounds are useful for diagnostics, therapeutics,
XX CC prophylaxis, or as research reagents or kits. The current sequence
XX CC represents a human IL-1 receptor-associated kinase-4 expression antisense
XX CC inhibitor oligonucleotide
XX CC Sequence 20 BP; 5 A; 3 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1646 TACAGTAATCCCTGAGAAAT 1665
DB 20 TACAGTAATCCCTGAGAAAT 1

RESULT 19
ACC58962/c
ID ACC58962 standard; DNA; 20 BP.
XX AC ACC58962;
XX AC ACC58962;
XX DT 11-JUL-2003 (first entry)
XX DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156534.
XX KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
XX KW ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 16..20

```

```

FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003028636-A2.
XX
XX
XX 10-APR-2003.
XX
XX 26-SEP-2002; 2002WO-US030574.
XX
XX 28-SEP-2001; 2001US-00966451.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
XX kinase-4 gene expression, particularly useful for preventing, delaying or
XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX infection.
XX
XX Claim 3; Page 75; 119pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases which is targeted
XX to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX the expression of the encoded product. Also disclosed is the compound
XX hybridising with an 8-nucleobase portion of an active site on a nucleic
XX acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX oligonucleotide is useful for treating an animal having a disease or
XX conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX (particularly renal cancer), inflammatory disease or an infection. The
XX antisense compounds are useful for diagnostics, therapeutics,
XX prophylaxis, or as research reagents or kits. The current sequence
XX represents a human IL-1 receptor-associated kinase-4 expression antisense
XX inhibitor oligonucleotide
XX
XX Sequence 20 BP; 4 A; 4 C; 4 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 2.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 12;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2218 CATTGGCTAAACCTAAAGG 2237
Dd |||||
Dd 20 CATTGGCTAAACCTAAAGG 1
XX
XX RESULT 20
XX ACC58946/c
XX ID ACC58946 standard; DNA; 20 BP.
XX
XX ACC58946;
XX
XX 11-JUL-2003 (first entry)
XX
XX Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156502.
XX
XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
XX ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers

```

```

FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX WO2003028636-A2.
XX
XX
XX 10-APR-2003.
XX
XX 26-SEP-2002; 2002WO-US030574.
XX
XX 28-SEP-2001; 2001US-00966451.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
XX kinase-4 gene expression, particularly useful for preventing, delaying or
XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX infection.
XX
XX Example 15; Page 75; 119pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases which is targeted
XX to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX the expression of the encoded product. Also disclosed is the compound
XX hybridising with an 8-nucleobase portion of an active site on a nucleic
XX acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX oligonucleotide is useful for treating an animal having a disease or
XX conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX (particularly renal cancer), inflammatory disease or an infection. The
XX antisense compounds are useful for diagnostics, therapeutics,
XX prophylaxis, or as research reagents or kits. The current sequence
XX represents a human IL-1 receptor-associated kinase-4 expression antisense
XX inhibitor oligonucleotide
XX
XX Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 2.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 12;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1711 CAAAAGAGCCTGGGCTGTA 1730
Dd |||||
Dd 20 CAAAAGAGCCTGGGCTGTA 1
XX
XX RESULT 21
XX ACC58955/c
XX ID ACC58955 standard; DNA; 20 BP.
XX
XX ACC58955;
XX
XX 11-JUL-2003 (first entry)
XX
XX Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156520.
XX
XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
XX interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
XX inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
XX
XX
XX

```

```

KW XX SS.
OS XX Homo sapiens.
FH XX Key Location/Qualifiers
FT FT modified_base 1..20
FT FT /tag= a
FT FT /mod_base= OTHER
FT FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT FT modified_base 1..5
FT FT /tag= b
FT FT /mod_base= OTHER
FT FT modified_base 16..20
FT FT /tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003028636-A2.
XX XX 10-APR-2003.
XX XX 26-SEP-2002; 2002WO-US030574.
XX PF 28-SEP-2001; 2001US-00966451.
XX XX (ISIS-) ISIS PHARM INC.
XX PI Bennett FC, Freier SM;
XX XX WPI; 2003-363256/34.
XX DR
XX PS Claim 3; Page 75; 119pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
XX CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX CC the expression of the encoded product. Also disclosed is the compound
XX CC hybridising with an 8-nucleobase portion of an active site on a nucleic
XX CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX CC oligonucleotide is useful for treating an animal having a disease or
XX CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX CC (particularly renal cancer), inflammatory disease or an infection. The
XX CC antisense compounds are useful for diagnostics, therapeutics,
XX CC prophylaxis, or as research reagents or kits. The current sequence
XX CC represents a human IL-1 receptor-associated kinase-4 expression antisense
XX CC inhibitor oligonucleotide
XX XX Sequence 20 BP; 7 A; 1 C; 4 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 2.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 12;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1951 TTACAAATCCTATTAGTCA 1970
DB 20 TTACAAATCCTATTAGTCA 1
RESULT 22
ACC58953/c
ID ACC58953 standard; DNA; 20 BP.
XX AC ACC58953;
XX AC
XX DT 11-JUL-2003 (first entry)
XX

```

```

DE XX Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156516.
KW XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW FH interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW FT inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW FT ss.
OS XX Homo sapiens.
FH XX Key Location/Qualifiers
FT FT modified_base 1..20
FT FT /tag= a
FT FT /mod_base= OTHER
FT FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT FT modified_base 1..5
FT FT /tag= b
FT FT /mod_base= OTHER
FT FT modified_base 16..20
FT FT /tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX PN WO2003028636-A2.
XX XX 10-APR-2003.
XX XX 26-SEP-2002; 2002WO-US030574.
XX PF 28-SEP-2001; 2001US-00966451.
XX XX (ISIS-) ISIS PHARM INC.
XX PI Bennett FC, Freier SM;
XX XX WPI; 2003-363256/34.
XX DR
XX PS Claim 3; Page 75; 119pp; English.
XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
XX CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
XX CC the expression of the encoded product. Also disclosed is the compound
XX CC hybridising with an 8-nucleobase portion of an active site on a nucleic
XX CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX CC oligonucleotide is useful for treating an animal having a disease or
XX CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX CC (particularly renal cancer), inflammatory disease or an infection. The
XX CC antisense compounds are useful for diagnostics, therapeutics,
XX CC prophylaxis, or as research reagents or kits. The current sequence
XX CC represents a human IL-1 receptor-associated kinase-4 expression antisense
XX CC inhibitor oligonucleotide
XX XX Sequence 20 BP; 6 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 2.2%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 12;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1854 TCTCTGACAGGTAGTCATGA 1873
DB 20 TCTCTGACAGGTAGTCATGA 1
RESULT 23
ACC58965/c
ID ACC58965 standard; DNA; 20 BP.

```

XX AC AC58965;
 XX DT 11-JUL-2003 (first entry)
 XX DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156540.
 XX KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
 KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
 KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
 KW ss.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages. All cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT WO2003028636-A2.
 XX PN 10-APR-2003.
 XX PD 26-SEP-2002; 2002WO-US030574.
 XX PF 28-SEP-2001; 2001US-00966451.
 XX PR (ISIS-) ISIS PHARM INC.
 XX PA Bennett FC, Freier SM;
 XX PI WPI; 2003-363256/34.
 XX DR New antisense oligonucleotides for modulating IL-1 receptor-associated
 XX kinase-4 gene expression, particularly useful for preventing, delaying or
 XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
 XX infection.
 XX PS Claim 3; Page 75; 119pp; English.
 XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
 CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
 CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
 CC the expression of the encoded product. Also disclosed is the compound
 CC hybridising with an 8-nucleobase portion of an active site on a nucleic
 CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
 CC oligonucleotide is useful for treating an animal having a disease or
 CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
 CC (particularly renal cancer), inflammatory disease or an infection. The
 CC antisense compounds are useful for diagnostics, therapeutics,
 CC prophylaxis, or as research reagents or kits. The current sequence
 CC represents a human IL-1 receptor-associated kinase-4 expression antisense
 CC inhibitor oligonucleotide
 XX SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 2.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2256 ACCTACCTCCAGTGTGCAG 2275
 DB ||||||||||||||||||||
 20 ACCTACCTCCAGTGTGCAG 1

RESULT 24
 AC58945/c
 ID ACC58945 standard; DNA; 20 BP.
 XX AC AC58945;
 XX DT 11-JUL-2003 (first entry)
 XX DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156500.
 XX KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
 KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
 KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
 KW ss.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate linkages. All cytosines are 5-
 FT methylcytosine"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT WO2003028636-A2.
 XX PN 10-APR-2003.
 XX PD 26-SEP-2002; 2002WO-US030574.
 XX PF 28-SEP-2001; 2001US-00966451.
 XX PR (ISIS-) ISIS PHARM INC.
 XX PA Bennett FC, Freier SM;
 XX PI WPI; 2003-363256/34.
 XX DR New antisense oligonucleotides for modulating IL-1 receptor-associated
 XX kinase-4 gene expression, particularly useful for preventing, delaying or
 XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
 XX infection.
 XX PS Claim 3; Page 75; 119pp; English.
 XX CC The invention relates to a compound of 8-50 nucleobases which is targeted
 CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
 CC kinase-4, specifically hybridising with the nucleic acid and inhibiting
 CC the expression of the encoded product. Also disclosed is the compound
 CC hybridising with an 8-nucleobase portion of an active site on a nucleic
 CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
 CC oligonucleotide is useful for treating an animal having a disease or
 CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
 CC (particularly renal cancer), inflammatory disease or an infection. The
 CC antisense compounds are useful for diagnostics, therapeutics,
 CC prophylaxis, or as research reagents or kits. The current sequence
 CC represents a human IL-1 receptor-associated kinase-4 expression antisense
 CC inhibitor oligonucleotide
 XX SQ Sequence 20 BP; 4 A; 2 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 2.2%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 12;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1674 AGCATCACCAACACAGTTT 1693
Db 20 AGCATCACCAACACAGTTT 1
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1985 GTGTTCCACAGCAATCATTTA 2004
Db 20 GTGTTCCACAGCAATCATTTA 1
RESULT 26
ACC58956/c
ID ACC58956 standard; DNA; 20 BP.
XX ACC58956;
AC ACC58956;
XX 11-JUL-2003 (first entry)
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156522.
XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX Homo sapiens.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
WO2003028636-A2.
XX 10-APR-2003.
XX 26-SEP-2002; 2002WO-US030574.
XX 28-SEP-2001; 2001US-00966451.
XX (ISIS-) ISIS PHARM INC.
XX Bennett FC, Freier SM;
XX WPI; 2003-363256/34.
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
XX kinase-4 gene expression, particularly useful for preventing, delaying or
XX treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
XX infection.
PS Claim 3; Page 75; 119pp; English.
XX The invention relates to a compound of 8-50 nucleobases which is targeted
XX to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
XX kinase-4, specifically hybridizing with the nucleic acid and inhibiting
XX the expression of the encoded product. Also disclosed is the compound
XX hybridizing with an 8-nucleobase portion of an active site on a nucleic
XX acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
XX oligonucleotide is useful for treating an animal having a disease or
XX conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
XX (particularly renal cancer), inflammatory disease or an infection. The
XX antisense compounds are useful for diagnostics, therapeutics,
XX prophylaxis, or as research reagents or kits. The current sequence
XX represents a human IL-1 receptor-associated kinase-4 expression antisense
XX inhibitor oligonucleotide
```

CC (particularly renal cancer), inflammatory disease or an infection. The
CC antisense compounds are useful for diagnostics, therapeutics,
CC prophylaxis, or as research reagents or kits. The current sequence
CC represents a human IL-1 receptor-associated kinase-4 expression antisense
CC inhibitor oligonucleotide

XX
SQ Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2191 GCCTTGAGAGTATGTGAG 2210
Db 20 GCCTTGAGAGTATGTGAG 1

RESULT 27
ACC58966/c
ID ACC58966 standard; DNA; 20 BP.
XX
XX ACC58966;
AC
XX 11-JUL-2003 (first entry)
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156542.
DE
XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003028636-A2.
XX
XX 10-APR-2003.
XX
XX 26-SEP-2002; 2002WO-US030574.
XX
XX 28-SEP-2001; 2001US-00966451.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
FT kinase-4 gene expression, particularly useful for preventing, delaying or
FT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
FT infection.
XX
XX Claim 3; Page 75; 119pp; English.
XX
XX The invention relates to a compound of 8-50 nucleobases which is targeted
CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC kinase-4, specifically hybridising with the nucleic acid and inhibiting

CC the expression of the encoded product. Also disclosed is the compound
CC hybridising with an 8-nucleobase portion of an active site on a nucleic
CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC oligonucleotide is useful for treating an animal having a disease or
CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC (particularly renal cancer), inflammatory disease or an infection. The
CC antisense compounds are useful for diagnostics, therapeutics,
CC prophylaxis, or as research reagents or kits. The current sequence
CC represents a human IL-1 receptor-associated kinase-4 expression antisense
CC inhibitor oligonucleotide

XX
SQ Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2267 AGTTGTCAGCAAGCAGGAAA 2286
Db 20 AGTTGTCAGCAAGCAGGAAA 1

RESULT 28
ACC58952/c
ID ACC58952 standard; DNA; 20 BP.
XX
XX ACC58952;
AC
XX 11-JUL-2003 (first entry)
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156514.
DE
XX Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003028636-A2.
XX
XX 10-APR-2003.
XX
XX 26-SEP-2002; 2002WO-US030574.
XX
XX 28-SEP-2001; 2001US-00966451.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX
XX New antisense oligonucleotides for modulating IL-1 receptor-associated
FT kinase-4 gene expression, particularly useful for preventing, delaying or
FT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
FT infection.

```
PS Claim 3; Page 75; 119pp; English.
XX The invention relates to a compound of 8-50 nucleobases which is targeted
CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC kinase-4, specifically hybridizing with the nucleic acid and inhibiting
CC the expression of the encoded product. Also disclosed is the compound
CC hybridizing with an 8-nucleobase portion of an active site on a nucleic
CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC oligonucleotide is useful for treating an animal having a disease or
CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC (particularly renal cancer), inflammatory disease or an infection. The
CC antisense compounds are useful for diagnostics, therapeutics,
CC prophylaxis, or as research reagents or kits. The current sequence
CC represents a human IL-1 receptor-associated kinase-4 expression antisense
CC inhibitor oligonucleotide
XX
SQ Sequence 20 BP; 7 A; 6 C; 5 G; 2 T; 0 U; 0 Other;

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1846 GCTGTGCTTCTCTGACAGGT 1865
DB 20 GCTGTGCTTCTCTGACAGGT 1

RESULT 29
ACCS8958/c
ID ACCS8958 standard; DNA; 20 BP.
XX
AC ACCS8958;
XX
DT 11-JUL-2003 (first entry)
DE Human IL-1 receptor-associated kinase-4 antisense oligo #ISIS 156526.
XX
KW Antisense therapy; cytostatic; antimicrobial; antiinflammatory;
KW interleukin-1 receptor-associated kinase-4; human; cancer; renal cancer;
KW inflammatory disease; infection; diagnostic; therapeutic; prophylaxis;
KW ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages. All cytosines are 5-
FT methylcytosine"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN WO2003028636-A2.
XX
PD 10-APR-2003.
XX
PF 26-SEP-2002; 2002WO-US030574.
XX
PR 28-SEP-2001; 2001US-00966451.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett FC, Freier SM;
XX
XX WPI; 2003-363256/34.
XX

PT New antisense oligonucleotides for modulating IL-1 receptor-associated
PT kinase-4 gene expression, particularly useful for preventing, delaying or
PT treating e.g. cancer (e.g. renal cancer), inflammatory disease or an
PT infection.
XX Claim 3; Page 75; 119pp; English.
XX The invention relates to a compound of 8-50 nucleobases which is targeted
CC to a nucleic acid encoding interleukin-1 (IL-1) receptor-associated
CC kinase-4, specifically hybridizing with the nucleic acid and inhibiting
CC the expression of the encoded product. Also disclosed is the compound
CC hybridizing with an 8-nucleobase portion of an active site on a nucleic
CC acid molecule encoding IL-1 receptor-associated kinase-4. The antisense
CC oligonucleotide is useful for treating an animal having a disease or
CC conditions associated with IL-1 receptor-associated kinase-4, e.g. cancer
CC (particularly renal cancer), inflammatory disease or an infection. The
CC antisense compounds are useful for diagnostics, therapeutics,
CC prophylaxis, or as research reagents or kits. The current sequence
CC represents a human IL-1 receptor-associated kinase-4 expression antisense
CC inhibitor oligonucleotide
XX
SQ Sequence 20 BP; 6 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2089 TTGGCAGATGCAGTTAAGGT 2108
DB 20 TTGGCAGATGCAGTTAAGGT 1

RESULT 30
AAC81214
ID AAC81214 standard; DNA; 20 BP.
XX
AC AAC81214;
XX
DT 23-FEB-2001 (first entry)
DE Human bcl-6 phosphorothioate antisense oligonucleotide, SEQ ID NO:80.
XX
KW Human; bcl-6; transcriptional repressor; germinal centre formation;
KW Th-2 mediated antibody affinity maturation; apoptosis regulator;
KW chromosome 3q27; lymphoma; acute lymphoblastic leukaemia;
KW post-transplant lymphoproliferative disorder; expression inhibition;
KW phosphorothioate; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN US6140125-A.
XX
PD 31-OCT-2000.
XX
PF 15-OCT-1999; 99US-00418640.
XX
PR 15-OCT-1999; 99US-00418640.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Taylor JK, Cowbert LM;
XX
XX WPI; 2001-048959/06.
XX
PT Antisense compounds which specifically hybridize with and inhibit human
PT bcl-6 expression, useful for treating bcl-6 related disorders, and
PT preventing or delaying inflammation or tumor formation.
XX
PS Example 15; Col 45-46; 42pp; English.
XX
CC Sequences AAC81144-C81223 represent antisense oligonucleotides targeted
CC to the human bcl-6 gene, which inhibit its expression. The antisense
CC oligonucleotides were designed to target different regions of the human
```

bcl-6 mRNA, and were analysed for their effect on bcl-6 mRNA levels by quantitative real-time PCR. Bcl-6 (also known as B-cell CLL/ lymphoma 6, zinc finger protein 51 and LAZ3) is a sequence-specific DNA-binding transcriptional repressor. The bcl-6 gene is expressed in germinal centre B- and T- cells and is required for germinal centre formation and Th-2 mediated antibody affinity maturation. Bcl-6 may also play a role in the regulation of apoptosis. The bcl-6 gene is located on chromosome 3q27, a region which undergoes a high frequency of translocation events. Such chromosomal translocations can result in aberrant forms of bcl-6, which are strongly implicated in the pathogenesis of several types of lymphoma, and have also been reported in acute lymphoblastic leukaemia and post-transplant lymphoproliferative disorders. The oligonucleotides of the invention are useful for diagnosis, prevention and treatment of conditions associated with aberrant forms of bcl-6, such as lymphomas, acute lymphoblastic leukaemia and post-transplant lymphoproliferative disorders

Sequence 20 BP; 8 A; 3 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 2.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1902 CACTTTGTAATTTGTA 1919
|||||
Db 3 CACTTTGTAATTTGTA 20

RESULT 31
ADFI3662
ID ADFI3662 standard; DNA; 22 BP.
XX
AC ADFI3662;
XX
DT 12-FEB-2004 (first entry)
XX
DE Vascular endothelial growth factor (VEGF), BaySNP 900097, PCR primer #3.
XX
KW Cardiant; antiarteriosclerotic; vasotropic; cerebroprotective;
KW hypotensive; gene therapy; human; Vascular endothelial growth factor;
KW VEGF; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003072813-A2.
XX
PD 04-SEP-2003.
XX
PF 14-FEB-2003; 2003WO-EP001514.
XX
PR 27-FEB-2002; 2002EP-00004258.
XX
PS (FARB) BAYER AG.
XX
PA Stropp U, Schwes S, Kallabis H;
XX
PI WPI; 2003-712738/67.
XX
PT New isolated polynucleotide encoded by a phenotype-associated gene,
PT useful for prognosticating statin therapy response, and diagnosing or
PT treating cardiovascular diseases, such as hypertension, myocardial
PT infarction and stroke.
XX
PS Example 1; Page 75; 182pp; English.
XX
CC The present invention relates to human phenotype-associated (PA) genes (I
CC ; ADFI3307-ADFI3386) which contain a Single Nucleotide Polymorphism
CC (SNP). The SNP is given in the sequence as a variant nucleotide. Also
CC claimed are methods for screening for agents which regulate the activity
CC of a PA gene and reagents that modulate the activity of a PA polypeptide
CC or a polynucleotide where the reagent is identified by the screening
CC methods. The methods and compositions of the present invention are useful
CC for prognosticating, diagnosing and treating cardiovascular diseases,

CC such as atherosclerosis, hypertension, restenosis, arterial inflammation,
CC myocardial infarction and stroke. The present sequence is a PCR primer,
CC used in the examples from the invention.
XX
SQ Sequence 22 BP; 5 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 1.9%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 29;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2295 GGGACCTCAGTTGCAACACA 2315
|||||
Db 1 GGGACCTCAGTTGCAACACA 21

RESULT 32
ADB43451
ID ADB43451 standard; DNA; 17 BP.
XX
AC ADB43451;
XX
XX 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #3774.
XX
KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KW primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
XX WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumors and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 473; 771pp; French.
XX
CC The invention relates to the isolation of 6327 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment
CC of viral infections or diseases characterized by development of tumours
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC Analysis of the expression of the nucleotides can be used for diagnosis
CC and/or prognosis of these diseases. The nucleotides and polypeptides can
CC also be used to screen for their specific interactive molecules,
CC potentially useful for treating diseases associated with abnormal
CC expression of the nucleotides.

```

XX SQ Sequence 17 BP; 4 A; 5 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 1.8%; Score 17; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 23;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1750 GATCTGAAGCCGACGCTG 1766
|||||
DB 1 GATCTGAAGCCGACGCTG 17

RESULT 33
ABS98265/C
ID ABS98265 standard; DNA; 21 BP.
XX
AC ABS98265;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human lactoferrin (LTF) gene polymorphic sequence #28.
XX
KW Human; da; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
KW cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW glutathione-S-transferase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW HMMT; kallikrein 2; KUK2; nicotinamide-N-methyl transferase; NNMT;
KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW multidrug resistance associated protein 3; cancer; prostate;
KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW altered drug metabolism; cardiovascular function; colorectal tumour;
KW central nervous system; pulmonary; immunological; SNP;
KW single nucleotide polymorphism.
XX
OS Homo sapiens.
XX
FN WO200257410-A2.
XX
PD 25-JUL-2002.
XX
PF 28-NOV-2001; 2001WO-US044838.
XX
PR 28-NOV-2000; 2000US-00724389.
XX
PA (DNAS-) DNA SCI LAB INC.
XX
PI Guida M, Hall J;
XX
XX WPI; 2002-698522/75.
XX
XX Isolated nucleic acid molecules having polymorphisms in known human genes
XX e.g. cytochrome P450 and cathepsin S useful as genetic linkage markers
XX for locating, identifying and characterizing the genes responsible for
XX disorder-related traits.
XX
XX Example 23; Page 148; 714pp; English.
XX
XX This invention relates to the sequence of an isolated nucleic acid
XX molecule comprising at least one base variation from that of a known
XX human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
XX cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),
XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
XX (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
XX inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase activating
XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
XX transferase (NNMT), (kallikrein 2) KUK2, nicotinamide -N-methyl
XX transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),

```

```

CC sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
CC (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
CC transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance 1
CC (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
CC (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
CC receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
CC The polymorphisms in the human genes cited in the invention are useful as
CC genetic linkage markers for locating and characterizing the genes that
CC are responsible for specific traits within the genome and eventually
CC identifying the genes responsible for a variety of disorder-related
CC traits as a result of their e.g., overexpression, constitutive
CC expression, mutation or underexpression, which may be used in diagnosing
CC and/or treating the disorders. The nucleic acid molecules comprising the
CC polymorphic sequences contained in CYP4501A1, CYP4501A2, CYP4502E1,
CC ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
CC MDR1 and/or MDR3 are useful for screening individuals for altered drug
CC metabolism. The polymorphic sequences contained in CYP4501A1, CYP4501A2,
CC AHR, MDR1 and/or MDR3 may also be used to screen individuals for
CC susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
CC used to screen for altered cardiovascular function, in COX2 for altered
CC susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
CC nervous system function, in FLAP and NNMT for altered pulmonary,
CC immunological or haematological function, in KUK2 for altered serine
CC protease activity in the prostate, in LTF for altered immunological or
CC haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC peripheral nervous system function. The present sequence represents a
CC polymorphic DNA sequence of the invention
XX
SQ Sequence 21 BP; 5 A; 11 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 1.8%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 37;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1718 AGCCTGGGCTGATGTAGG 1737
|||||
DB 21 AGCCTGGGCTGATGTAGG 2

RESULT 34
ADC05059/C
ID ADC05059 standard; DNA; 17 BP.
XX
AC ADC05059;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1506.
XX
KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHEP1; passive replacement therapy; vaccine; diagnosis.
XX
OS Homo sapiens.
XX
FN EP1273660-A2.
XX
PD 08-JAN-2003.
XX
PF 25-JAN-2002; 2002EP-00001160.
XX
PR 30-JAN-2001; 2001WO-US000666.
XX
PR 23-MAY-2001; 2001US-00864761.
XX
PR 21-DEC-2001; 2001US-0343331P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Gu Y;
XX
XX WPI; 2003-302724/30.
XX
XX New human sodium-hydrogen exchanger like protein 1 (NHEP1), useful as a
XX passive replacement therapy or as a vaccine for treating or preventing
XX disorders associated with aberrant expression or activity of human

```

PT NHELP1.
 XX
 PS Example 2; SEQ ID NO 1546; 468pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHELP1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHELP1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 16; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. NO. 32;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1745 ACTCTGATCTGAAGCC 1760
 Db 16 ACTCTGATCTGAAGCC 1
 RESULT 35
 ADC05058/c
 ID ADC05058 standard; DNA; 17 BP.
 XX
 AC ADC05058;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1505.
 XX
 KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHELP1; passive replacement therapy; vaccine; diagnosis.
 XX
 OS Homo sapiens.
 XX
 DN EP1273660-A2.
 XX
 PD 08-JAN-2003.
 XX
 PF 25-JAN-2002; 2002EP-00001160.
 XX
 PR 30-JAN-2001; 2001WO-US000666.
 PR 23-MAY-2001; 2001US-00864761.
 PR 21-DEC-2001; 2001US-0343331P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y;
 XX
 DR WPI; 2003-302724/30.
 XX
 PT New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHELP1.
 XX
 PS Example 2; SEQ ID NO 1545; 468pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with

CC decreased expression or activity of human NHELP1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHELP1. The NHELP1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHELP1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 16; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. NO. 32;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1745 ACTCTGATCTGAAGCC 1760
 Db 17 ACTCTGATCTGAAGCC 2
 RESULT 36
 AAZ77372
 ID AAZ77372 standard; DNA; 19 BP.
 XX
 AC AAZ77372;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker downstream amplification primer SEQ ID NO:11728.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB000822.
 XX
 PR 21-APR-1999; 98US-0082614P.
 PR 23-NOV-1998; 98US-0109732P.
 XX
 PA (GEST) GENSET.
 XX
 PI Cohen D, Blumenfeld M, Chumakov I;
 XX
 DR WPI; 2000-013267/01.
 XX
 PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.
 XX
 PS Claim 9; Page 2731; 2745pp; English.
 XX
 CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention

SQ Sequence 19 BP; 9 A; 5 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 1.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 43;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2146 GACCTAATCCAGTGAACC 2164
||| ||||| ||||| |||||
Db 1 GAACAAATCCAGTGAACC 19

RESULT 37

ADF36507

ID ADF36507 standard; RNA; 19 BP.

XX

AC ADF36507;

XX

DT 12-FEB-2004 (first entry)

XX

DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:796.

XX

XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytosolic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO2003070910-A2.

XX

PD 28-AUG-2003.

XX

PF 20-FEB-2003; 2003WO-US005022.

XX

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 29-MAY-2002; 2002WO-US017674.

PR 06-JUN-2002; 2002US-0386782P.

PR 03-JUL-2002; 2002US-0393796P.

PR 29-JUL-2002; 2002US-0399348P.

PR 05-SEP-2002; 2002US-0408378P.

PR 29-AUG-2002; 2002US-0406784P.

PR 09-SEP-2002; 2002US-0409293P.

PR 04-NOV-2002; 2002US-00287949.

PR 27-NOV-2002; 2002US-00306747.

PR 15-JAN-2003; 2003US-0440129P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Mcswiggen J, Beigelman L, Pavco P;

XX

XX WPI; 2003-679876/64.

XX

DR New double-stranded interfering nucleic acid, useful e.g. for treatment and diagnosis of cancer, downregulates the vascular endothelial growth factor receptor gene.

PT

PT

XX

PS Example 3; SEQ ID NO 796; 207pp; English.

XX

CC The present invention describes a double-stranded short interfering nucleic acid (siNA) that downregulates expression of the vascular endothelial growth factor receptor (VEGFR) gene. Also described: (1) a siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors that express siNA; and (5) single-stranded siNA with similar properties. CC The siNA have antiangiogenic, cytosolic, antidiabetic, ophthalmological, antiarthritic, antipsoriatic, nephrotropic and gynaecological activities. The siNA are useful for modulating

CC

CC (downregulating) the expression of VEGFR genes. The siNA are potentially useful for treating a wide range of angiogenesis-associated conditions, particularly cancers, diabetic retinopathy, macular degeneration, neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma, and polycystic kidney disease. The siNA may also be useful for diagnosis, drug screening, target identification and validation, genetic engineering, studying gene function, and also for gene mapping (e.g. of single-nucleotide polymorphisms). The present sequence is used in the exemplification of the present invention.

XX

SQ Sequence 19 BP; 8 A; 3 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 1.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 43;
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1893 ATATACAGCACTTTGTAA 1911
|: ||||| |||||::|:
Db 1 AUGAACAGCACUUGUAA 19

RESULT 38

ADF36080/C

ID ADF36080 standard; RNA; 19 BP.

XX

AC ADF36080;

XX

DT 12-FEB-2004 (first entry)

XX

DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:369.

XX

XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytosolic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO2003070910-A2.

XX

PD 28-AUG-2003.

XX

PF 20-FEB-2003; 2003WO-US005022.

XX

PR 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 29-MAY-2002; 2002WO-US017674.

PR 06-JUN-2002; 2002US-0386782P.

PR 03-JUL-2002; 2002US-0393796P.

PR 29-JUL-2002; 2002US-0399348P.

PR 05-SEP-2002; 2002US-0408378P.

PR 29-AUG-2002; 2002US-0406784P.

PR 09-SEP-2002; 2002US-0409293P.

PR 04-NOV-2002; 2002US-00287949.

PR 27-NOV-2002; 2002US-00306747.

PR 15-JAN-2003; 2003US-0440129P.

XX

PA (RIBO-) RIBOZYME PHARM INC.

XX

PI Mcswiggen J, Beigelman L, Pavco P;

XX

XX WPI; 2003-679876/64.

XX

DR New double-stranded interfering nucleic acid, useful e.g. for treatment and diagnosis of cancer, downregulates the vascular endothelial growth factor receptor gene.

PT

PT

XX

PS Example 3; SEQ ID NO 369; 207pp; English.

XX

XX The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiodioma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX Sequence 19 BP; 5 A; 3 C; 3 G; 0 T; 8 U; 0 Other;
 SQ

Query Match 1.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 43;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1893 ATATACAGCAGCTTTGTAA 1911
 Db 19 ATGACAGCAGCTTTGTAA 1

RESULT 39
 ADR77901
 ID ADR77901 standard; DNA; 19 BP.
 XX
 AC ADR77901;
 XX
 DT 16-DEC-2004 (first entry)
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 2386.
 XX
 KW antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; musculla; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465655P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.

PR 07-NOV-2003; 2003US-0518453P.
 PA (ALNY-) ALNYLAM PHARM.
 XX
 PI Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 DR
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 PS
 XX Example 5; SEQ ID NO 2386; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 1.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 43;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1575 ACTTCAAAATATAAAAT 1593
 Db 1 ACTTAAATAATATAAAAT 19

RESULT 40
 ADR77863
 ID ADR77863 standard; DNA; 19 BP.
 XX
 AC ADR77863;
 XX
 DT 16-DEC-2004 (first entry)
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 2348.
 XX
 KW antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; musculla; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

XX OS Homo sapiens.
 XX PN WO2004080406-A2.
 XX PD 23-SEP-2004.
 XX PF 08-MAR-2004; 2004WO-US0007070.
 XX PR 07-MAR-2003; 2003US-0452682P.
 XX PR 12-MAR-2003; 2003US-0454265P.
 XX PR 13-MAR-2003; 2003US-0454962P.
 XX PR 13-MAR-2003; 2003US-0455050P.
 XX PR 14-APR-2003; 2003US-0462894P.
 XX PR 17-APR-2003; 2003US-0463772P.
 XX PR 25-APR-2003; 2003US-0465665P.
 XX PR 25-APR-2003; 2003US-0465802P.
 XX PR 09-MAY-2003; 2003US-0469612P.
 XX PR 08-AUG-2003; 2003US-0493986P.
 XX PR 11-AUG-2003; 2003US-0494597P.
 XX PR 26-SEP-2003; 2003US-0506341P.
 XX PR 09-OCT-2003; 2003US-0510246P.
 XX PR 10-OCT-2003; 2003US-0510318P.
 XX PR 07-NOV-2003; 2003US-0518453P.
 XX PA (ALNY-) ALNYLAM PHARM.
 XX PI Manoharan M, Bumcrot D;
 XX DR WPI; 2004-677362/66.
 XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 2348; 378pp; English.
 XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX SQ Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 SQ Query Match 1.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred.No.43;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1575 ACTTCAAAAATATAAAAAT 1593

Db 1 ACTTCAAAAATATAAAAAT 19
 RESULT 41
 ADR80521
 ID ADR80521 standard; DNA; 19 BP.
 XX AC ADR80521;
 XX DT 16-DEC-2004 (first entry)
 XX DE Human apolipoprotein B (ApoB) oligonucleotide segid 5018.
 XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apob; ss.
 OS Homo sapiens.
 XX WO2004080406-A2.
 XX PD 23-SEP-2004.
 XX PF 08-MAR-2004; 2004WO-US0007070.
 XX PR 07-MAR-2003; 2003US-0452682P.
 XX PR 12-MAR-2003; 2003US-0454265P.
 XX PR 13-MAR-2003; 2003US-0454962P.
 XX PR 13-MAR-2003; 2003US-0455050P.
 XX PR 14-APR-2003; 2003US-0462894P.
 XX PR 17-APR-2003; 2003US-0463772P.
 XX PR 25-APR-2003; 2003US-0465665P.
 XX PR 25-APR-2003; 2003US-0465802P.
 XX PR 09-MAY-2003; 2003US-0469612P.
 XX PR 08-AUG-2003; 2003US-0493986P.
 XX PR 11-AUG-2003; 2003US-0494597P.
 XX PR 26-SEP-2003; 2003US-0506341P.
 XX PR 09-OCT-2003; 2003US-0510246P.
 XX PR 10-OCT-2003; 2003US-0510318P.
 XX PR 07-NOV-2003; 2003US-0518453P.
 XX PA (ALNY-) ALNYLAM PHARM.
 XX PI Manoharan M, Bumcrot D;
 XX DR WPI; 2004-677362/66.
 XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 5018; 378pp; English.
 XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.

CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 43;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1575 ACTTCCAAATATATAAAAT 1593
 Db 1 ACTTAAATAATATAAAAT 19
 RESULT 42
 ADR80559
 ID ADR80559 standard; DNA; 19 BP.
 XX
 AC ADR80559;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human apolipoprotein B (ApoB) oligonucleotide seqid 5056.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 XX (ALNY-) ALNYLAM PHARM.

PI Manoharan M, Bumcrot D;
 XX
 DR WPI; 2004-677362/66.
 XX
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 PS Example 5; SEQ ID NO 5056; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
 CC can be used to control ApoB gene expression.
 XX
 SQ Sequence 19 BP; 13 A; 1 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 1.7%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 43;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1575 ACTTCCAAATATATAAAAT 1593
 Db 1 ACTTAAATAATATAAAAT 19
 RESULT 43
 ADR80559/C
 ID ADR80559 standard; DNA; 17 BP.
 XX
 AC ADR80559;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1503.
 XX
 KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHEPL1; passive replacement therapy; vaccine; diagnosis.
 XX
 OS Homo sapiens.
 XX
 PN EP1273660-A2.
 XX
 PD 08-JAN-2003.
 XX
 PF 25-JAN-2002; 2002EP-00001160.
 XX
 PR 30-JAN-2001; 2001WO-US000666.
 PR 23-MAY-2001; 2001US-00864761.

PR 21-DEC-2001; 2001US-0343331P.
 XX (AEOM-) AEOMICA INC.
 PA Gu Y;
 XX WPI; 2003-302724/30.
 DR New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
 XX passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHEPL1.
 PT
 XX Example 2; SEQ ID NO 1543; 468pp; English.
 PS
 XX The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHEPL1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHEPL1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

 Query Match 1.7%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 39;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 QY 1747 TCTGATCTGAAGCCAG 1763
 |||||
 DB 17 TCTGATCTGAAGCCAG 1

 RESULT 44
 ADC05057/C
 ID ADC05057 standard; DNA; 17 BP.
 XX
 AC ADC05057;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1504.
 XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHEPL1; passive replacement therapy; vaccine; diagnosis.
 XX
 OS Homo sapiens.
 XX
 PN EP1273660-A2.
 XX
 PD 08-JAN-2003.
 XX
 PF 25-JAN-2002; 2002EP-00001160.
 XX
 PR 30-JAN-2001; 2001WO-US000666.
 XX
 PR 23-MAY-2001; 2001US-00864761.
 XX
 PR 21-DEC-2001; 2001US-0343331P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y;
 XX WPI; 2003-302724/30.
 DR
 XX New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHEPL1.

PT disorders associated with aberrant expression or activity of human
 XX NHEPL1.
 XX Example 2; SEQ ID NO 1544; 468pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHEPL1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHEPL1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

 Query Match 1.7%; Score 15.4; DB 1; Length 17;
 Best Local Similarity 94.1%; Pred. No. 39;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

 QY 1746 CTCTGATCTGAAGCCCA 1762
 |||||
 DB 17 CTCTGATCTGAAGCCCA 1

 RESULT 45
 AD015165/C
 ID AD015165 standard; RNA; 19 BP.
 XX
 AC AD015165;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human PDGFR-targeted siRNA lower strand SEQ ID NO:596.
 XX
 KW cytosolic; vasotropic; nephrotropic; cerebroprotective;
 KW treating leukaemia; solid tumors; restenosis; polycystic kidney disease;
 KW bronchiolitis; glomerulonephritis; stroke; RNA interference;
 KW short interfering nucleic acid; siRNA; short interfering RNA; siRNA;
 KW double-stranded RNA; micro-RNA; siRNA; short hairpin RNA; shRNA;
 KW expression modulation; gene therapy; drug screening; diagnosis;
 KW therapeutic target identification; pharmacogenomics;
 KW gene function analysis; gene mapping; human;
 KW platelet derived growth factor receptor; PDGFR; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003072704-A2.
 XX
 PD 04-SEP-2003.
 XX
 PF 05-FEB-2003; 2003WO-US003473.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 XX
 PR 11-MAR-2002; 2002US-0363124P.
 XX
 PR 06-JUN-2002; 2002US-0386782P.
 XX
 PR 29-AUG-2002; 2002US-0406784P.
 XX
 PR 09-SEP-2002; 2002US-0408378P.
 XX
 PR 09-SEP-2002; 2002US-0409293P.
 XX
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Beigelman L, Chowrira B;
 XX WPI; 2003-731605/69.
 DR
 XX New short interfering nucleic acid, useful e.g. for treatment and

diagnosis of tumors, downregulates expression of the platelet-derived growth factor receptor gene.

Example 3; SEQ ID NO 596; 148pp; English.

The invention relates to short interfering nucleic acids (siNA) which downregulate expression of the human platelet-derived growth factor receptor (PDGFR) gene by RNA interference. The siNAs may or may not comprise ribonucleotides and may be double or single stranded. They further comprise sense and antisense regions, or alternatively are assembled from a sense oligonucleotide and an antisense oligonucleotide. Specifically, the siNAs include short interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified, can contain deoxyribonucleotides, and can be chemically synthesised, expressed from a vector or enzymatically synthesised. The invention also relates to kits for the *in vitro* or *in vivo* delivery of siRNA; conjugates and/or complexes of siRNA; and vectors that express siNA. The siNAs are used to modulate expression of the PDGFR gene in cells, tissue explants or organisms (e.g., by *ex vivo* gene therapy), or in grafts and transplants for the treatment of a variety of conditions. They may be used for treating leukaemia and solid tumours, restenosis, polycystic kidney disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also useful for drug screening, diagnosis, therapeutic target identification and validation, genetic engineering, pharmacogenomics, studying gene function, and gene mapping (e.g., of single nucleotide polymorphisms). The present sequence represents the lower strand of a human PDGFR-targeted double-stranded siNA, which is identical to the PDGFR transcript target sequence.

Sequence 19 BP; 2 A; 8 C; 2 G; 0 T; 7 U; 0 Other;
 1.7%; Score 15.4; DB 1; Length 19;
 Every Match

2197 AAGAAGTATGTGAGAGG 2213
 |||||
 17 AAGAAGGATGTGAGAGG 1

LT 46
4854
ADOL4854 standard; RNA: 19 BP.

ADO14854:

01-III.-2004 (first entry)

Human pNGFr-targeted siNA upper strand SEQ ID NO:285.

cytostatic; vasotropic; nephrotropic; cerebroprotective; treating leukaemia; solid tumors; restenosis; polycystic kidney disease; bronchitis; glomerulonephritis; stroke; RNA interference; short interfering nucleic acid; siRNA; short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA; expression modulation; gene therapy; drug screening; diagnosis; therapeutic target identification; pharmacogenomics; gene function analysis; gene mapping; human; platelet derived growth factor receptor; PDGFR; ss.

Homo sapiens

WQ3003072704-A2

04-SEP-2003

05 SEP 2003: 2003W0115002473

00

11-MAR-2002; 2002US-0363124P.

29-AUG-2002; 2002US-0406784P.

05-SEP-2002; 2002US-0408378P.
09-SEP-2002; 2002US-0409293P.
15-JAN-2003; 2003US-0440129P.

(RIBO-) RIBOZYME PHARM INC.

Mcswiggen J. Beigelman L. Chowrira B:

WPT: 2003-731605/69.

New short interfering nucleic acid, useful e.g. for treatment and diagnosis of tumors, downregulates expression of the platelet-derived growth factor receptor gene

Examined 2. SEC IN NO 285. 148pp. Encl 18b

The invention relates to short interfering nucleic acids (siNA) which downregulate expression of the human platelet-derived growth factor receptor (PDGFR) gene by RNA interference. The siNAs may or may not comprise ribonucleotides and may be double or single stranded. They further comprise sense and antisense regions, or alternatively are assembled from a sense oligonucleotide and an antisense oligonucleotide. Specifically, the siNAs include short interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified, can contain deoxyribonucleotides, and can be chemically synthesised, expressed from a vector or enzymatically synthesised. The invention also relates to kits for the *in vitro* or *in vivo* delivery of siRNA; conjugates and/or complexes of siNA; and vectors that express siNA. The siNAs are used to modulate expression of the PDGFR gene in cells, tissue explants or organisms (e.g., by *ex vivo* gene therapy), or in grafts and transplants for the treatment of a variety of conditions. They may be used for treating leukaemia and solid tumours, restenosis, polycystic kidney disease, bronchiolitis, glomerulonephritis and stroke. The siNAs are also useful for drug screening, diagnosis, therapeutic target identification and validation, genetic engineering, pharmacogenomics, studying gene function, and gene mapping (e.g., of single nucleotide polymorphisms). The present sequence represents the upper strand of a human PDGFR-targeted double-stranded siNA, which is identical to the PDGFR transcript target sequence.

Sequence 19 BP: 7 A; 2 C; 8 G; 0 T; 2 U; 0 Other;

Very Match 1.7%; Score 15.4; DB 1; Length 19;
 1st Local Similarity 82.4%; Pred. No. 48;
 Mismatches 2: Mismatches 1: Indels
 14: Conservative

2197 AAGAAGTATGTGACAGC 2213

3 AACAGCGATTCGACGG 19

47

5060/c

ADC05060 standard; DNA; 17 BP.

ADC05060;

18-DEC-2003 (first entry)

Human Na/H exchanger-like protein 1 gene oligonucleotide #1507.

ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein; NHEP1; passive replacement therapy; vaccine; diagnosis.

Homo sapiens.

FD-1273660-A2

08-JAN-2003

25--JAN-2002: 2002EP-00001160

```

PR 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX (AEOM-) AEOMICA INC.
XX Gu Y;
XX WPI; 2003-302724/30.
XX New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
XX passive replacement therapy or as a vaccine for treating or preventing
XX disorders associated with aberrant expression or activity of human
XX NHELP1.
XX Example 2; SEQ ID NO 1547; 468pp; English.
XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
XX exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
XX polypeptide, an antibody against the protein or its antigen-binding
XX fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
XX polypeptide and an agonist are particularly useful for manufacturing a
XX medicament for treating or preventing a disorder associated with
XX decreased expression or activity of human NHELP1. The antibody or its
XX antigen-binding fragment, and an antagonist, are useful for manufacturing
XX a medicament for treating or preventing a disorder associated with
XX increased expression or activity of human NHELP1. The NHELP1 nucleic acid
XX or protein is useful as passive replacement therapy, as a vaccine, or in
XX diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
XX spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1745 ACTCTGATCTGAAGC 1759
DB 15 ACTCTGATCTGAAGC 1

RESULT 48
ABL45402
ID ABL45402 standard; DNA; 18 BP.
XX
AC ABL45402;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 21q22.1 PCR primer SEQ ID NO:2446.
XX
KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
XX
OS Homo sapiens.
XX
PN JP2001321190-A.
XX
PD 20-NOV-2001.
XX
PF 12-MAR-2001; 2001JP-00068285.
XX
PR 10-MAR-2000; 2000JP-00066716.
XX
PA (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
XX
XX WPI; 2002-144136/19.
XX
XX Arraying genome clones.
PT
XX Claim 6; Page 53; 528pp; Japanese.
PS

```

The present invention describes a method of arraying genome clones. The method comprises: (a) clones of the genomic libraries contained in multiwell plates numbered for discrimination are mixed in each of the multiwell plates; (b) a primer designed based on the chromosome marker sequence is added to the mixture to carry out an amplification reaction; (c) a signal corresponding to the marker is detected from the resultant amplified product to specify the discrimination Nos. of the multiwell plates containing the clones having said marker sequence; (d) the order of the markers is changed so that the same discrimination Nos. succeed to the maximum in the specified discrimination Nos. to array the multiwell plates; (e) the clones in the multiwell plates of the specified discrimination Nos. are mixed respectively in each wells of longitudinal and lateral directions; (f) the mixed clones are cultured and the resultant cultures are amplified by using the above primer; (g) signals are detected from the amplified products; (h) the clones in the multiwell plates are specified from the detected result; and (i) the clones are reconstituted as the positions on the chromosome and arrayed. The microarray is useful for gene analysis. ABL42957 to ABL45322 represent PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634 represent PCR primers for human chromosome 21q22.1, which are specifically claimed for use in the present invention

Sequence 18 BP; 7 A; 5 C; 1 G; 5 T; 0 U; 0 Other;

```

Query Match 1.6%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1955 AAAATCCTATTAGTC 1969
DB 4 AAAATCCTATTAGTC 18

RESULT 49
ADH36295/c
ID ADH36295 standard; DNA; 18 BP.
XX
AC ADH36295;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human purinergic receptor P2X4-related PCR primer 71.
XX
KW fat deposition; leanness; non-insulin dependent diabetes mellitus; NIDDM;
KW purinergic receptor; P2X4; antidiabetic; anorectic; diabetes; obesity;
KW human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003101177-A2.
XX
PD 11-DEC-2003.
XX
PF 04-JUN-2003; 2003WO-US017676.
XX
PR 04-JUN-2002; 2002US-0386012P.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Adam GIR, Langdown ML, Roth RB, Denissenko MF, Smylie KJ;
XX WPI; 2004-053318/05.
XX
DR Diagnosing predisposition to fat deposition, leanness or non-insulin
PT dependent diabetes mellitus (NIDDM) comprises detecting the presence or
PT absence of a polymorphic variation in a purinergic receptor.
XX
XX Example 3; Page 70; 154pp; English.
PS
XX This invention relates to a novel method of diagnosing a predisposition
XX to fat deposition, leanness or non-insulin dependent diabetes mellitus
XX (NIDDM) in a subject. The method comprises detecting the presence or
CC

```

CC absence of a polymorphic variation associated with fat deposition,
 CC leanness or NIDDM at a polymorphic site in a purinergic receptor (P2X4)
 CC nucleotide sequence in a nucleic acid sample from a subject. The
 CC invention may be useful for the development of compounds with an
 CC antidiabetic or anorectic activity. The method is useful for diagnosing a
 CC prediabetic or anorectic condition, leanness or NIDDM. The nucleic acid
 CC encoding the polypeptide is useful for diagnosing conditions or diseases
 CC including fat deposition or NIDDM, also in treating diabetes and obesity.
 CC The present sequence is that of a PCR primer which was used for
 CC amplification of a region of the human purinergic receptor (P2X4) gene
 CC sequence in the exemplification of the invention.
 XX
 SQ Sequence 18 BP; 3 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 1.6%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 53;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2374 TGATACACACAGCTGGG 2391
 DB 18 TTAATACACAGCTGGG 1
 RESULT 50
 ADB43841
 ID ADB43841 standard; DNA; 17 BP.
 XX
 AC ADB43841;
 XX
 DT 18-DEC-2003 (revised)
 DT 04-DEC-2003 (first entry)
 XX
 DE Tumour suppression/reversion associated nucleotide #4164.
 XX
 KW cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
 KW primer; probe; tumour suppression; tumour reversion; apoptosis;
 KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
 KW diagnosis.
 XX
 OS Homo sapiens.
 XX
 PN WO2003040369-A2.
 XX
 PD 15-MAY-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004219.
 XX
 PR 17-SEP-2001; 2001FR-00011981.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Anson R, Tuijnder M;
 XX
 DR WPI; 2003-441574/41.
 XX
 XX New nucleic acid encoding human prostate membrane-specific antigen,
 PT useful e.g. for treatment of tumors and viral infection, also related
 PT polypeptide and antibodies.
 XX
 XX Disclosure; Page 518; 771pp; French.
 XX
 CC The invention relates to the isolation of 6327 nucleotide sequences,
 CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
 CC sequence having at least 80% identity, after optimal alignment, with the
 CC nucleotides, a sequence that hybridizes under stringent conditions with
 CC the nucleotides, or the complement, or corresponding RNA, of the
 CC nucleotides. The nucleotides are used as probes or primers for detecting,
 CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
 CC sense and antisense sequences, of nucleotides involved in tumour
 CC suppression or reversion, apoptosis and or viral resistance, to produce
 CC recombinant polypeptides, and to prepare transgenic animals, as
 CC experimental models. The nucleotides (also vectors containing them and
 CC cells containing the vectors), the encoded polypeptides and antibodies

CC (Ab) against the polypeptide are useful for prevention and/or treatment
 CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 1.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 54;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1750 GATCTGAAGCCAGCT 1765
 DB 1 GATCTGAAGCCAGGT 16
 RESULT 51
 ADC05055/c
 ID ADC05055 standard; DNA; 17 BP.
 XX
 AC ADC05055;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human Na/H exchanger-like protein 1 gene oligonucleotide #1502.
 XX
 KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHEP1; passive replacement therapy; vaccine; diagnosis.
 XX
 OS Homo sapiens.
 XX
 PN EP1273660-A2.
 XX
 PD 08-JAN-2003.
 XX
 PF 25-JAN-2002; 2002EP-00001160.
 XX
 PR 30-JAN-2001; 2001WO-US000666.
 PR 23-MAY-2001; 2001US-00864761.
 PR 21-DEC-2001; 2001US-0343331P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y;
 XX
 DR WPI; 2003-302724/30.
 XX
 PT New human sodium-hydrogen exchanger like protein 1 (NHEP1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHEP1.
 XX
 PS Example 2; SEQ ID NO 1542; 468pp; English.
 XX
 CC The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHEP1). The NHEP1 nucleic acid molecule, NHEP1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHEP1 nucleic acid molecule, NHEP1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHEP1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing
 CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHEP1. The NHEP1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHEP1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

	Query Match	1.6%; Score 14.4; DB 1; Length 17;	
	Best Local Similarity	93.8%; Pred. No. 54;	
	Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1748 CTGATCTGAAGCCAG 1763		
DB	17 CTGATCTGAAGCCAG 2		
RESULT 52			
ID	ADB44962		
ID	ADB44962 standard; DNA; 17 BP.		
XX	AC ADB44962;		
XX	DT 18-DEC-2003 (first entry)		
DE	Tumour suppression/reversion associated nucleotide #5285.		
KW	Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;		
KW	primer; probe; tumour suppression; tumour reversion; apoptosis;		
KW	virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;		
KW	diagnosis.		
OS	Homo sapiens.		
PN	WO2003040369-A2.		
PD	15-MAY-2003.		
Pf	17-SEP-2002; 2002WO-IB004219.		
PR	17-SEP-2001; 2001FR-00011981.		
PA	(MOLE-) MOLECULAR ENGINES LAB.		
PI	Telerman A, Amson R, Tuijnder M;		
DR	WPI; 2003-441574/41.		
PT	New nucleic acid encoding human prostate membrane-specific antigen,		
PT	useful e.g. for treatment of tumors and viral infection, also related		
PT	polypeptide and antibodies.		
PS	Disclosure; Page 649; 71pp; French.		
XX	This invention relates to the isolation of 6327 nucleotide sequences,		
CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a		
CC	sequence having at least 80% identity, after optimal alignment, with the		
CC	nucleotides, a sequence that hybridizes under stringent conditions with		
CC	the nucleotides, or the complement, or corresponding RNA, of the		
CC	nucleotides. The nucleotides are used as probes or primers for detecting,		
CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro		
CC	sense and antisense sequences, of nucleotides involved in tumour		
CC	suppression or reversion, apoptosis and/or viral resistance, to produce		
CC	recombinant polypeptides, and to prepare transgenic animals, as		
CC	experimental models. The nucleotides (also vectors containing them and		
CC	cells containing the vectors), the encoded polypeptides and antibodies		
CC	(Ab) against the polypeptide are useful for prevention and/or treatment		
CC	of viral infections or diseases characterized by development of tumours		
CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).		
CC	Analysis of the expression of the nucleotides can be used for diagnosis		
CC	and/or prognosis of these diseases. The nucleotides and polypeptides can		
CC	also be used to screen for their specific interactive molecules,		
CC	potentially useful for treating diseases associated with abnormal		
CC	expression of the nucleotides.		
XX	Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;		
SQ	Query Match	1.6%; Score 14.4; DB 1; Length 17;	
	Best Local Similarity	93.8%; Pred. No. 54;	
	Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1750 GATCTGAAGCCAGCT 1765		
DB	1 GATCTTAAGCCAGCT 16		
RESULT 53			
ID	AD147575/C		
ID	AD147575 standard; DNA; 17 BP.		
XX	AC AD147575;		
XX	DT 15-APR-2004 (first entry)		
DE	Human tumour suppression/reversion-related DNA sequence SeqID78.		
XX	tumour suppression; tumour reversion; apoptosis; virus resistance;		
KW	Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; probe;		
KW	primer; PCR; gene chip; antisense; viral disease; tumour;		
KW	cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.		
OS	Homo sapiens.		
XX	WO2003025177-A2.		
XX	27-MAR-2003.		
PF	17-SEP-2002; 2002WO-IB004523.		
XX	17-SEP-2001; 2001FR-00011980.		
PA	(MOLE-) MOLECULAR ENGINES LAB.		
PI	Telerman A, Amson R, Tuijnder M;		
DR	WPI; 2003-313354/30.		
PT	New isolated nucleic acid, useful for treating viral diseases associated		
PT	with tumors and cell degeneration, also related polypeptides, antibodies		
PT	and transfected cells.		
PS	Disclosure; SEQ ID NO 78; 30pp; French.		
XX	This invention relates to novel isolated nucleic acid sequences involved		
CC	in the phenomena of tumour suppression, tumour reversion, apoptosis		
CC	and/or resistance to viruses. The invention may be useful for the		
CC	development of compounds with a cytostatic, virucide, neuroprotective,		
CC	nootropic or neuroleptic activity. The DNA sequences may be useful as		
CC	probes and primers for detecting, identifying, quantifying and/or		
CC	amplifying nucleic acid, for example as one component of a gene chip, in		
CC	vitro as antisense reagents and for production of recombinant		
CC	polypeptides. The invention may therefore be useful for preparation of		
CC	pharmaceuticals for prevention and/or treatment of viral diseases that		
CC	are characterised by development of tumours or cell degeneration,		
CC	specifically cancer but also Alzheimer's disease and schizophrenia. The		
CC	present sequence is that of a nucleic acid sequence of the invention.		
CC	Note: The sequence data for this patent did not form part of the printed		
CC	specification, but was obtained in electronic format directly from WIPO		
CC	at ftp.wipo.int/pub/publishedpct_sequences		
XX	Sequence 17 BP; 6 A; 2 C; 3 G; 6 T; 0 U; 0 Other;		
SQ	Query Match	1.6%; Score 14.4; DB 1; Length 17;	
	Best Local Similarity	93.8%; Pred. No. 54;	
	Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	2016 AATATCCCTTGATGAT 2031		
DB	17 AATATCCCTTGATGAT 2		
RESULT 54			
ID	ADI47517/c		

AD147517 standard; DNA; 17 BP.
 AD147517;
 15-APR-2004 (first entry)
 Human tumour suppression/reversion-related DNA sequence SeqID20.
 tumour suppression; tumour reversion; apoptosis; virus resistance;
 cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
 primer; PCR; gene chip; antisense; viral disease; tumour;
 cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
 Homo sapiens.
 WO2003025177-A2.
 27-MAR-2003.
 17-SEP-2002; 2002WO-IB004523.
 17-SEP-2001; 2001FR-00011980.
 (MOLE-) MOLECULAR ENGINES LAB.
 Telerman A, Anson R, Tuijnder M;
 WPI; 2003-313354/30.
 New isolated nucleic acid, useful for treating viral diseases associated
 with tumors and cell degeneration, also related polypeptides, antibodies
 and transfected cells.
 Disclosure; SEQ ID NO 20; 30pp; French.
 This invention relates to novel isolated nucleic acid sequences involved
 in the phenomena of tumour suppression, tumour reversion, apoptosis
 and/or resistance to viruses. The invention may be useful for the
 development of compounds with a cytostatic, virucide, neuroprotective,
 nontropic or neuroleptic activity. The DNA sequences may be useful as
 probes and primers for detecting, identifying, quantifying and/or
 amplifying nucleic acid, for example, as one component of a gene chip, in
 vitro as antisense reagents and for production of recombinant
 polypeptides. The invention may therefore be useful for preparation of
 pharmaceuticals for prevention and/or treatment of viral diseases that
 are characterised by development of tumours or cell degeneration. The
 specifically cancer but also Alzheimer's disease and schizophrenia. The
 present sequence is that of a nucleic acid sequence of the invention.
 Note: The sequence data for this patent did not form part of the printed
 specification, but was obtained in electronic format directly from WIPO
 at ftp.wipo.int/pub/publishedpct_sequences
 Sequence 17 BP; 4 A; 1 C; 2 G; 10 T; 0 U; 0 Other;
 Query Match 1.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 54;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1583 AATATAAAATAGAGC 1598
 Db 16 AATATAAAATAGATC 1
 RESULT 55
 AAX73192/c
 ID AAX73192 standard; RNA; 17 BP.
 AC AAX73192;
 28-JUL-1999 (first entry)
 Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #625.
 Query Match 1.6%; Score 14.4; DB 1; Length 17;
 Best Local Similarity 93.8%; Pred. No. 54;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1583 AATATAAAATAGAGC 1598
 Db 16 AATATAAAATAGATC 1
 RESULT 55
 AAX73192/c
 ID AAX73192 standard; RNA; 17 BP.
 AC AAX73192;
 28-JUL-1999 (first entry)
 Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #625.

KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 FN WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US017480.
 XX
 PR 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX
 PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 XX
 DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 XX stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX
 PS Claim 4; Page 142; 218pp; English.
 CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX57275 to AAX5752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 1 G; 0 T; 11 U; 0 Other;
 Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 62;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1870 ATGAAATCAATG 1883
 Db 14 ATGAAATCAATG 1
 RESULT 56
 AAX71637/c
 ID AAX71637 standard; RNA; 17 BP.
 XX
 AC AAX71637;
 XX
 DT 28-JUL-1999 (first entry)
 XX
 DE Human KDR VEGF receptor hammerhead ribozyme substrate #649.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX

XX 25-OCT-1996; 96WO-US017480.
 XX
 XX
 PR 26-OCT-1995; 95US-0005974P.
 PR 11-JAN-1996; 96US-00584040.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (CHIR) CHIRON CORP.
 XX
 XX Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
 XX WPI; 1997-259017/23.
 DR
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.
 XX
 XX Claim 4; Page 116; 218pp; English.
 XX
 CC The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention
 XX
 XX Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 10 U; 0 Other;
 SQ
 Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 62;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1870 ATGAAATCAAAATG 1883
 DB 14 ATGAAATCAAAATG 1
 RESULT 57
 ACC67935/c
 ID ACC67935 standard; DNA; 17 BP.
 XX
 XX AC ACC67935;
 XX
 DT 01-JUL-2003 (first entry)
 XX
 XX Murine oligonucleotide associated with tumour suppression, SEQ ID 5182.
 DE
 XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; murine;
 XX tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW viral disease; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; ss.
 XX
 XX Mus musculus.
 OS
 XX
 XX WO2003025176-A2.
 PN
 XX 27-MAR-2003.
 PD
 XX 17-SEP-2002; 2002WO-IB004210.
 PF
 XX 17-SEP-2001; 2001FR-00011979.
 PR
 XX (MOLE-) MOLECULAR ENGINES LAB.
 PA
 XX Telerman A, Amson R, Tuijnder M;
 PI WPI; 2003-333167/31.
 XX
 XX New isolated nucleic acid, useful for treating viral diseases associated

PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 XX Disclosure; Page 636; 738pp; French.
 XX
 CC The present invention relates to murine oligonucleotides (ACC62754-
 CC ACC6806), which are associated with tumour suppression, tumour
 CC reversion, apoptosis and virus resistance. The oligonucleotides are
 CC useful as (1) as probes and primers for detecting, identifying,
 CC quantifying and/or amplifying nucleic acid, e.g. as one component of a
 CC gene chip; in vitro as (anti)sense reagents; and (2) for production of
 CC recombinant polypeptides. The oligonucleotides are useful for preparation
 CC of pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia
 XX
 XX Sequence 17 BP; 3 A; 3 C; 1 G; 10 T; 0 U; 0 Other;
 SQ
 Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 62;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 2282 GGAAGAAAAAATG 2295
 DB 17 GGAAGAAAAAATG 4
 RESULT 58
 ADC05061/c
 ID ADC05061 standard; DNA; 17 BP.
 XX
 XX AC ADC05061;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 XX Human Na/H exchanger-like protein 1 gene oligonucleotide #1508.
 DE
 XX ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
 KW NHEPL1; passive replacement therapy; vaccine; diagnosis.
 XX
 XX Homo sapiens.
 OS
 XX EPI273660-A2.
 PN
 XX 08-JAN-2003.
 PD
 XX 25-JAN-2002; 2002EP-00001160.
 PF
 XX 30-JAN-2001; 2001WO-US000666.
 PR 23-MAY-2001; 2001US-00864761.
 PR 21-DEC-2001; 2001US-0343331P.
 XX
 XX (AEOM-) AEOMICA INC.
 PA
 XX Gu Y;
 PI WPI; 2003-302724/30.
 XX
 XX New human sodium-hydrogen exchanger like protein 1 (NHEPL1), useful as a
 PT passive replacement therapy or as a vaccine for treating or preventing
 PT disorders associated with aberrant expression or activity of human
 PT NHEPL1.
 XX
 XX Example 2; SEQ ID NO 1548; 468pp; English.
 PS
 XX The invention relates to a nucleic acid molecule which encodes a Na⁺/H⁺
 CC exchanger like protein (NHEPL1). The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide, an antibody against the protein or its antigen-binding
 CC fragment is useful in therapy. The NHEPL1 nucleic acid molecule, NHEPL1
 CC polypeptide and an agonist are particularly useful for manufacturing a
 CC medicament for treating or preventing a disorder associated with
 CC decreased expression or activity of human NHEPL1. The antibody or its
 CC antigen-binding fragment, and an antagonist, are useful for manufacturing

CC a medicament for treating or preventing a disorder associated with
 CC increased expression or activity of human NHEPL1. The NHEPL1 nucleic acid
 CC or protein is useful as passive replacement therapy, as a vaccine, or in
 CC diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
 CC spanning the sequence of the human NHEPL1 gene (ADC03514).
 XX
 SQ Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 62;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1745 ACTCTGATCTGAAG 1758
 Db 14 ACTCTGATCTGAAG 1

RESULT 59
 ADI47840
 ID ADI47840 standard; DNA; 17 BP.
 XX
 AC ADI47840;
 XX
 DT 15-APR-2004 (first entry)
 XX
 DE Human tumour suppression/reversion-related DNA sequence SeqID343.
 KW tumour suppression; tumour reversion; apoptosis; virus resistance;
 KW cytostatic; virucide; neuroprotective; neuroleptic; probe;
 KW primer; PCR; gene chip; antisense; viral disease; tumour;
 KW cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
 XX
 OS Homo sapiens.

WO2003025177-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB004523.
 XX
 PR 17-SEP-2001; 2001FR-00011980.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313354/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases associated
 PT with tumors and cell degeneration, also related polypeptides, antibodies
 PT and transfected cells.
 XX
 PS Disclosure; SEQ ID NO 343; 30pp; French.

XX This invention relates to novel isolated nucleic acid sequences involved
 CC in the phenomena of tumour suppression, tumour reversion, apoptosis
 CC and/or resistance to viruses. The invention may be useful for the
 CC development of compounds with a cytostatic, virucide, neuroprotective,
 CC neuroleptic or neuroleptic activity. The DNA sequences may be useful as
 CC probes and primers for detecting, identifying, quantifying and/or
 CC amplifying nucleic acid, for example as one component of a gene chip, in
 CC vitro as antisense reagents and for production of recombinant
 CC polypeptides. The invention may therefore be useful for preparation of
 CC pharmaceuticals for prevention and/or treatment of viral diseases that
 CC are characterised by development of tumours or cell degeneration,
 CC specifically cancer but also Alzheimer's disease and schizophrenia. The
 CC present sequence is that of a nucleic acid sequence of the invention.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/publishedpct_sequences
 XX
 SQ Sequence 17 BP; 7 A; 3 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 62;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1954 CAAAATCTCTATTAG 1967
 Db 4 CAAAATCTCTATTAG 17

RESULT 60
 ADL50250
 ID ADL50250 standard; RNA; 17 BP.
 XX
 AC ADL50250;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Human PKR substrate sequence #1364.

XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
 KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
 KW protein kinase PKR; cerebrovascular accident;
 KW central nervous system injury; CNS injury; spinal cord injury; cancer;
 KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
 KW restenosis; asthma; Crohn's disease; diabetes; obesity;
 KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
 KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
 KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
 KW substrate; ds.

XX Unidentified.
 OS WO200281628-A2.

PN 17-OCT-2002.
 XX
 PD 03-APR-2002; 2002WO-US010512.

XX
 PF 05-APR-2001; 2001US-00827395.
 PR 29-MAY-2001; 2001US-0294412P.
 PR 28-AUG-2001; 2001US-0315315P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.

XX Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
 PI WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite
 PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
 PT protein kinase PKR genes, for treating cancer and inflammatory disease.
 XX
 PS Claim 59; SEQ ID NO 3783; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
 CC that down regulate the expression or inhibit the function of a receptor
 CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
 CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
 CC invention are useful for treating: cerebrovascular accident, central
 CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
 CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
 CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
 CC disease, lupus, multiple sclerosis, transplant/graft rejection, and allergic
 CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
 CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
 CC nucleic acids of the invention are also useful for down-regulating the
 CC expression of a target gene and as a diagnostic tool to examine genetic
 CC drifts and mutations within diseased cells or to detect the presence of a
 CC target RNA in a cell. The present RNA sequence represents a human PKR
 CC substrate sequence.
 XX
 SQ Sequence 17 BP; 6 A; 0 C; 3 G; 0 T; 8 U; 0 Other;

DE Human Calpain I gene PCR primer, SM-37.
XX Polymerase chain reaction; recombinant calpain I; calpain inhibitor;
KW meat tenderising; thrombosis; blood clot dissolving; primer; ss.
XX Synthetic.
OS
XX WO9602634-A1.
PN
XX 01-FEB-1996.
PD
XX 06-JUL-1995; 95WO-US008487.
PF
XX 15-JUL-1994; 94US-00275683.
PR
XX (CEPH-) CEPHALON INC.
PA
XX Meyer SL, Scott RW, Siman R;
PI WPI; 1996-105900/11.
PN
XX Recombinant mammalian calpain and vectors encoding it - useful for
PT screening potential calpain inhibitors, and to tenderise meat and
PT dissolve blood clots.
XX
PS Disclosure; Page 15; 59pp; English.
XX
XX AAT12724-T12735 are PCR primers used to produce a recombinant human
CC calpain I, produced by infecting insect cells (partic. Spodoptera
CC frugiperda) with a recombinant virus (e.g. baculovirus Autographa
CC californica). Recombinant calpain can be expressed at high levels in the
CC baculovirus/insect cell system and loses no enzymatic activity. Calpain
CC produced can be used in assays to screen for potential calpain
CC inhibitors, to treat diseases in which calpain is implicated, as a meat
CC tenderiser and for dissolving blood clots
XX
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.58; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 CACTCTGATCTGAAGCC 1760
Db 1 CACCTGATCTGAAGAC 17

RESULT 64
AAT81498/c
ID AAT81498 standard; RNA; 17 BP.
XX
XX AAT81498;
AC
XX 07-DEC-1997 (first entry)
DT
XX Human c-myb hammerhead ribozyme target sequence (nt. position 2690).
DE
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
XX smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
KW
XX Homo sapiens.
OS
XX WO9531541-A2.
PN
XX 23-NOV-1995.
PD
XX 18-MAY-1995; 95WO-US006368.
PF
XX 18-MAY-1994; 94US-00245466.
PR
XX 13-JAN-1995; 95US-00373124.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA

XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
PI WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
PT
XX Claim 1; Page 76; 128pp; English.
PS
XX The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC line. The c-myb sequence was screened for optimal ribozyme target sites
CC using a computer folding algorithm, and regions of the mRNA which did not
CC form secondary folding structures and contained potential ribozyme
CC cleavage sites were identified. Ribozymes were synthesised and their
CC activities optimised by either varying the length of the binding arms or
CC by modification to prevent degradation by nucleases. The ribozymes cleave
CC the c-myb sequence and can be used to prevent smooth muscle cell
CC hyperproliferation in restenosis, especially after coronary angioplasty,
CC and in cancers
XX
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1638 CCAGTTCCTTACAGTAAT 1654
Db 17 CTATTCTTACAGTAAT 1

RESULT 65
AAT81623/c
ID AAT81623 standard; RNA; 17 BP.
XX
XX AAT81623;
AC
XX 21-DEC-1997 (first entry)
DT
XX Human c-myb hammerhead ribozyme target sequence (nt. position 3079).
DE
XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
KW coronary angioplasty; ss.
KW
XX Homo sapiens.
OS
XX WO9531541-A2.
PN
XX 23-NOV-1995.
PD
XX 18-MAY-1995; 95WO-US006368.
PF
XX 18-MAY-1994; 94US-00245466.
PR
XX 13-JAN-1995; 95US-00373124.
PR
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;
PI WPI; 1996-010927/01.
XX
XX New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
PT for treating restenosis or cancer.
PT
XX Claim 1; Page 80; 128pp; English.
PS
XX The present sequence represents the preferred target sequence for an
CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
CC the human c-myb sequence at the base position indicated in the descriptor
CC

CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers

SQ Sequence 17 BP; 4 A; 0 C; 4 G; 0 T; 9 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 66;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1574 AACTTCCAAATATATAA 1590
 Db 17 AACTTCCAAATATATAA 1

RESULT 66

AAT81624/c
 ID AAT81624 standard; RNA; 17 BP.

AC AAT81624;

XX 21-DEC-1997 (first entry)

DE Human c-myb hammerhead ribozyme target sequence (nt. position 3080).

XX Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;
 KW smooth muscle cell; hyperproliferation; restenosis; cancer; c-myb;
 KW coronary angioplasty; ss.

XX Homo sapiens.

OS WO9531541-A2.

PN 23-NOV-1995.

XX 18-MAY-1995; 95WO-US006368.

XX 18-MAY-1994; 94US-00245466.

PR 13-JAN-1995; 95US-00373124.

XX (RIBO-) RIBOZYME PHARM INC.

PA Stinchcomb DT, Draper K, Mcswiggen J, Jarvis T;

XX WPI; 1996-010927/01.

DR New enzymatic nucleic acid molecules - cleave RNA produced by e.g. c-myb,
 PT for treating restenosis or cancer.

PS Claim 1; Page 80; 128pp; English.

XX The present sequence represents the preferred target sequence for an
 CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves
 CC the human c-myb sequence at the base position indicated in the descriptor
 CC line. The c-myb sequence was screened for optimal ribozyme target sites
 CC using a computer folding algorithm, and regions of the mRNA which did not
 CC form secondary folding structures and contained potential ribozyme
 CC cleavage sites were identified. Ribozymes were synthesised and their
 CC activities optimised by either varying the length of the binding arms or
 CC by modification to prevent degradation by nucleases. The ribozymes cleave
 CC the c-myb sequence and can be used to prevent smooth muscle cell
 CC hyperproliferation in restenosis, especially after coronary angioplasty,
 CC and in cancers

SQ Sequence 17 BP; 4 A; 1 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 66;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1573 GAACCTCCAAATATATAA 1589
 Db 17 GAACCTCCAAATATATAA 1

RESULT 67

AAX71636/c
 ID AAX71636 standard; RNA; 17 BP.

XX AAX71636;

XX 28-JUL-1999 (first entry)

DE Human KDR VEGF receptor hammerhead ribozyme substrate #648.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
 KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

XX Homo sapiens.

PN WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US017480.

XX 26-OCT-1995; 95US-0005974P.

PR 11-JAN-1996; 96US-00584040.

XX (RIBO-) RIBOZYME PHARM INC.

PA (CHIR) CHIRON CORP.

PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;

XX WPI; 1997-259017/23.

DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
 PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
 PT rheumatoid arthritis, etc., in a human patient.

PS Claim 4; Page 116; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate the
 CC synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
 CC treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention

XX Sequence 17 BP; 3 A; 4 C; 3 G; 0 T; 7 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 66;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1871 TGAATAATCAATGATGC 1887
 Db 17 TGAATAATCAATGATGC 1

RESULT 68

AAX73191/c
 ID AAX73191 standard; RNA; 17 BP.

XX AC AAX73191;
XX DT 28-JUL-1999 (first entry)
XX DE Mouse flk-1 VEGF receptor hammerhead ribozyme substrate #624.
XX DE Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
XX KW KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
XX KW foetal liver kinase 1; ss.
XX OS Mus sp.
XX PN WO9715662-A2.
XX PD 01-MAY-1997.
XX PF 25-OCT-1996; 96WO-US017480.
XX PR 26-OCT-1995; 95US-0005974P.
XX PR 11-JAN-1996; 96US-00584040.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (CHIR) CHIRON CORP.
XX PI Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
XX DR WPI; 1997-259017/23.
XX XX Nucleic acid molecule modulating VEGF receptor (s) gene expression or mRNA
PT stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT rheumatoid arthritis, etc., in a human patient.
XX PS Claim 4; Page 142; 218pp; English.
XX CC The present invention describes nucleic acid molecules which modulate the
CC synthesis, expression and/or stability of a mRNA encoding 1 or more
CC receptors of vascular endothelial growth factor (VEGF). A patient
CC (preferably human) having a condition associated with the level of the
CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC treated by administering the nucleic acid molecule or the expression
CC vector to the patient. AAX67275 to AAX75752 represent specific examples
CC of nucleic acid molecules from the present invention
XX SQ Sequence 17 BP; 4 A; 4 C; 2 G; 0 T; 7 U; 0 Other;
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1871 TGAATAATCAATGATGC 1887
DB 17 TGAATAATCAATGATGC 1
RESULT 69
AAV49159/c
ID AAV49159 standard; DNA; 17 BP.
XX AC AAV49159;
XX DT 15-OCT-1998 (first entry)
XX DE rb gene antisense oligonucleotide rb-N-107.
XX KW rb gene; antisense oligonucleotide; modulate; gene expression; ss.
XX OS Synthetic.
XX OS Homo sapiens.

XX PN EP856579-A1.
XX PD 05-AUG-1998.
XX PF 31-JAN-1997; 97EP-00101531.
XX PR 31-JAN-1997; 97EP-00101531.
XX PA (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX PI Schlingensiepen K, Brysch W;
XX DR WPI; 1998-400910/35.
XX PT Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of residues
PT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
PT culture.
XX XX Example 7; Fig 9c; 286pp; English.
XX PS AAV49008-236 represent antisense oligonucleotides directed against the rb
XX CC gene. Of these, only oligonucleotides AAV49008-52 resulted in effective
CC downregulation of negative growth control by rb, while oligonucleotides
CC AAV49052-236 had little effect. The oligonucleotides exemplify the
CC invention. The specification describes oligonucleotides that contain 8-30
CC nucleotides, which contain at most 8 nucleotides that can each form three
CC hydrogen bonds to cytosine; do not contain four consecutive nucleotides
CC able to form three H-bonds each to four consecutive cytosines; do not
CC contain two sequences of three consecutive nucleotides each able to form
CC three H-bonds to three consecutive cytosines, and the ratio between
CC residues able to form two H-bonds each (2R) or three such bonds (3R) is
CC given by 2R/3R = 0.33-0.72. The oligonucleotides are used to modulate
CC expression of genes, particularly the genes for p53, ErbB-2, junB, junD,
CC TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
CC (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
CC and/or keratinocytes). The oligonucleotides can also be used to analyse
CC function of proteins (by altering their expression or activity) and
CC therapeutically, e.g. in cases of cancer or (targeting TGF) for
CC stimulating the immune system
XX SQ Sequence 17 BP; 5 A; 1 C; 1 G; 10 T; 0 U; 0 Other;
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1918 AAATGATACAAATTTA 1934
DB 17 AAATGATACAAATTTA 1
RESULT 70
AAV91108/c
ID AAV91108 standard; RNA; 17 BP.
XX AC AAV91108;
XX DT 18-FEB-1999 (first entry)
XX DE Human C-raf target site nucleotide position 1199.
XX KW Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
XX KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
XX KW screening; identification; synthesis; deprotection; purification; cancer;
XX KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
XX KW restenosis; rheumatoid arthritis; ss.
XX OS Homo sapiens.
XX OS WO9850530-A2.

```

XX 12-NOV-1998.
XX 05-MAY-1998; 98WO-US009249.
XX 09-MAY-1997; 97US-0046059P.
XX 09-JUN-1997; 97US-0049002P.
XX 03-JUL-1997; 97US-0051718P.
XX 22-AUG-1997; 97US-0056808P.
XX 02-OCT-1997; 97US-0061321P.
XX 02-OCT-1997; 97US-0061324P.
XX 05-NOV-1997; 97US-0064866P.
XX 19-DEC-1997; 97US-0068212P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
XX Parry T, Beigelman L, Mcswiggen JA, Karpelsky A, Burgin A;
XX Thompson J, Workman CT, Beaudry A, Sweedler D;
XX WPI; 1999-009494/01.
XX Identifying new catalytic nucleic acid that modulates selected processes
XX - especially ribozymes that cleave Raf RNA for treating cancer,
XX restenosis, and also new ribozymes and modified nucleoside triphosphates
XX used as antiviral agents and synthons.
XX Claim 177; Page 149; 259pp; English.
XX A method has been developed for the identification of a nucleic acid
XX capable of modulating a process in a biological system. The method
XX comprises: (a) introducing into the system a random library of nucleic
XX acid catalysts (NAC) having a substrate binding domain (SBD), comprising
XX a random sequence, and a catalytic domain (CD); and (b) identifying NAC
XX in systems where modulation has occurred and/or determining the sequence
XX of at least part of the SBDs in such systems. Nucleic acid molecules with
XX endonuclease activity and catalytic activity, from the present invention,
XX are used to modulate gene expression in plant and mammalian cells and to
XX cleave target nucleic acid, particularly for treating systemic diseases
XX caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
XX ascites and infection. They may also be used to detect genetic drift and
XX mutations in diseased cells and to determine c-raf RNA. Specifically NACs
XX with RNA-cleaving activity that modulate expression of the Raf gene, are
XX used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
XX generally any condition associated with the level of c-raf. Introduction
XX of sugar/phosphate modifications increases stability against nuclease and
XX activity. AAV90922 to AAV93877 represent NACs that can be used in the
XX method, specifically for modulating the expression of a Raf gene
XX Sequence 17 BP; 2 A; 3 C; 6 G; 0 T; 6 U; 0 Other;
XX Query Match 1.5%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 66;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX QY 2138 AAGGCGCTGACCTTAATC 2154
XX Db 17 AAGAGCTGACCCCAATC 1
XX RESULT 71
XX ID AAV91107/c
XX ID AAV91107 standard; RNA; 17 BP.
XX AC AAV91107;
XX AC AAV91107;
XX DT 18-FEB-1999 (first entry)
XX DE Human C-raf target site nucleotide position 1194.
XX DE Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
XX KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;
XX KW screening; identification; synthesis; deprotection; purification; cancer;
inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;
restenosis; rheumatoid arthritis; ss.
Homo sapiens.
WO9850530-A2.
12-NOV-1998.
05-MAY-1998; 98WO-US009249.
09-MAY-1997; 97US-0046059P.
09-JUN-1997; 97US-0049002P.
03-JUL-1997; 97US-0051718P.
22-AUG-1997; 97US-0056808P.
02-OCT-1997; 97US-0061321P.
02-OCT-1997; 97US-0061324P.
05-NOV-1997; 97US-0064866P.
19-DEC-1997; 97US-0068212P.
(RIBO-) RIBOZYME PHARM INC.
Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;
Parry T, Beigelman L, Mcswiggen JA, Karpelsky A, Burgin A;
Thompson J, Workman CT, Beaudry A, Sweedler D;
WPI; 1999-009494/01.
Identifying new catalytic nucleic acid that modulates selected processes
- especially ribozymes that cleave Raf RNA for treating cancer,
restenosis, and also new ribozymes and modified nucleoside triphosphates
used as antiviral agents and synthons.
Claim 177; Page 149; 259pp; English.
A method has been developed for the identification of a nucleic acid
capable of modulating a process in a biological system. The method
comprises: (a) introducing into the system a random library of nucleic
acid catalysts (NAC) having a substrate binding domain (SBD), comprising
a random sequence, and a catalytic domain (CD); and (b) identifying NAC
in systems where modulation has occurred and/or determining the sequence
of at least part of the SBDs in such systems. Nucleic acid molecules with
endonuclease activity and catalytic activity, from the present invention,
are used to modulate gene expression in plant and mammalian cells and to
cleave target nucleic acid, particularly for treating systemic diseases
caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
ascites and infection. They may also be used to detect genetic drift and
mutations in diseased cells and to determine c-raf RNA. Specifically NACs
with RNA-cleaving activity that modulate expression of the Raf gene, are
used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
generally any condition associated with the level of c-raf. Introduction
of sugar/phosphate modifications increases stability against nuclease and
activity. AAV90922 to AAV93877 represent NACs that can be used in the
method, specifically for modulating the expression of a Raf gene
Sequence 17 BP; 3 A; 3 C; 7 G; 0 T; 4 U; 0 Other;
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2143 CCTGACCTTAATCCAAGT 2159
Db 17 CCTGACCCCAATCCGAGT 1
RESULT 72
ID AAA25079
ID AAA25079 standard; DNA; 17 BP.
XX AAA25079;
XX AC AAA25079;
XX DT 19-JUL-2000 (first entry)

```

XX	Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1577.
DE	
XX	
KW	Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
KW	hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
KW	gene expression modification; cancer; phosphorothioate; endonuclease;
KW	anticancer; breast cancer; endometrium cancer; ss.
XX	
OS	Homo sapiens.
XX	
PN	WO954459-A2.
PD	28-OCT-1999.
XX	
PF	19-APR-1999; 99WO-US008547.
XX	
PR	20-APR-1998; 98US-0082404P.
PR	23-JUN-1998; 98US-00103636.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
XX	
PI	Thompson JD, Beigelman L, Mcwiggan JA, Karpeisky A, Bellon L;
PI	Reynolds M, Zwick M, Jarvis T, Woolf T, Haerberli P;
PI	Matulic-Adamic J;
XX	
DR	WPI; 2000-013248/01.
XX	
PT	New nucleic acids that interact, and optionally cleave, target sequences,
PT	used to treat cancer.
XX	
PS	Claim 77; Page 67; 148pp; English.
XX	
CC	The present invention describes nucleic acids (A) that interact stably
CC	with a target sequence and contain at least one phosphoro(di)thioate
CC	link, having endonuclease activity. (A), and more generally any catalytic
CC	nucleic acid (A') that modulates expression of the oestrogen receptor
CC	gene, are used to treat cancer (particularly of breast or endometrium),
CC	in vivo or by transforming cells ex vivo and implanting treated cells, or
CC	for other conditions associated with levels of oestrogen receptor.
CC	Because of the high selectivity for targeted RNA, (A) can also be used to
CC	correlate inhibition of gene expression with alterations in phenotype,
CC	particularly for identification of therapeutic targets, and as research
CC	reagents (for RNA, in the same way that restriction endonucleases are
CC	used with DNA). The combination of modifications in (A) improves
CC	resistance to nucleases, binding affinity and/or activity. AAA23503 to
CC	AAA24747 represent oestrogen receptor hammerhead ribozyme sequences, and
CC	AAA24748 to AAA25992 represent their corresponding target sequences.
CC	AAA25993 to AAA26105 represent oestrogen receptor hairpin ribozyme
CC	sequences, and AAA26107 to AAA26218 represent their corresponding target
CC	sequences. AAA26219 to AAA26271 represent other ribozyme sequences and
CC	antisense oligonucleotides used in the exemplification of the present
CC	invention
XX	
SQ	Sequence 17 BP; 6 A; 2 C; 3 G; 6 T; 0 U; 0 Other;
	Query Match 1.5%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 66;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps
QY	1899 AAGCATTCTTCTAAATTC 1915
Db	1 AAGCATTCTTCTAAATTC 17
RESULT 73	
ABN02789	
ID	ABN02789 standard; DNA; 17 BP.
XX	
AC	ABN02789;
XX	
XX	29-MAY-2002 (first entry)
DE	Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2781.

```

XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
PI WPI; 2002-684061/74.
XX
DR
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 697; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, AB883999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 AAGGAACCTGAATTCCTGC 2331
DB 17 AAGGAACCTGAATTCCTGC 1

RESULT 75
ABV89984/c
ID ABV89984 standard; DNA; 17 BP.
XX
AC ABV89984;
XX
XX 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 697.

XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
PN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-00001165.
XX
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 10-OCT-2001; 2001US-0328205P.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
PI WPI; 2002-684061/74.
XX
DR
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide, POSHL
PT -1, useful for treating disorders associated with decreased expression or
PT activity of human POSHL1.
XX
PS Example 2; SEQ ID NO 697; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, AB883999), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention. Note: The present sequence did not form part of the
CC printed specification, but is based on sequence information supplied to
CC Derwent by the European Patent Office
XX
SQ Sequence 17 BP; 8 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 AAGGAACCTGAATTCCTGC 2331
DB 17 AAGGAACCTGAATTCCTGC 1

RESULT 74
AAS17003/c
ID AAS17003 standard; DNA; 17 BP.
XX
AC AAS17003;
XX
XX 27-FEB-2002 (first entry)
XX
DE Human p21 sense PCR primer 1A.
XX
KW Human; ss; PCR primer; p53; 1A; p16; p21; ovarian carcinoma;
KW ovarian tumour; cystadenoma.
XX
OS Homo sapiens.
XX
XX US6287775-B1.
XX
PD 11-SEP-2001.
XX
XX 01-JUL-1999; 99US-00346200.
XX
XX 21-MAR-1996; 96US-0041554P.
XX
XX 21-MAR-1996; 96US-00621180.
XX
XX 17-MAR-1997; 97US-00819358.
XX
XX (UYAR-) UNIV ARKANSAS.
XX
XX O'brien TJ, Shigemasa K;
XX
XX WPI; 2002-048215/06.
XX
DR
XX
PT Detecting changes in ovarian epithelium, especially for early diagnosis
PT of ovarian carcinomas, comprises quantifying p16 gene products.
XX
PS Disclosure; Col 6; 16pp; English.
XX
CC The invention relates to detecting changes in the ovarian epithelium of a
CC test subject, comprising removing a sample from the subject's ovarian
CC epithelium, quantifying p16 gene products in the sample, and comparing
CC the amount of p16 gene products with a known control. An increase or
CC decrease in the amount of p16 gene products relative to the control
CC indicates a change in the subject's ovarian epithelium. The method is
CC used for early diagnosis of ovarian carcinomas on the basis of increased
CC p16 gene expression. Increased p16 expression is a sensitive marker for
CC ovarian tumours. In a study on 38 ovarian epithelium samples, p16
CC overexpression (at least 2 standard deviations) was observed in 0/6
CC normal samples, 1/2 benign cystadenoma samples, 5/6 cystadenoma samples
CC of low malignant potential and 22/24 carcinoma samples. The present
CC sequence represents a quantitative PCR primer for human p21 used in an
CC experiment comparing levels of p16, p53 and p21 ovarian samples
XX
SQ Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 AAGGAACCTGAATTCCTGC 2331
DB 17 AAGGAACCTGAATTCCTGC 1

RESULT 75
ABV89984/c
ID ABV89984 standard; DNA; 17 BP.
XX
AC ABV89984;
XX
XX 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 697.

```



```

PD 05-DEC-2002.
XX
PF 29-MAY-2002; 2002WO-US016840.
XX
PR 29-MAY-2001; 2001US-0294140P.
XX
PR 06-JUN-2001; 2001US-0296249P.
PR 10-SEP-2001; 2001US-0318471P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Mcswiggen J;
XX
XX WPI; 2003-140484/13.
DR
PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
PS Claim 58; Page 103; 185pp; English.
XX
CC The invention relates to a novel short interfering RNA (siRNA) nucleic
CC acid molecule or an enzymatic nucleic acid molecule, that modulates
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-
CC rheumatic activity. The nucleic acid molecules are useful for reducing
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
CC also useful for treating breast, ovarian, colorectal, lung, prostate,
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human
CC ribozymes of the invention
XX
SQ Sequence 17 BP; 5 A; 1 C; 2 G; 0 T; 9 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1877 TCAATGATGCAAAATA 1893
DB 17 TCAATGATACATATA 1

RESULT 79
ACD54840/C
ID ACD54840 standard; RNA; 17 BP.
XX
AC ACD54840;
XX
DT 24-SEP-2003 (first entry)
XX
DE HBV DNAzyme substrate sequence #144.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.
XX
OS Hepatitis B virus.
XX
PN WO200281494-A1.
XX
PD 17-OCT-2002.
XX
PF 26-MAR-2002; 2002WO-US0009187.
XX
PR 26-MAR-2001; 2001US-00817879.
PR 08-JUN-2001; 2001US-00877478.
PR

08-JUN-2001; 2001US-0296876P.
24-OCT-2001; 2001US-0335059P.
05-DEC-2001; 2001US-0337055P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MACE/) MACEJAK D.
PA (MCSW/) MCSWIGGEN J.
PA (MORR/) MORRISSEY D.
PA (PAVC/) PAVCO P.
PA (LEEF/) LEE P.
PA (DRAP/) DRAPER K.
PA (ROBE/) ROBERTS E.
XX
PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
PI Draper K, Roberts E;
XX WPI; 2003-229207/22.
DR
PT Novel compound useful for treating cirrhosis, liver failure,
PT hepatocellular carcinoma, or condition associated with hepatitis C virus
PT infection.
XX
PS Example 1; Page 189; 387pp; English.
XX
CC The present invention relates to nucleic acid molecules which modulate
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNAzymes,
CC inozymes, zinzymes, amberyms, and G-cleaver ribozymes. Also disclosed
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC as oligonucleotides that specifically bind the Enhancer I region of HBV
CC DNA. The nucleic acids may be used to modulate the expression of HBV
CC genes and HBV viral replication. Also disclosed is a method for screening
CC compounds and/or potential therapies directed against HBV, and compounds
CC that modulate the expression and/or replication of HCV. The compounds and
CC methods of the invention are useful for the treatment of degenerative and
CC disease states related to HBV and HCV infection, replication and gene
CC expression such as cirrhosis, liver failure, and hepatocellular
CC carcinoma. The present sequence represents a substrate for one of the HBV
CC ribozyme, inozyme, G-cleaver, zinzyme, DNAzyme or amberyms sequences
CC disclosed in the present invention
XX
SQ Sequence 17 BP; 5 A; 4 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1824 TAATAACATTGGCTAA 1840
DB 17 TAGTACATTGGGTAA 1

RESULT 80
ACD51179
ID ACD51179 standard; RNA; 17 BP.
XX
AC ACD51179;
XX
DT 23-SEP-2003 (first entry)
XX
DE HBV hammerhead ribozyme substrate sequence #441.
XX
KW Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;
KW RNA stability; RNA expression; RNA synthesis; antisense;
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;
KW amberyms; G-cleaver ribozyme; decoy molecule; aptamer;
KW HBV reverse transcriptase; Enhancer I region; viral replication;
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;
KW virucide; antiinflammatory; substrate; ss.

```

XX OS Hepatitis B virus.
XX PN WO200281494-A1.
XX PD 17-OCT-2002.
XX PF 26-MAR-2002; 2002WO-US009187.
XX PR 26-MAR-2001; 2001US-00817879.
XX PR 08-JUN-2001; 2001US-00877478.
XX PR 08-JUN-2001; 2001US-0296876P.
XX PR 24-OCT-2001; 2001US-0335059P.
XX PR 05-DEC-2001; 2001US-0337055P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (BLAT/) BLATT L.
XX PA (MACE/) MACEJAK D.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (MORR/) MORRISSEY D.
XX PA (PAVC/) PAVCO P.
XX PA (LEEP/) LEE P.
XX PA (DRAP/) DRAPER K.
XX PA (ROBE/) ROBERTS E.
XX PI Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;
XX PI Draper K, Roberts E;
XX PI WPI; 2003-229207/22.
XX DR Novel compound useful for treating cirrhosis, liver failure,
XX PT hepatocellular carcinoma, or condition associated with hepatitis C virus
XX PT infection.
XX PS Example 1; Page 144; 387pp; English.
XX CC The present invention relates to nucleic acid molecules which modulate
XX CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
XX CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
XX CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
XX CC inozymes, zinzymes, amberyms, and G-cleaver ribozymes. Also disclosed
XX CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse
XX CC transcriptase and/or HBV reverse transcriptase primer sequences, as well
XX CC as oligonucleotides that specifically bind the Enhancer I region of HBV
XX CC DNA. The nucleic acids may be used to modulate the expression of HBV
XX CC genes and HBV viral replication. Also disclosed is a method for screening
XX CC compounds and/or potential therapies directed against HBV, and compounds
XX CC that modulate the expression and/or replication of HCV. The compounds and
XX CC methods of the invention are useful for the treatment of degenerative and
XX CC disease states related to HBV and HCV infection, replication and gene
XX CC expression such as cirrhosis, liver failure, and hepatocellular
XX CC carcinoma. The present sequence represents a substrate for one of the HBV
XX CC ribozyme, inozyme, G-cleaver, zinzyme, DNazyme or amberyms sequences
XX CC disclosed in the present invention
XX SQ Sequence 17 BP; 7 A; 0 C; 5 G; 0 T; 5 U; 0 Other;
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 66;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 2081 GAAGGAATTTGGCAGAT 2097
DB 1 GAAGUAAUUUGGAGAU 17
RESULT 81
ADB42393
ID ADB42393 standard; DNA; 17 BP.
XX AC ADB42393;
XX DT 18-DEC-2003 (revised)

DT 04-DEC-2003 (first entry)
XX Tumour suppression/reversion associated nucleotide #2716.
DE cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
XX primer; probe; tumour suppression; tumour reversion; apoptosis;
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KW diagnosis.
XX Homo sapiens.
XX WO2003040369-A2.
XX PD 15-MAY-2003.
XX PF 17-SEP-2002; 2002WO-IB004219.
XX PR 17-SEP-2001; 2001FR-00011981.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX DR WPI; 2003-441574/41.
XX PT New nucleic acid encoding human prostate membrane-specific antigen,
XX PT useful e.g. for treatment of tumors and viral infection, also related
XX PT polypeptide and antibodies.
XX PS Disclosure; Page 349; 771pp; French.
XX CC The invention relates to the isolation of 6327 nucleotide sequences,
XX CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
XX CC sequence having at least 80% identity, after optimal alignment, with the
XX CC nucleotides, a sequence that hybridizes under stringent conditions with
XX CC the nucleotides, or the complement, or corresponding RNA, of the
XX CC nucleotides. The nucleotides are used as probes or primers for detecting,
XX CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
XX CC sense and antisense sequences, of nucleotides involved in tumour
XX CC suppression or reversion, apoptosis and or viral resistance, to produce
XX CC recombinant polypeptides, and to prepare transgenic animals, as
XX CC experimental models. The nucleotides (also vectors containing them and
XX CC cells containing the vectors), the encoded polypeptides and antibodies
XX CC (Ab) against the polypeptide are useful for prevention and/or treatment
XX CC of viral infections or diseases characterized by development of tumours
XX CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
XX CC Analysis of the expression of the nucleotides can be used for diagnosis
XX CC and/or prognosis of these diseases. The nucleotides and polypeptides can
XX CC also be used to screen for their specific interactive molecules,
XX CC potentially useful for treating diseases associated with abnormal
XX CC expression of the nucleotides.
XX SQ Sequence 17 BP; 3 A; 5 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2095 GATGCAGTTTACGTTCC 2111
DB 1 GATCCAGTTTCAGTTCC 17
RESULT 82
ADC04546/c
ID ADC04546 standard; DNA; 17 BP.
XX AC ADC04546;
XX DT 18-DEC-2003 (first entry)
XX DE Human Na/H exchanger-like protein 1 gene oligonucleotide #993.

KW ss; gene therapy; vaccine; sodium/hydrogen exchanger like protein;
KW NHELP1; passive replacement therapy; vaccine; diagnosis.
OS Homo sapiens.
XX EP1273660-A2.
XX 08-JAN-2003.
XX 25-JAN-2002; 2002BP-00001160.
XX 30-JAN-2001; 2001WO-US000666.
PR 23-MAY-2001; 2001US-00864761.
PR 21-DEC-2001; 2001US-0343331P.
XX (AEOM-) AEOMICA INC.
XX Gu Y;
PI WPI; 2003-302724/30.
DR New human sodium-hydrogen exchanger like protein 1 (NHELP1), useful as a
XX passive replacement therapy or as a vaccine for treating or preventing
XX disorders associated with aberrant expression or activity of human
XX NHELP1.
XX Example 2; SEQ ID NO 1033; 468pp; English.
XX The invention relates to a nucleic acid molecule which encodes a Na+/H+
XX exchanger like protein (NHELP1). The NHELP1 nucleic acid molecule, NHELP1
XX polypeptide, an antibody against the protein or its antigen-binding
XX fragment is useful in therapy. The NHELP1 nucleic acid molecule, NHELP1
XX polypeptide and an agonist are particularly useful for manufacturing a
XX medicament for treating or preventing a disorder associated with
XX decreased expression or activity of human NHELP1. The antibody or its
XX antigen-binding fragment, and an antagonist, are useful for manufacturing
XX a medicament for treating or preventing a disorder associated with
XX increased expression or activity of human NHELP1. The NHELP1 nucleic acid
XX or protein is useful as passive replacement therapy, as a vaccine, or in
XX diagnostic methods. This sequence corresponds to a 17-mer oligonucleotide
XX spanning the sequence of the human NHELP1 gene (ADC03514).
XX
SQ Sequence 17 BP; 0 A; 4 C; 2 G; 11 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 66;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2274 AGCAAGCAGGAAAAA 2290
DB 17 AGAAGCAGGAAAAACA 1

RESULT 83
ADL46517
ID ADL46517 standard; RNA; 17 BP.
XX
AC ADL46517;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human NOGO receptor hammerhead ribozyme substrate sequence #50.
DE
DE antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor hammerhead ribozyme; substrate; ds.

XX Unidentified.
OS WO200281628-A2.
XX
PN 17-OCT-2002.
XX
XX 03-APR-2002; 2002WO-US010512.
XX
XX 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Blatt L, Chowrita B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
XX growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
XX protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 9; SEQ ID NO 50; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
XX that down regulate the expression or inhibit the function of a receptor
XX for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
XX IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
XX invention are useful for treating: cerebrovascular accident, central
XX nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
XX lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
XX restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
XX disease, lupus, multiple sclerosis, transplant/graft rejection,
XX ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
XX conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
XX nucleic acids of the invention are also useful for down-regulating the
XX expression of a target gene and as a diagnostic tool to examine genetic
XX drifts and mutations within diseased cells or to detect the presence of a
XX target RNA in a cell. The present RNA sequence represents a human NOGO
XX receptor hammerhead ribozyme substrate sequence.
XX
SQ Sequence 17 BP; 4 A; 4 C; 2 G; 0 T; 7 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 66;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 2428 ATGAGAATCTATCTGTT 2444
DB 1 AUGACACUCUUCUGUU 17

RESULT 84
ADL50306/c
ID ADL50306 standard; RNA; 17 BP.
XX
AC ADL50306;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human PKR substrate sequence #1420.
DE
DE antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;
KW substrate; ds.

XX OS Unidentified.

XX WO200281628-A2.

XX PD 17-OCT-2002.

XX PF 03-APR-2002; 2002WO-US010512.

XX PR 05-APR-2001; 2001US-00827395.

XX PR 29-MAY-2001; 2001US-0294412P.

XX PR 28-AUG-2001; 2001US-0315315P.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;

XX WPI; 2003-058513/05.

XX Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.

XX Claim 59; SEQ ID NO 3839; 317pp; English.

XX The invention comprises nucleic acids (e.g. antisense oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis)). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a target RNA in a cell. The present RNA sequence represents a human PKR substrate sequence.

XX SQ Sequence 17 BP; 4 A; 3 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 66;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1657 CTGAGAAATCTCCTTCA 1673

DB 17 CTGAGAGTCACCTTCA 1

RESULT 85

ADM59993/c

ID ADM59993 standard; RNA; 17 BP.

XX AC ADM59993;

XX 03-JUN-2004 (first entry)

XX Hepatitis B virus (HBV) RNA target sequence #2127.

XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;

XX hepatitis B virus infection; hepatitis; hepatocellular carcinoma;

XX cirrhosis; liver failure; lamivudine; interferon; genetic drift;

XX virucide; hepatotropic; antiinflammatory; cytostatic.

XX Hepatitis B virus.

XX US2004054156-A1.

XX 18-MAR-2004.

XX PF 15-JAN-2003; 2003US-00342902.

XX PR 14-MAY-1992; 92US-00882712.

XX PR 07-FEB-1994; 94US-00193627.

XX PR 08-NOV-1999; 99US-00436430.

XX PR 20-MAR-2000; 2000US-00531025.

XX PR 09-AUG-2000; 2000US-00636385.

XX PR 24-OCT-2000; 2000US-00696347.

XX PR 08-JUN-2001; 2001US-00877478.

XX (DRAP/) DRAPER K.

XX (BLAT/) BLATT L.

XX (MCSW/) MCSWIGGEN J A.

XX (MORR/) MORRISSEY D.

XX Draper K, Blatt L, Mcswiggen JA, Morrissey D;

XX WPI; 2004-247781/23.

XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes specifically cleaving RNA derived from hepatitis B virus and comprising one or more binding arms, useful for treating hepatitis and cirrhosis.

XX Disclosure; SEQ ID NO 2127; 122pp; English.

XX The invention relates to an enzymatic nucleic acid molecule that specifically cleaves RNA derived from hepatitis B virus (HBV) and comprising one or more binding arms, without requiring the presence of a 2'-OH group within the molecule for activity. The nucleic acids are useful for treating hepatitis B virus infection, hepatitis, hepatocellular carcinoma, cirrhosis and liver failure, either alone or in combination with other therapies such as lamivudine and interferons. The nucleic acids are useful as diagnostic tools to examine genetic drift and mutations within diseased cells, for detecting the presence of HBV RNA in a cell, for the study of RNA and for down-regulating gene expression of target genes in bacterial, fungal, viral, plant or mammalian cells. This sequence represents an HBV RNA target sequence, used in the scope of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 17 BP; 5 A; 4 C; 1 G; 0 T; 7 U; 0 Other;

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 66;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1824 TAATAACATTCGGCTAA 1840

DB 17 TAGTAACATTCGGGATAA 1

RESULT 86

ADM58340

ID ADM58340 standard; RNA; 17 BP.

XX AC ADM58340;

XX 03-JUN-2004 (first entry)

XX Hepatitis B virus (HBV) RNA target sequence #474.

XX Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;

XX hepatitis B virus infection; hepatitis; hepatocellular carcinoma;

XX cirrhosis; liver failure; lamivudine; interferon; genetic drift;

XX virucide; hepatotropic; antiinflammatory; cytostatic.

XX Hepatitis B virus.

XX US2004054156-A1.

XX 18-MAR-2004.

XX WO2003091454-A1.
 PN
 XX
 PD 06-NOV-2003.
 XX
 XX 26-APR-2002; 2002WO-US013328.
 XX
 PR 26-APR-2002; 2002WO-US013328.
 XX
 XX (GENA-) GENAISANCE PHARM INC.
 PA
 XX Chew A, Kazeml A, Koshy B;
 PI
 XX WPI; 2003-877338/81.
 DR
 XX
 PS Claim 39; Page 14; Opp; English.
 PS
 XX The present invention provides the protein and coding sequences of human
 CC fructose-bisphosphate aldolase B (ALDOB) and single nucleotide
 CC polymorphisms (SNPs) which have been identified in each sequence. The
 CC method of haplotyping the sequences is useful for haplotyping the
 CC fructose-bisphosphate aldolase B (ALDOB) gene of an individual or for
 CC validating the ALDOB protein as a candidate target for treating a medical
 CC condition predicted to be associated with ALDOB activity. The present
 CC sequence is an allele-specific primer/probe used to identify the
 CC haplotype of the human ALDOB gene in the exemplification of the invention
 CC
 XX Sequence 15 BP; 6 A; 1 C; 3 G; 4 T; 0 U; 1 Other;
 SQ

Query Match 1.5%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 56;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1960 CCTATTAGTCATAT 1973
 Db :|||||
 14 YCTATTAGTCATAT 1

RESULT 89
 AAF47767
 ID AAF47767 standard; DNA; 15 BP.
 XX
 AC AAF47767;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP3 oligonucleotide #1187.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX

PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.
 XX
 PS Example 7; Page 51; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-
 CC F45161). The method is useful for ameliorating the effects of psoriasis,
 CC ichthyosis, ptyriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
 CC neoplasia, scleroderma, warts, benign growths, cancers of the skin, a
 CC hyperneovascular condition such as a neovascular condition of the retina,
 CC brain or skin, growth factor-mediated malignancies, other sclerotic
 CC disease, kidney disease, hyperproliferation of the inside of blood
 CC vessels or any other hyperplasia
 XX
 SQ Sequence 15 BP; 4 A; 4 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 1.5%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 59;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2263 TTCAGTGTGTCAGCA 2277
 Db :|||||
 1 TTCCAGTAGTCAGCA 15

RESULT 90
 AAF47768
 ID AAF47768 standard; DNA; 15 BP.
 XX
 AC AAF47768;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE IGFBP3 oligonucleotide #1188.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU000693.
 XX
 PR 21-JUN-1999; 99US-0140345P.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wright CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
 PT inhibits or reduces growth factor mediated cell proliferation and/or
 PT inflammation.

XX Example 7; Page 51; 201pp; English.

XX The present invention relates to a method for ameliorating the effects of

CC skin disorders. The method comprises contacting the skin with an

CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1

CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

CC inhibiting or reducing growth factor mediated cell proliferation,

CC inflammation and/or other disorders. The present sequence is an

CC oligonucleotide which can be used to design the antisense

CC oligonucleotides of the present invention (see AAF45151 and AAF45153-

CC F45161). The method is useful for ameliorating the effects of psoriasis,

CC ichthyosis, pityriasis, ruba, pilaris, seborrheoa, keloids, keratosis,

CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a

CC hyperneovascular condition such as a neovascular condition of the retina,

CC brain or skin, growth factor-mediated malignancies, other sclerotic

CC disease, kidney disease, hyperproliferation of the inside of blood

CC vessels or any other hyperplasia

XX

SQ Sequence 15 BP; 5 A; 4 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 59;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2264 TCCAGTTGTCAGCAA 2278

DB 1 TCCAGTAGTCAGCAA 15

RESULT 91

AB233935/C

ID AB233935 standard; DNA; 16 BP.

XX

AC AB233935;

XX

DT 31-JAN-2003 (first entry)

DE

DE HIV-1 reverse transcriptase mutation detection probe SEQ ID NO:177.

KW Human immunodeficiency virus; HIV; reverse transcriptase; RT; enzyme;

KW detection; mutation; anti-HIV drug resistance; polymorphism; resistance;

KW probe; ss.

XX

OS Human immunodeficiency virus 1.

OS Synthetic.

XX

PN WO200255741-A2.

XX

PD 18-JUL-2002.

XX

XX 09-JAN-2002; 2002WO-EP000153.

PF

XX 11-JAN-2001; 2001EP-00870005.

PR

XX 20-APR-2001; 2001EP-00870085.

PR

XX 24-APR-2001; 2001US-0286102P.

XX

PA (INNO-) INNOGENETICS NV.

XX

XX De Smet K, Stuyver L;

PI

XX WPI; 2002-590680/63.

DR

XX

XX Detecting mutations associated with anti-HIV drug resistance comprises

PT detecting at least one of the mutations in the HIV reverse transcriptase

PT gene by using probes optimized to function together in a reverse-

PT hybridization assay.

XX

XX Claim 2; Page 15; 117pp; English.

PS

XX The present invention describes a method for detecting mutations

CC associated with anti-HIV drug resistance in a patient by detecting at

CC least one of the mutations K103N/R, V106A/I/L, Y181C/I, M184V/I, Y188L,

CC

CC G190A/S/R, T215Y/F/D/S/A and/or Q151M/L in the reverse transcriptase (RT)

CC of HIV strains in a biological sample using a specific set of probes

CC optimised to function together in a reverse-hybridisation assay. The

CC method and the nucleic acid sequences used in the method are useful for

CC determining viral mutations and/or polymorphisms in the HIV RT gene

CC associated with resistance. The probes are useful for the genetic

CC detection, preferably in vitro detection of the mutations K103N/R,

CC V106A/I/L, Y181C/I, Q151M/L, M184V/I, Y188L, G190A/S/R and/or

CC T215Y/F/D/S/A in the RT of HIV strains in a biological sample, where the

CC mutation is associated with anti-HIV drug resistance. The method provides

CC a rapid, reliable and precise assay or determination and monitoring of

CC antiviral drug resistance or mutations associated with drug resistance of

CC viruses containing RT genes. AB233759 to AB234642 represent HIV RT

CC sequences and probes which are used in the exemplification of the present

CC invention

XX

SQ Sequence 16 BP; 6 A; 3 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 67;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1969 CATATATTTATAGAT 1983

DB 16 CATATATTGATAGAT 2

RESULT 92

ADQ30355/C

ID ADQ30355 standard; DNA; 16 BP.

XX

AC ADQ30355;

XX

DT 09-SEP-2004 (first entry)

DE

DE Human VRI exon 1d transcription factor binding fragment #74.

XX

KW ds; VRI receptor; vanilloid receptor type 1; modulator;

KW pain transmission; primary sensory neuron; transcription factor;

KW detection; MZP1; NFkappaB; NFAT; GATA1; sensitivity disorder; analgesia;

KW hypalgesia; hyperalgesia; neuralgia; myalgia; human.

XX

OS Homo sapiens.

XX

XX WO2004053120-A2.

PN

XX 24-JUN-2004.

PD

XX 01-DEC-2003; 2003WO-EP013522.

PF

XX 09-DEC-2002; 2002DE-01057421.

PR

XX (CHEF) GRUENENTHAL GMBH.

XX

PA Weihe B, Bieller A, Schaefer MKH;

XX

XX WPI; 2004-468868/44.

DR

XX

XX New nucleic acid that modulates expression of the vanilloid receptor-1,

PT useful for control of pain or sensitivity disorders, comprises sequences

PT from control regions of the receptor gene.

XX

XX Disclosure; Page 53; 68pp; German.

PS

XX This invention describes a novel nucleic acid containing a specific

CC segment having at least one region that modulates expression of the VRI

CC (vanilloid receptor type 1) receptor, or a functional derivative, allele

CC or fragment of this region, or a sequence that hybridises to it under

CC standard conditions. The VRI modulator is derived from one or more of

CC positions 221931-223344 of GenBank AF670399, 31673-36359 of AF663116, or

CC 44731-43231 or 36616-33151 of AF168787 and is involved in transmission of

CC pain, particularly in primary sensory neurons. The invention also

CC describes a vector that contains the VRI modulator, host cells containing

CC this vector (other than human germ or embryonal stem cells) and a method
 CC for modulating expression of the VRL receptor by introducing the
 CC modulator or the vector into a cell that contains the VRL gene. The
 CC products of the invention are used for detecting a transcription factor
 CC from its binding to a regulatory sequence (or a double-stranded
 CC oligonucleotide fragment of it), e.g. by Western blotting or enzyme-
 CC linked immunosorbent assay, particularly for diagnosis of diseases
 CC associated with overexpression or underexpression of the transcription
 CC factor. The region that modulates VRL receptor expression includes a
 CC binding site for a transcription factor, e.g. MZF1, NFKBpab, NFAT or
 CC GATA1. The nucleic acids of the invention, or vectors containing them,
 CC are used for prevention or treatment of pain, also for treating
 CC sensitivity disorders, e.g. analgesia, hypalgesia or hyperalgesia, also
 CC neuralgia and myalgia, that are associated with activity of the VRL
 CC receptor. This sequence represents a fragment of human VRL exon 1d DNA
 CC which is capable of binding to a transcription factor.

XX Sequence 16 BP; 10 A; 0 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 1.5%; Score 13.4; DB 1; Length 16;
 Best Local Similarity 93.3%; Pred. No. 67;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1970 ATATATTTATAGATT 1984
 DB 15 ATATATTTATATATT 1

RESULT 93
 ABZ03275/c
 ID ABZ03275 standard; DNA; 50 BP.
 XX
 AC ABZ03275;
 XX
 DT 09-JAN-2003 (first entry)
 XX
 DE Human leukocyte gene expression profiling probe SEQ ID NO 3266.
 XX
 KW T7; leukocyte; gene expression profiling; allograft rejection;
 KW atherosclerosis; congestive heart failure; systemic lupus erythematosus;
 KW rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection; probe;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200257414-A2.
 XX
 PD 25-JUL-2002.
 XX
 PF 22-OCT-2001; 2001WO-US047856.
 XX
 PR 20-OCT-2000; 2000US-0241994P.
 PR 08-JUN-2001; 2001US-0296764P.
 XX
 PA (BIOC-) BIOCARDIA INC.
 XX
 PI Wohlgenuth J, Fry K, Matcuk G, Altman P, Prentice J, Phillips J;
 PI Ly N, Woodward R, Quertermous T, Johnson F;
 XX
 DR WPI; 2002-636525/68.

XX New system for leukocyte expression profiling, diagnosing a disease, or
 XX monitoring (the rate of) progression of a disease, e.g. atherosclerosis
 XX or congestive heart failure, comprises diagnostic oligonucleotides.
 XX
 PS Claim 1; Page 431; Opp; English..

XX The invention relates to a system for detecting gene expression, which
 CC comprises one or two isolated DNA molecules that detect expression of a
 CC gene, where the gene corresponds to any of 8143 oligonucleotides
 CC (ABZ00010-ABZ08152) each having 50 base pairs (bp). The system is useful
 CC for leukocyte expression profiling. It is particularly useful for
 CC diagnosing a disease, monitoring (rate of) progression of a disease,

CC predicting therapeutic outcome, determining prognosis for a patient,
 CC predicting disease complications in an individual or monitoring response
 CC to treatment in an individual. The diseases include cardiac allograft
 CC rejection, kidney allograft rejection, liver allograft rejection,
 CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,
 CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection
 XX
 SQ Sequence 50 BP; 12 A; 11 C; 11 G; 16 T; 0 U; 0 Other;

Query Match 1.4%; Score 13.2; DB 1; Length 50;
 Best Local Similarity 61.8%; Pred. No. 98;
 Matches 21; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1883 GATGCAAAATATATACAGCACCTTTGTAAATTTGT 1916
 DB 37 GAAGCACAGCAGATATTAGCCCAATGTTATTAGT 4

RESULT 94
 ABC12913/c
 ID ABC12913 standard; DNA; 13 BP.
 XX
 AC ABC12913;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 12920 for detecting SNP TSC0003014.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB0000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

XX Claim 1; SEQ ID NO 12920; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 52;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 2 C; 0 G; 3 T; 0 U; 0 Other;

  Query Match      1.4%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 52;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1887 CAAATATATACA 1899
DB 1 CAAATATATACA 13

RESULT 100
ABF62300/C
ID ABF62300 standard; DNA; 13 BP.
XX
AC ABF62300;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 162297 for detecting SNP TSC0009377.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 162297; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;

  Query Match      1.4%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 52;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1770 CCACTACTAATTT 1782
DB 13 CCACTACTAATTT 1

RESULT 102
ABC50481
ID ABC50481 standard; DNA; 13 BP.
XX
AC ABC50481;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 50498 for detecting SNP TSC0014187.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
RESULT 101
ABH47035/C
ID ABH47035 standard; DNA; 13 BP.
XX
AC ABH47035;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 247012 for detecting SNP TSC0060369.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 247012; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 2 C; 0 G; 4 T; 0 U; 0 Other;

  Query Match      1.4%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 52;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1974 ATTTATAGATTCT 1986
DB 13 ATTTATAGATTCT 1

RESULT 102
ABC50481
ID ABC50481 standard; DNA; 13 BP.
XX
AC ABC50481;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 50498 for detecting SNP TSC0014187.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```


CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 8 A; 0 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 52;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1585 TATAAAATAGAG 1597

Db 1 TATAAAATAGAG 13

RESULT 105

ABF79797/c
 ID ABF79797 standard; DNA; 13 BP.

XX AC ABF79797;

XX DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 179794 for detecting SNP TSC0044520.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 179794; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 3 A; 2 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 52;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1585 TATAAAATAGAG 1597

Db 13 TATAAAATAGAG 1

RESULT 106

ABF00805/c
 ID ABF00805 standard; DNA; 13 BP.

XX AC ABF00805;

XX DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 100802 for detecting SNP TSC0025074.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 100802; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SQ Sequence 13 BP; 7 A; 1 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 52;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1972 ATATTATAGATT 1984

Db 13 ATATTATAGATT 1

RESULT 107

ABF32140/c
 ID ABF32140 standard; DNA; 13 BP.

XX AC ABF32140;


```
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 52315; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 1.4%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 52;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2008 ACAATAAAATAT 2020
DB 13 ACAATAAAATAT 1
|||||
ACAAATAAAATAT 1

RESULT 110
ABC52299
ID ABC52299 standard; DNA; 13 BP.
XX AC ABC52299;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 52316 for detecting SNP TSC0014536.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 52316; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 1 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 1.4%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 52;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2008 ACAATAAAATAT 2020
DB 13 ACAATAAAATAT 1
|||||
ACAAATAAAATAT 1

RESULT 111
ABH47034
ID ABH47034 standard; DNA; 13 BP.
XX AC ABH47034;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 247011 for detecting SNP TSC0060369.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 247011; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 2 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 1.4%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 52;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1974 ATTTATAGATTCT 1986
|||||
```

Db 1 ATTATAGATTCT 13

RESULT 112

ABC23755

ID ABC23755 standard; DNA; 13 BP.

XX AC ABC23755;

XX DT 20-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 23772 for detecting SNP TSC0005308.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPITG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 23772; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX CC Sequence 13 BP; 10 A; 0 C; 0 G; 3 T; 0 U; 0 Other;

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX CC Sequence 13 BP; 10 A; 0 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 52;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1581 AAAATATATAAAT 1593

DB 1 AAAATATATAAAT 13

RESULT 113

ABF32141

ID ABF32141 standard; DNA; 13 BP.

XX AC ABF32141;

XX DT 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 132138 for detecting SNP TSC0032979.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is

XX PT designed to detect single-nucleotide polymorphisms and cytosine

XX PT methylation status.

XX PS Claim 1; SEQ ID NO 132138; 29pp + Sequence Listing; German.

XX CC This invention describes novel oligonucleotide primers or peptide nucleic

XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

XX CC range of diseases including immune system, gastrointestinal, respiratory,

XX CC central nervous system, cardiovascular and metabolic disorders. The

XX CC oligomers are also used for detecting cell type differentiation. ABC00010

XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073

XX CC represent the oligomers described in the invention. NOTE: The sequence

XX CC data for this patent did not form part of the printed specification, but

XX CC was obtained in electronic format from WIPO at

XX CC ftp.wipo.int/pub/published_pct_sequences

XX CC Sequence 13 BP; 10 A; 1 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 52;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1580 CAAAATATAAAAA 1592

DB 1 CAAAATATAAAAA 13

RESULT 114

ABF93762/c

ID ABF93762 standard; DNA; 13 BP.

XX AC ABF93762;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 193759 for detecting SNP TSC0047657.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 193759; 29pp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX Query Match 1.4%; Score 13; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 52;
 XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX

QY 1951 TTACAAATCCTA 1963
 Db 13 TTACAAATCCTA 1

RESULT 115
 ABH53075/C
 ID ABH53075 standard; DNA; 13 BP.
 XX AC ABH53075;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 253052 for detecting SNP TSC0006570.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 253052; 29pp + Sequence Listing; German.
 XX

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

XX Query Match 1.4%; Score 13; DB 1; Length 13;
 XX Best Local Similarity 100.0%; Pred. No. 52;
 XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX

QY 1908 GTAAATTTGTA AAA 1920
 Db 13 GTAAATTTGTA AAA 1

RESULT 116
 ABF93763
 ID ABF93763 standard; DNA; 13 BP.
 XX AC ABF93763;
 XX 22-FEB-2002 (first entry)
 XX Oligonucleotide SEQ ID NO 193760 for detecting SNP TSC0047657.
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX Claim 1; SEQ ID NO 193760; 29pp + Sequence Listing; German.
 XX

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

```
SQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1951 TTACAAATCCTA 1963
Db 1 TTACAAATCCTA 13

RESULT 117
ABF62301
ID ABF62301 standard; DNA; 13 BP.
XX
AC ABF62301;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 162298 for detecting SNP TSC0009377.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
AC ABF62301;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 162298 for detecting SNP TSC0009377.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 162298; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;
Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1770 CCACTACTAATT 1782
Db 1 CCACTACTAATT 13

RESULT 118
ABF00804
ID ABF00804 standard; DNA; 13 BP.
XX
AC ABF00804;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 100801 for detecting SNP TSC0025074.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 100801; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 0 C; 1 G; 7 T; 0 U; 0 Other;
Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1972 ATATTATAGATT 1984
Db 1 ATATTATAGATT 13

RESULT 119
ABH15318/C
ID ABH15318 standard; DNA; 13 BP.
XX
AC ABH15318;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 215295 for detecting SNP TSC0006400.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
```

```

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (BPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 215295; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABCG00010
CC -ABCG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1821 CACTAATAACATT 1833
DB 13 CACTAATAACATT 1
RESULT 120
ADF61903
ID ADF61903 standard; RNA; 14 BP.
XX
AC ADF61903;
XX
DT 12-FEB-2004 (first entry)
XX
DE Ribosome binding site RNA SEQ ID 56 located downstream of promoter.
XX
KW artificial promoter; bacterial clone; strain performance;
KW fermentation process; cell viability; ss; RBS; ribosome binding site.
XX
OS Unidentified.
XX
XX WO2003089605-A2.
XX
PD 30-OCT-2003.
XX
XX 18-APR-2003; 2003WO-US012045.
XX
XX 22-APR-2002; 2002US-0374627P.
XX (GENV ) GENENCOR INT INC.
XX
XX Soucaille P;
XX
XX WPI; 2003-854112/79.
XX
XX Creating a library of artificial promoters comprises mixing
PT oligonucleotides in a polymerase chain reaction with an insertion DNA
PT cassette to obtain a library of double-stranded amplified products
PT comprising artificial promoters.
XX Claim 15; SEQ ID NO 56; 44pp; English.
XX The invention relates to a novel method for creating a library of
CC artificial promoters comprising mixing a first oligonucleotide and a
CC second oligonucleotide in an amplification reaction with an insertion DNA
CC cassette to obtain a library of double-stranded amplified products
CC comprising artificial promoters. The method of the invention may be
CC useful in creating a library of bacterial clones with varying levels of
CC gene expression and in developing a quick and efficient means of
CC determining the optimum expression level of a gene in a metabolic pathway
CC which, in turn, results in an optimisation of strain performance for a
CC desired product. A direct advantage of the method is that a bacterial
CC clone may be selected based on the expression level obtained from DNA
CC libraries and then be ready for use in a fermentation process where cell
CC viability is not negatively affected by expression of the gene of
CC interest. The current sequence is that of the ribosome binding site (RBS)
CC RNA of the invention which is located downstream of precursor promoter.
XX
XX Sequence 14 BP; 11 A; 0 C; 2 G; 0 T; 1 U; 0 Other;
Query Match 1.4%; Score 13; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 60;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 2281 AGGAAAAAAAT 2293
DB 2 AGGAAAAAAAU 14
RESULT 121
AAT55633/c
ID AAT55633 standard; RNA; 15 BP.
XX
AC AAT55633;
XX
DT 25-MAR-2003 (revised)
DT 21-MAR-1997 (first entry)
XX
DE Human TNF-alpha hammerhead ribozyme target sequence (nt position 39).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
XX ss.
XX
OS Homo sapiens.
XX
XX WO9523225-A2.
XX
PD 31-AUG-1995.
XX
XX 23-FEB-1995; 95WO-IB000156.
XX
XX 23-FEB-1994; 94US-00201109.
XX 29-MAR-1994; 94US-00218934.
XX 04-APR-1994; 94US-00222795.
XX 07-APR-1994; 94US-00224483.
XX 15-APR-1994; 94US-00227958.
XX 15-APR-1994; 94US-00228041.
XX 18-MAY-1994; 94US-00245736.

```

```

PR 06-JUL-1994; 94US-00271280.
PR 15-AUG-1994; 94US-00291932.
PR 16-AUG-1994; 94US-00291433.
PR 17-AUG-1994; 94US-00292620.
PR 19-AUG-1994; 94US-00293520.
PR 02-SEP-1994; 94US-00300000.
PR 08-SEP-1994; 94US-00303039.
PR 23-SEP-1994; 94US-00311486.
PR 23-SEP-1994; 94US-00311749.
PR 23-SEP-1994; 94US-00314397.
PR 03-OCT-1994; 94US-00316771.
PR 07-OCT-1994; 94US-00319492.
PR 11-OCT-1994; 94US-00321993.
PR 04-NOV-1994; 94US-00334847.
PR 10-NOV-1994; 94US-00337608.
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
XX Stinchcomb DT, Chowira B, Direnzo A, Draper KG, Dudycz LW;
PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott FE, Woolf T;
XX
XX WPI; 1995-351090/45.
XX
XX Ribozymes having modified bases and methods for producing them - for use
PT in inhibiting disease related genes.
PT
XX
XX Claim 2; Page 241; 407pp; English.
XX
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves TNP-alpha mRNA at
CC the nucleotide base position indicated in the DE line. Regions of the
CC mRNA that do not form secondary folding structures and that contain
CC potential hammerhead and hairpin ribozyme cleavage sites were identified
CC by computer analysis. Ribozymes directed against these mRNA sequences
CC were designed and synthesised with modifications that improve their
CC nuclease resistance. The ribozymes are designed to cleave the target
CC sequences and thereby inhibit TNF-alpha expression, making them
CC potentially useful for treating rheumatoid arthritis, septic shock and
CC other inflammatory disorders including psoriasis, as well as for
CC treatment of AIDS. (Updated on 25-MAR-2003 to correct PI field.)
XX
XX Sequence 15 BP; 3 A; 6 C; 0 G; 0 T; 6 U; 0 Other;
SQ
Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 67;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2201 AGTATGTGAGAGG 2213
DB 15 AGTATGTGAGAGG 3

RESULT 122
ABS51921/c
ID ABS51921 standard; DNA; 15 BP.
XX
XX ABS51921;
AC
XX
XX 05-NOV-2002 (first entry)
DT
XX
XX Human FMO2 gene polymorphism detection ASO primer #42.
DE
XX
XX Human; flavin containing monooxygenase-2; FMO2; isogene; drugs targeting;
KW drug toxicity; bone disorder; gene therapy; polymorphism; chromosome 1q;
KW allele-specific oligonucleotide; ASO; primer; ss.
XX
XX Homo sapiens.
OS

XX 06-JUL-1994; 94US-00271280.
XX PN WO200253579-A2.
XX
XX 11-JUL-2002.
PD
XX
XX 18-DEC-2001; 2001WO-US049059.
PF
XX
XX 29-DEC-2000; 2000US-0259062P.
PR
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX Bentivegna SC, Duda A, Kazemi A, Lee HH, Messer C, Parks KE;
PI WPI; 2002-590627/63.
XX
XX Novel genetic variants of Flavin Containing Monooxygenase 2 isogenes,
PT useful for improving efficiency and reliability in drug development for
PT treating developmental bone disorders.
PT
XX
XX Claim 15; Page 16; 140pp; English.
PS
XX
XX The present invention relates to a new polynucleotide which comprises
CC flavin containing monooxygenase-2 (FMO2) isogenes. The invention is
CC useful in screening for drugs that are useful for treating drug toxicity.
CC The methods of the invention are useful for improving the efficiency and
CC reliability of several steps in the discovery and development of drugs
CC for treating diseases associated with FMO2 activity. The methods are also
CC used by the pharmaceutical research scientist to validate FMO2 as a
CC candidate target for treating a specific condition or disease predicted
CC to be associated with FMO2 activity, e.g. drug toxicity, and in the
CC design of clinical trials for treating a specific condition of disease
CC associated with FMO2 activity. The methods are also useful for screening
CC compounds targeting FMO2. The nucleic acid of the invention is useful in
CC studying the expression and function of FMO2, and in expressing FMO2
CC protein for use in screening for candidate drugs to treat diseases
CC related to FMO2 activity. It is also useful in studying the effect of the
CC variation on the biological activity of FMO2 as well as on the binding
CC affinity of candidate drugs targeting FMO2 for the treatment of drug
CC toxicity. The invention is useful for studying the expression of FMO2
CC isogenes in vivo, for in vivo screening and testing of drugs targeted
CC against FMO2 protein, and for testing the efficacy of therapeutic agents
CC and compounds for treating drug toxicity in a biological system. The
CC present nucleic acid sequence represents an allele-specific
CC oligonucleotide (ASO) primer that was used in the methods of the
CC invention to detect polymorphisms in the human FMO2 gene located on
CC chromosome 1q
XX
XX Sequence 15 BP; 2 A; 3 C; 0 G; 9 T; 0 U; 1 Other;
SQ
Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 67;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2261 AGGAAAAAATTC 2295
DB 15 AKGAAAAAGGATTC 1

RESULT 123
ABI99114
ID ABI99114 standard; DNA; 15 BP.
XX
XX ABI99114;
AC
XX
XX 27-FEB-2002 (first entry)
DT
XX
XX Human PCDH2 ASO PCR primer SEQ ID NO 71.
DE
XX
XX Human; PCDH2; protocadherin 2; haplotyping; polymorphic variant; SNP;
KW single nucleotide polymorphism; cytostatic; cancer; chromosome 5q31;
KW allele-specific oligonucleotide; ASO; PCR primer; ss.
XX
XX Homo sapiens.
OS

```

XX PN WO200194361-A2.
XX PD 13-DEC-2001.
XX PF 06-JUN-2001; 2001WO-US018321.
XX PR 06-JUN-2000; 2000US-0209564P.
XX PA (GENA-) GENAISSANCE PHARM INC.
XX PI Kliem SE, Koshy B, Tanguay DA;
XX PF WI; 2002-097928/13.
XX DR New protocadherin 2 (PCDH2) polymorphic variants and encoding genes,
XX PT useful in expressing PCDH2 protein for screening candidate drugs to treat
XX PT diseases related to PCDH2 activity.
XX PS Claim 16; Page 14; 127pp; English.
XX CC The invention relates to haplotyping the protocadherin 2 (PCDH2) gene,
XX CC comprising determining which of the haplotypes given in the specification
XX CC defines one or both copies of the individual's PCDH2 gene. The
XX CC polymorphisms are within a 30244 base pair sequence (ABA05413), fully
XX CC defined in the specification. The polymorphic variants are useful in
XX CC studying the expression and function of PCDH2, in expressing PCDH2
XX CC protein for use in screening for candidate drugs to treat diseases such
XX CC as cancer, related to PCDH2 activity, in studying the effect of the
XX CC variation on the biological activity of PCDH2 and the binding affinity of
XX CC candidate drugs targeting PCDH2. The haplotyping methods are useful in
XX CC validating PCDH2 as a candidate target for treating a specific condition
XX CC or disease predicted to be associated with PCDH2 activity or in the
XX CC design of clinical trials of candidate drugs for treating a specific
XX CC condition or disease associated with PCDH2 activity. The present sequence
XX CC is that of a PCDH2 allele-specific oligonucleotide (ASO) PCR primer of
XX CC the invention
XX SQ Sequence 15 BP; 2 A; 4 C; 5 G; 3 T; 0 U; 1 Other;
Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 67;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
OY 2386 CCTGGGCTGACACT 2400
Db 1 CCTGGGCTGACACT 15
RESULT 124
ADR74580/c
ID ADR74580 standard; DNA; 16 BP.
XX AC ADR74580;
XX DT 16-DEC-2004 (first entry)
XX DE Allele specific primer A for human stenosis marker hCV15850923.
XX KW Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
XX KW angina; ischaemic chest pain; myocardial infarction;
XX KW sudden cardiac death; SNP; single nucleotide polymorphism.
XX OS Homo sapiens.
XX PN WO2004081186-A2.
XX PD 23-SEP-2004.
XX PF 10-MAR-2004; 2004WO-US007140.
XX PR 10-MAR-2003; 2003US-0453050P.
XX PR 30-APR-2003; 2003US-0466437P.

XX PA (APPL-) APPLERA CORP.
XX PI Cargill M, Devlin JJ, Luke MM;
XX PF WI; 2004-668949/65.
XX PT Identifying an individual who has altered risk for developing stenosis
XX PT comprises detecting single nucleotide polymorphism (SNP), in the
XX PT individual's nucleic acids.
XX PS Claim 19; SEQ ID NO 67892; 146pp; English.
XX CC The invention relates to identifying an individual who has altered risk
XX CC for developing coronary stenosis comprising detecting a single nucleotide
XX CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
XX CC given in the specification), in the individual's nucleic acids, where the
XX CC presence of the SNP is correlated with an altered risk for stenosis in
XX CC the individual. Also included are an isolated nucleic acid molecule
XX CC (comprising at least 8 contiguous nucleotides where one of the
XX CC nucleotides is an SNP as cited above, or their complement), an isolated
XX CC polypeptide comprising an amino acid sequence selected from any of the
XX CC 696 amino acid sequences (not defined in the specification), an antibody
XX CC that specifically binds to the polypeptide (or its antigen-binding
XX CC fragment), an amplified polynucleotide containing the SNP as cited (where
XX CC the amplified polynucleotide is between about 16 and about 1,000
XX CC nucleotides in length), an isolated polynucleotide which specifically
XX CC hybridises to a nucleic acid molecule containing the SNP, a kit for
XX CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
XX CC molecule, detecting a variant polypeptide and identifying an agent useful
XX CC in therapeutically or prophylactically treating stenosis. The detection
XX CC step of the method is carried out by a process selected from allele-
XX CC specific probe hybridisation, allele-specific primer extension, allele-
XX CC specific amplification, sequencing, 5' nuclease digestion, molecular
XX CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
XX CC stranded conformation polymorphism. The method is useful for identifying
XX CC an individual who has altered risk for developing coronary stenosis,
XX CC which can lead to angina (ischaemic chest pain), myocardial infarction
XX CC and ultimately sudden cardiac death. The present sequence is an allele
XX CC specific primer for amplifying a SNP-containing region of a human marker
XX CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
XX CC specification but are provided on a CD-R named CL001510CDR which was not
XX CC supplied with the specification.
XX SQ Sequence 16 BP; 2 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 2302 CAGTTGCAACAC 2314
Db 13 CAGTTGCAACAC 1
RESULT 125
ADR74581/c
ID ADR74581 standard; DNA; 16 BP.
XX AC ADR74581;
XX DT 16-DEC-2004 (first entry)
XX DE Allele specific primer B for human stenosis marker hCV15850923.
XX KW Human; ss; PCR; primer; Allele specific primer; coronary stenosis;
XX KW angina; ischaemic chest pain; myocardial infarction;
XX KW sudden cardiac death; SNP; single nucleotide polymorphism.
XX OS Homo sapiens.
XX PN WO2004081186-A2.
XX PR 30-APR-2003; 2003US-0466437P.

```

PD XX 23-SEP-2004.
PF XX
PR XX 10-MAR-2004; 2004WO-US007140.
PR XX
PR XX 10-MAR-2003; 2003US-0453050P.
PR XX 30-APR-2003; 2003US-0466437P.
PR XX
PA (APPL-) APPLERA CORP.
XX
XX Cargill M, Devlin JJ, Luke MM;
XX WPI; 2004-668949/65.
XX
XX Identifying an individual who has altered risk for developing stenosis
PT comprises detecting single nucleotide polymorphism (SNP), in the
PT individual's nucleic acids.
XX
XX Claim 19; SEQ ID NO 67893; 146pp; English.
XX
XX The invention relates to identifying an individual who has altered risk
CC for developing coronary stenosis comprising detecting a single nucleotide
CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not
CC given in the specification), in the individual's nucleic acids, where the
CC presence of the SNP is correlated with an altered risk for stenosis in
CC the individual. Also included are an isolated nucleic acid molecule
CC comprising at least 8 contiguous nucleotides where one of the
CC nucleotides is an SNP as cited above, or their complement), an isolated
CC polypeptide comprising an amino acid sequence selected from any of the
CC 696 amino acid sequences (not defined in the specification), an antibody
CC that specifically binds to the polypeptide (or its antigen-binding
CC fragment), an amplified polynucleotide containing the SNP as cited (where
CC the amplified polynucleotide is between about 16 and about 1,000
CC nucleotides in length), an isolated polynucleotide which specifically
CC hybridises to a nucleic acid molecule containing the SNP, a kit for
CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid
CC molecule, detecting a variant polypeptide and identifying an agent useful
CC in therapeutically or prophylactically treating stenosis. The detection
CC step of the method is carried out by a process selected from allele-
CC specific probe hybridisation, allele-specific primer extension, allele-
CC specific amplification, sequencing, 5' nuclease digestion, molecular
CC beacon assay, oligonucleotide ligation assay, size analysis, and single-
CC stranded conformation polymorphism. The method is useful for identifying
CC an individual who has altered risk for developing coronary stenosis,
CC which can lead to angina (ischaemic chest pain), myocardial infarction
CC and ultimately sudden cardiac death. The present sequence is an allele
CC specific primer for amplifying a SNP-containing region of a human marker
CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the
CC specification but are provided on a CD-R named CL001510CDR which was not
CC supplied with the specification.
XX
XX Sequence 16 BP; 2 A; 2 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2302 CAGTTCACACCAC 2314
DB 13 CAGTTCACACCAC 1

RESULT 126
AAQ05541/c
ID AAQ05541 standard; DNA; 15 BP.
XX
XX AAQ05541;
XX
XX 25-MAR-2003 (revised)
DT 10-DEC-1990 (first entry)
XX
XX Probe to sequence encoding homing receptor unit mLHRC.
DE
XX Alpha 4m; core protein gp. 90ME1-14; metastasis; cancer;

KW regional ileitis; ulcerative colitis; lymphadenitides.
XX Synthetic.
XX WO9007321-A.
XX 12-JUL-1990.
XX 23-DEC-1988; 88US-00289201.
XX 23-DEC-1988; 88US-00289201.
XX 24-FEB-1989; 89US-00315736.
XX (STRD ) UNIV LELAND STANFORD JUNIOR.
XX Weismann IL, Holzmann B, Siegelman MH;
XX WPI; 1990-238876/31.
XX
XX DNA sequence for encoding homing receptor - of e.g. alpha 4m or core
PT protein gp. 90ME1-14 free of ubiquitin.
XX
XX Example 1; Page 23; 60pp; English.
XX
XX Probe is to the degenerate code of five amino terminal residues of the
CC mature ubiquitin homing receptor unit protein. Receptor unit may be used
CC in directing a component to a homing ligand of a high endothelial venule
CC associated with a mucosal membrane, lymphoid organ, tissue or lymph node
CC in the mammalian host. Homing may be inhibited in treatment of
CC inflammatory bowel diseases such as regional ileitis, ulcerative colitis,
CC lymphadenitides, histiocytic disorders or other inflammatory conditions.
CC (Updated on 25-MAR-2003 to correct PA field.)
XX
XX Sequence 15 BP; 4 A; 3 C; 2 G; 3 T; 0 U; 3 Other;

Query Match 1.4%; Score 12.8; DB 1; Length 15;
Best Local Similarity 78.6%; Pred. No. 72;
Matches 11; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2039 TAATCATATGTCCA 2052
DB 14 TARTGRTAYGTCCA 1

RESULT 127
AAQ050518/c
ID AAQ050518 standard; DNA; 16 BP.
XX
XX AAQ050518;
XX
XX 25-MAR-2003 (revised)
DT 25-MAY-1994 (first entry)
XX
XX tRNAtyr/CAT chimeric tRNA gene primer #1.
DE
XX H1 DNA; transcription; H1 RNA; RNase P; RNasease P; cleavage; enzyme;
XX external guide sequence; EGS; prevention; expression; vital gene;
XX disease causing gene; oncogene; tumour suppressor gene; antibody;
XX cellular mRNA; hormone; co-factors; growth factor;
XX chloramphenicol acetyltransferase; CAT; ss.
XX
XX Synthetic.
XX WO9322434-A2.
XX
XX 11-NOV-1993.
XX
XX 28-APR-1993; 93WO-US003961.
XX
XX 28-APR-1992; 92US-00875099.
XX 18-AUG-1992; 92US-00931937.
XX
XX (UYVA ) UNIV YALE.

```

XX
PI Yuan Y, Guerrier-Takada CL, Altman S;
XX WPI; 1993-368793/46.
XX
XX Targetted RNA cleavage with ribonuclease P and external guide sequence -
PT forms a hybrid with the target RNA used for inactivating oncogene(s),
PT viral genes, etc.
XX
XX Example 5; Page 27; 40pp; English.
XX
XX The sequences given in AAQ50518-19 are primers which were used in the
CC construction a chimeric tRNA gene that contains sequences from the
CC chloramphenicol acetyltransferase (CAT) mRNA and tRNA^{Tyr} from E. coli.
CC These sequences were used in the production of the composition of the
CC invention. The composition targets an RNA substrate for cleavage by RNase
CC P and comprises a recombinant external guide sequence (EGS), which
CC includes a targeting site for cleavage by RNase P and a nucleotide
CC sequence complementary to the substrate. This composition is useful for
CC preventing the expression of disease causing genes in vivo, eg. to
CC inactivate RNA from oncogenes, tumour suppressor genes, viral genes or
CC cellular mRNAs encoding proteins such as enzymes, hormones, co-factors,
CC antibodies or growth factors. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 16 BP; 4 A; 1 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CCTTCAGCATCACCA 1683
Db 16 CCTTCATGCTCACCA 1

RESULT 128
AAQ98791/C
ID AAQ98791 standard; DNA; 16 BP.
XX
XX AAQ98791;
XX
XX 29-AUG-1996 (first entry)
XX CAT mRNA/E.coli tRNA-Tyr RNase P product PCR primer SEC-1C.
XX
XX external guide sequence; EGS; messenger RNA cleavage;
KW chloramphenicol acetyltransferase; RNase P; ribonuclease; PCR;
KW polymerase chain reaction; chimeric tRNA; ss.
XX
XX Synthetic.
XX
XX WO952489-A1.
XX
XX 14-SEP-1995.
XX
XX 07-MAR-1995; 95WO-US0002816.
XX
XX 07-MAR-1994; 94US-00207547.
XX 18-MAR-1994; 94US-00215082.
XX (UYUA) UNIV YALE.
XX
XX Yuan Y, Guerrier-Takada C, Altman S, Liu F;
PI WPI; 1995-328280/42.
XX
XX Targetted ribonuclease P cleavage of RNA using an oligo:nucleotide -
PT comprising a target recognition sequence and a RNase P binding sequence,
PT useful for treating cancers and viral and bacterial infections.
XX
XX Example 5; Page 31; 94pp; English.

CC Any RNA can be targetted for cleavage by RNase P, using a suitably
CC designed oligonucleotide as "external guide sequence" (EGS) to form a
CC hybrid with the target RNA and create a substrate for RNase P cleavage.
CC The EGSs contain sequences which are complementary to the target RNA and
CC which form secondary and tertiary structure similar to portions of a tRNA
CC molecule. A chimeric tRNA gene which contains sequences from CAT mRNA and
CC E.coli tRNA-Tyr as well as 9 randomised nucleotides was synthesised (see
CC e.g. AAQ98567) and was used to select for EGS sequences that guide RNase
CC P to target chloramphenicol acetyltransferase (CAT) mRNA. In the in vitro
CC selection procedure, ds DNA templates for chimeric CAT mRNA-EGS sequences
CC were constructed using two overlapping oligonucleotides SEC-1A and SEC-1B
CC (AAQ98568 and AAQ98569, respectively). SEC-1A was also used as the 5'-
CC primer for PCR in order to restore the T7 promoter and the leader
CC sequence of the RNase P-cleaved chimeric RNA for the next cycle of
CC selection. The present sequence is that of the 3'-primer SEC-1C used for
CC this amplification
XX
SQ Sequence 16 BP; 4 A; 1 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CCTTCAGCATCACCA 1683
Db 16 CCTTCATGCTCACCA 1

RESULT 129
AAV49158/C
ID AAV49158 standard; DNA; 16 BP.
XX
XX AAV49158;
XX
XX 15-OCT-1998 (first entry)
XX rb gene antisense oligonucleotide rb-N-106.
DE
XX rb gene; antisense oligonucleotide; modulate; gene expression; ss.
KW
XX Synthetic.
OS Homo sapiens.
XX
XX EP856579-A1.
XX
XX 05-AUG-1998.
XX
XX 31-JAN-1997; 97EP-00101531.
PF
XX 31-JAN-1997; 97EP-00101531.
PR
XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
PA
XX Schlingensiepen K, Brysch W;
PI WPI; 1998-400910/35.
XX
XX Preparation of antisense oligo:nucleotide(s) which lack long runs of
PT consecutive guanosine or inosine - and have specific ratio of residues
PT able to form two or three hydrogen bonds, have greater activity and
PT reduced toxicity, used therapeutically or to modulate growth of cells in
PT culture.
XX
XX Example 7; Fig 9c; 286pp; English.
PS
XX AAV49008-236 represent antisense oligonucleotides directed against the rb
CC gene. Of these, only oligonucleotides AAV49008-52 resulted in effective
CC downregulation of negative growth control by rb, while oligonucleotides
CC AAV49052-236 had little effect. The oligonucleotides exemplify the
CC invention. The specification describes oligonucleotides that contain 8-30
CC nucleotides, which contain at most 8 nucleotides that can each form three
CC hydrogen bonds to cytosine; do not contain four consecutive nucleotides
CC able to form three H-bonds each to four consecutive cytosines; do not

CC contain two sequences of three consecutive nucleotides each able to form
CC three H-bonds to three consecutive cytosines, and the ratio between
CC residues able to form two H-bonds each (2R) or three such bonds (3R) is
CC given by $2R/3R = 0.33-0.72$. The oligonucleotides are used to modulate
CC expression of genes, particularly the genes for p53, ErB-2, junB, junD,
CC TGF-beta 1 or beta 2 to control proliferation of primary cell cultures
CC (e.g. bone marrow stem, liver or kidney cells, osteoclasts, osteoblasts
CC and/or keratinocytes). The oligonucleotides can also be used to analyse
CC function of proteins (by altering their expression or activity) and
CC therapeutically, e.g. in cases of cancer or (targeting TGF) for
CC stimulating the immune system

XX SQ Sequence 16 BP; 5 A; 1 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 AAATGATACAAATTT 1933
Db 16 AAATGATACAAATTT 1

RESULT 130
AAZ23160/c
ID AAZ23160 standard; DNA; 16 BP.

AC AAZ23160;

DT 17-JAN-2000 (first entry)

DE p21 gene amplifying sense primer 1A.

KW Ovarian carcinoma; p16 gene; ovarian epithelium; detection; diagnosis;
KW p53 gene; p21 gene; beta-tubulin gene; tumor; PCR primer; ss.

XX Synthetic.

OS Homo sapiens.

PN US5976799-A.

PD 02-NOV-1999.

PF 17-MAR-1997; 97US-00819358.

PR 21-MAR-1996; 96US-0041554P.

XX (UYAR-) UNIV ARKANSAS.

PI Shigemasa K, O'Brien TJ;

DR WPI; 1999-619647/53.

XX Early detection of ovarian carcinoma.

PS Disclosure; Col 6; 18pp; English.

CC The invention provides a method for early detection of ovarian carcinoma
CC that comprises detecting overexpression of p16 mRNA in a sample derived
CC from ovarian epithelium. The method comprises: (a) taking a sample
CC containing p16 mRNA derived from the subject's ovarian epithelium; (b)
CC isolating the p16 mRNA from the sample; (c) preparing cDNA to the p16
CC mRNA; (d) combining the cDNA with primers complementary to p16 DNA target
CC sequences and to control DNA sequences; (e) amplifying the DNA in the
CC sample; (f) quantifying the amplification products; and (g) comparing the
CC amount of p16 amplification product with the amount of p16 amplification
CC product from a similarly treated reference sample. p16 mRNA is
CC overexpressed in ovarian tumors but not in normal ovaries. The methods
CC are useful for early diagnosis of ovarian carcinoma. Sequences AAZ23160-
CC 61 represent primers for amplifying the p21 gene. This is used to
CC demonstrate the mRNA expression levels of p53, p21 and p16 genes relative
CC to a beta-tubulin gene. Most tumors investigated showed an elevated p53
CC expression, low p21 expression and a very high p16 expression

XX SQ Sequence 16 BP; 3 A; 5 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 AAGGAACCTGAATTCGTG 2330
Db 16 AAGGAACCTGACTTCGG 1

RESULT 131
AAZ48622
ID AAZ48622 standard; DNA; 16 BP.

AC AAZ48622;

DT 03-MAR-2000 (first entry)

DE PCR primer for human prolactin gene.

KW PCR primer; prolactin; human; proliferation inhibitor; breast cancer;
KW prostate cancer; prolactin receptor; therapy; proliferative disorder;
KW apoptosis induction; therapy; ss.

XX Synthetic.

OS Homo sapiens.

PN WO958142-A1.

PD 18-NOV-1999.

PF 11-MAY-1999; 99WO-US010232.

PR 12-MAY-1998; 98US-0085128P.

PR 05-FEB-1999; 99US-00246041.

XX (CHEN/) CHEN W Y.
XX (WAGN/) WAGNER T E.

PI Chen WY, Wagner TE;

DR WPI; 2000-062263/05.

XX Use of human prolactin variants to treat breast or prostate cancer,
XX methods of inducing apoptosis.

PS Example; Page 30; 77pp; English.

CC This sequence represents a PCR primer for the human prolactin gene. The
CC invention relates to a method of inhibiting the proliferation of a breast
CC or prostate cancer cell which expresses a prolactin receptor comprises
CC exposing the cell to an effective concentration of a variant of human
CC prolactin having a substitution of the glycine at position 129 or a cell-
CC free truncated prolactin receptor. The method is used to treat human
CC breast and prostate cancer and proliferative disorders. The method is
CC also useful for inducing apoptosis in cells expressing the prolactin
CC receptor. The prolactin variants act as antagonists at the prolactin
CC receptor. Also provided is a cell-based assay system that can be used to
CC identify compounds that modulate prolactin receptor activity

XX SQ Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1870 ATGAACATCAATGAT 1885
Db 1 ATGAACATCAATGAT 16

DR WPI; 2001-611503/70.
XX Novel polypeptides that are the regulators of BRCA-1, useful for treating
PT cancer and diagnosing the presence of neoplastic cells in biological
PT sample.
XX Disclosure; Fig 8; 97pp; English.
XX Sequences AAS56729-AAS56968 represent DNA encoding BRCA-1 regulators, RNA
CC ribozyme target recognition RNA sequences, DNA fragments encoding the
CC and primers used in the methods of the invention. Hybridisation of
CC ribozymes to their targets results in cleavage of the RNA target. The
CC ribozymes can be used to cleave regulators of the tumour suppressor BRCA-
CC 1, resulting in upregulation or downregulation of BRCA-1 in a cell. The
CC mRNA targets include those encoding the BRCA-1 regulator BR1 inhibitor
CC dominant-negative 4 (ID4), breast basic conserved protein 1 (BBC1),
CC CHIR2, Af6, BR2 and BR3. Regulation of BRCA-1 is useful for treating and
CC diagnosing cancer and other proliferative disorders. The severity of an
CC incidence of cancer can be lessened by regulating tumour proliferation
CC through modulation of BRCA-1 expression. The sequences of the invention
CC are useful in the development of anti-cancer drugs
XX
SQ Sequence 16 BP; 1 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2289 AAAATTGGGACCTCAG 2304
DB 16 AAAATAGGACCAACAG 1
RESULT 135
ACA60933
ID ACA60933 standard; DNA; 16 BP.
XX
AC ACA60933;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human prolactin sense RT-PCR primer.
XX
KW Human; prolactin; antagonist; cancer cell proliferation; breast cancer;
KW prostate cancer; cellular apoptosis; primer; ss; reverse transcriptase;
KW RT-PCR.
XX
OS Homo sapiens.
XX
PN US2003022833-A1.
XX
PD 30-JAN-2003.
XX
PF 08-MAY-2002; 2002US-00140293.
XX
PR 13-MAY-1998; 98US-0085228P.
PR 05-FEB-1999; 99US-00246041.
XX
PA (GREE-) GREENVILLE HOSPITAL SYSTEM.
XX
PI Chen WY, Wagner TE;
XX
DR WPI; 2003-438990/41.
XX
PT Use of a variant of human prolactin for inhibiting the proliferation of
PT breast and prostate cancer cells.
XX
PS Example 7; Page 8; 68pp; English.
XX
CC The invention relates to a method of inhibiting the proliferation of
CC breast and prostate cancer cells expressing a prolactin receptor which
CC involves exposing the cell to a variant of human prolactin having a
CC substitution of the glycine at position 129, or a cell-free truncated

CC prolactin receptor. The method is useful for inhibiting the proliferation
CC of a breast cancer and prostate cancer cells; and for inducing cellular
CC apoptosis in a cell expressing the prolactin receptor. The human
CC prolactin variant in combination with an anti-oestrogen induces a
CC synergistic inhibitory effect on cell proliferation. The present sequence
CC represents the human prolactin sense reverse transcriptase (RT)-PCR
XX primer
XX
SQ Sequence 16 BP; 8 A; 2 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 80;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1870 ATGAACATCAATGAT 1885
DB 1 ATGAACATCAAGGAT 16
RESULT 136
ABP11493/c
ID ABP11493 standard; DNA; 13 BP.
XX
AC ABP11493;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 111490 for detecting SNP TSC0027841.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 111490; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 2 C; 0 G; 9 T; 0 U; 1 Other;
Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```
QY 2282 GGAAAAAAATTT 2294
DB 13 GGAAAAAAATTT 1
RESULT 137
ABC14272/c
ID ABC14272 standard; DNA; 13 BP.
XX AC ABC14272;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 14279 for detecting SNP TSC0003242.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 14279; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 3 A; 0 C; 1 G; 8 T; 0 U; 1 Other;
QY Query Match 1.4%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 59;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1888 AAAATATATACAA 1900
DB 13 AAAATATATACAA 1
RESULT 138
ABC31897
ID ABC31897 standard; DNA; 13 BP.
XX AC ABC31897;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 4851 for detecting SNP TSC0001714.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 14279; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 1 Other;
QY Query Match 1.4%; Score 12.6; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 59;
XX Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1997 ATCATTTAACCAC 2009
DB 1 RTCATTTAACCAC 13
RESULT 139
ABC04860
ID ABC04860 standard; DNA; 13 BP.
XX AC ABC04860;
XX DT 20-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 4851 for detecting SNP TSC0001714.
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 31914; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 4 C; 0 G; 4 T; 0 U; 1 Other;
```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 4851; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;
Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2057 TAGATTATGTTAC 2069
Db 1 TAGATTATGTTAY 13
|||||
RESULT 140
ABF11492
ID ABF11492 standard; DNA; 13 BP.
XX
AC ABF11492;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 111489 for detecting SNP TSC0027841.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 4851; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 2 G; 6 T; 0 U; 1 Other;
Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2057 TAGATTATGTTAC 2069
Db 1 TAGATTATGTTAY 13
|||||
RESULT 140
ABF11492
ID ABF11492 standard; DNA; 13 BP.
XX
AC ABF11492;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 111489 for detecting SNP TSC0027841.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 4851; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 1 Other;
Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2282 GGAAAAAAAATT 2294
Db 1 GGAAAAAAAATT 13
|||||
RESULT 141
ABC14273
ID ABC14273 standard; DNA; 13 BP.
XX
AC ABC14273;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 14280 for detecting SNP TSC0003242.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPITG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 14280; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

```

```
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 1 C; 0 G; 3 T; 0 U; 1 Other;

Query Match          1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1888 AAAATATATACAA 1900
Db 1 RAAATATATACAA 13

RESULT 142
ABC59749
ID ABC59749 standard; DNA; 13 BP.
XX
AC ABC59749;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 59766 for detecting SNP TSC0015985.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 59766; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
-ABC59989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 0 G; 3 T; 0 U; 1 Other;

This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
-ABC59989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 0 G; 3 T; 0 U; 1 Other;

Query Match          1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1582 AAATATATAAATA 1594
Db 1 RAAATATATAAATA 13

RESULT 143
ABC31896/C
ID ABC31896 standard; DNA; 13 BP.
XX
AC ABC31896;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 31913 for detecting SNP TSC0009939.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX
Claim 1; SEQ ID NO 31913; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
-ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABT00010-ABT82073
represent the oligomers described in the invention. NOTE: The sequence
data for this patent did not form part of the printed specification, but
was obtained in electronic format from WIPO at
ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 1 Other;

Query Match          1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 59;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1997 ATCATTTTAAACCAC 2009
Db 13 RTCATTTTAAACCAC 1

RESULT 144
ABC59748/C
ID ABC59748 standard; DNA; 13 BP.
XX
AC ABC59748;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 59765 for detecting SNP TSC0015985.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
```

KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 PN WO200177384-A2.
 XX 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 59765; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 0 G; 9 T; 0 U; 1 Other;
 XX
 Query Match 1.4%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 59;
 Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1582 AAATATAAAATA 1594
 Db 13 RAATATAAAATA 1
 :|||||
 RESULT 145
 ABC38162/c
 ID ABC38162 standard; DNA; 13 BP.
 XX
 AC ABC38162;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 38179 for detecting SNP TSC0011829.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 38179; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 0 C; 0 G; 9 T; 0 U; 1 Other;
 XX
 Query Match 1.4%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 59;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 1581 AAAATATAAAAT 1593
 Db 13 RAAATATAAAAT 1
 :|||||
 RESULT 146
 ABC38163
 ID ABC38163 standard; DNA; 13 BP.
 XX
 AC ABC38163;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 38180 for detecting SNP TSC0011829.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 38180; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 9 A; 0 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 59;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1581 ARAATATAAAAT 1593
 DB 1 ARAATATAAAAT 13

RESULT 147
 ABC04861/C
 ID ABC04861 standard; DNA; 13 BP.

XX AC ABC04861;

DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 4852 for detecting SNP TSC0001714.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPITG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX Claim 1; SEQ ID NO 4852; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 2 C; 0 G; 4 T; 0 U; 1 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 59;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2057 TAGATTATGTTAC 2069
 DB 13 TAGATTATGTTAY 1

RESULT 148
 AAQ05538/C
 ID AAQ05538 standard; DNA; 15 BP.

XX AC AAQ05538;

XX DT 25-MAR-2003 (revised)

DT 10-DEC-1990 (first entry)

XX Probe to sequence encoding homing receptor unit MLHRC.

XX Alpha 4m; core protein gp. 90ME1-14; metastasis; cancer;
 KW regional ileitis; ulcerative colitis; lymphadenitides.

XX OS Synthetic.

XX WO9007321-A.

PD 12-JUL-1990.

PF 23-DEC-1988; 88US-00289201.

PR 23-DEC-1988; 88US-00289201.

PR 24-FEB-1989; 89US-00315736.

PA (STRD) UNIV LELAND STANFORD JUNIOR.

XX Weismann IL, Holzmam B, Siegelman MH;

XX WPI; 1990-238876/31.

PT DNA sequence for encoding homing receptor - of e.g. alpha 4m or core
 PT protein gp. 90ME1-14 free of ubiquitin.

XX Example 1; Page 23; 60pp; English.

XX Probe is to the degenerate code of five amino terminal residues of the
 CC mature ubiquitin homing receptor unit protein. Receptor unit may be used
 CC in directing a component to a homing ligand of a high endothelial venule
 CC associated with a mucosal membrane, lymphoid organ, tissue or lymph node
 CC in the mammalian host. Homing may be inhibited in treatment of
 CC inflammatory bowel diseases such as regional ileitis, ulcerative colitis,
 CC lymphadenitides, histiocytic disorders or other inflammatory conditions.
 CC (Updated on 25-MAR-2003 to correct PA field.)

XX Sequence 15 BP; 4 A; 2 C; 2 G; 4 T; 0 U; 3 Other;

Query Match 1.4%; Score 12.6; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 76;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2038 ATAATGATATGTCCA 2052
 DB 15 ATATGRTATGTCCA 1

RESULT 149
 ABL01281
 ID ABL01281 standard; DNA; 15 BP.

XX AC ABL01281;

XX DT 12-MAR-2002 (first entry)

DE Human MMP3 gene polymorphism detection ASO primer SEQ ID NO:60.
 XX Human; matrix metalloproteinase 3; MMP3; chromosome 11q22.3; SNP;
 KW haplotype; polymorphism; polymorphic; single nucleotide polymorphism;
 KW probe; primer; detection; genotyping; vulnerable; cytosolic; cancer;
 KW antiarteriosclerotic; gene therapy; coronary atherosclerosis;
 KW wound healing; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179238-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 17-APR-2001; 2001WO-US012452.
 XX
 PR 17-APR-2000; 2000US-0197911P.
 PR 13-JUL-2000; 2000US-0218092P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Bentivegna SC, Chew A, Choi JY, Koshy B, Stephens JC;
 XX
 DR WPI; 2002-075067/10.
 XX
 PT Genotyping human matrix metalloproteinase 3 gene of an individual for
 PT determining the haplotype of the individual, comprises determining the
 PT identity of a nucleotide pair at specific polymorphic sites for two
 PT copies of the gene.
 XX
 PS Claim 15; Page 15; 83pp; English.
 XX
 CC The present invention describes a method for genotyping a human matrix
 CC metalloproteinase 3 (MMP3) gene of an individual. MMP3 has vulnerary,
 CC cytosolic and antiarteriosclerotic activity, and can be used in gene
 CC therapy. The method can be used for improving the efficacy and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with MMP3 activity, e.g., wound healing,
 CC cancer and coronary atherosclerosis; to validate MMP3 as a candidate
 CC agent for treating a specific condition or disease predicted to be
 CC associated with MMP3 activity; and in the design of clinical trials of
 CC candidate drugs for treating a specific condition or disease predicted to
 CC be associated with MMP3 activity. Polymorphic variants of a reference
 CC sequence for MMP3 (see ABL01223) are useful in studying the expression
 CC and function of MMP3, and in expressing MMP3 protein for use in screening
 CC for candidate drugs to treat diseases related to MMP3 activity. ABL01225
 CC to ABL01246 and ABL01247 to ABL01290 represent allele-specific
 CC oligonucleotide (ASO) probes and primers used in the detection of
 CC polymorphisms in the human MMP3 gene. ABL01291 to ABL01334 represent
 CC preferred primers used in the detection of polymorphisms in the human
 CC MMP3 gene
 XX
 SQ Sequence 15 BP; 8 A; 3 C; 1 G; 2 T; 0 U; 1 Other;
 Query Match 1.4%; Score 12.6; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. NO. 76;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 1869 CATGAATCAAA 1881
 DB 3 CATGAATCAAA 15
 Search completed: April 6, 2005, 15:54:27
 Job time : 2 secs

; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-52

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 GACAGTGGTTATTAAAGCAT 1567
|||||
DB 20 GACAGTGGTTATTAAAGCAT 1

RESULT 2
US-09-966-451-53/c
; Sequence 53, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-53

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1560 TAAAGCATGGTTGAACCTC 1579
|||||
DB 20 TAAAGCATGGTTGAACCTC 1

RESULT 3
US-09-966-451-54/c
; Sequence 54, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-54

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1646 TACAGTAATCCCTGAGAAAT 1665
|||||
DB 20 TACAGTAATCCCTGAGAAAT 1

RESULT 4

US-09-966-451-55/c
; Sequence 55, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 55

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-55

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1674 AGCATCACCAACACAGTTT 1693
|||||
DB 20 AGCATCACCAACACAGTTT 1

RESULT 5

US-09-966-451-56/c
; Sequence 56, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 56

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-56

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 CAAAAGAGCCTGGCTCTA 1730
|||||
DB 20 CAAAAGAGCCTGGCTCTA 1

RESULT 6

US-09-966-451-57/c
; Sequence 57, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 57

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-57

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CCTGGGCTGTATAGGCTG 1739
|||||
DB 20 CCTGGGCTGTATAGGCTG 1

RESULT 7
US-09-966-451-58/c
; Sequence 58, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-58

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1737 GTGGAACACTCTGATCTGA 1756
|||||
DB 20 GTGGAACACTCTGATCTGA 1

RESULT 8
US-09-966-451-59/c
; Sequence 59, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-59

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1756 AAGCCCGCTGACTCCACTA 1775
|||||
DB 20 AAGCCCGCTGACTCCACTA 1

RESULT 9
US-09-966-451-60/c
; Sequence 60, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-60

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1810 CTGCTGTGAGCCACTAATAA 1829
|||||
DB 20 CTGCTGTGAGCCACTAATAA 1

RESULT 10
US-09-966-451-61/c
; Sequence 61, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-61

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1829 ACATTGGGCTAATATCTGCT 1848
|||||
DB 20 ACATTGGGCTAATATCTGCT 1

RESULT 11
US-09-966-451-62/c
; Sequence 62, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-62

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1846 GCTGTGCTTCTCTGACAGGT 1865
|||||
DB 20 GCTGTGCTTCTCTGACAGGT 1

RESULT 12

US-09-966-451-63/c
; Sequence 63, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-63

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1854 TCTCTGACAGGTAGTCATGA 1873
|||||
DB 20 TCTCTGACAGGTAGTCATGA 1

RESULT 13

US-09-966-451-64/c
; Sequence 64, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-64

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1894 TATCAAGCACTTTGTAAAT 1913
|||||
DB 20 TATCAAGCACTTTGTAAAT 1

RESULT 14

US-09-966-451-65/c
; Sequence 65, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-65

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1951 TTACAAATCCTATTAGTCA 1970
|||||
DB 20 TTACAAATCCTATTAGTCA 1

RESULT 15

US-09-966-451-66/c
; Sequence 66, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-66

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1985 GTGTTACAGCAATCATTTA 2004
|||||
DB 20 GTGTTACAGCAATCATTTA 1

RESULT 16

US-09-966-451-67/c
; Sequence 67, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-67

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2066 TTACATGACAAAGTTGAAGG 2085
|||||
Db 20 TTACATGACAAAGTTGAAGG 1

RESULT 17

US-09-966-451-68/c
; Sequence 68, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 68
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-68

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2089 TTGGCAGATGCAGTTAAGGT 2108
|||||
Db 20 TTGGCAGATGCAGTTAAGGT 1

RESULT 18

US-09-966-451-69/c
; Sequence 69, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 69
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-69

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2137 AAAGGCCCTGACCTAATCCA 2156
|||||
Db 20 AAAGGCCCTGACCTAATCCA 1

RESULT 19

US-09-966-451-70/c
; Sequence 70, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 70
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-70

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2191 GCCTTGACAGACTATGTGAG 2210
|||||
Db 20 GCCTTGACAGACTATGTGAG 1

RESULT 20

US-09-966-451-71/c
; Sequence 71, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 71
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-71

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2211 AGGGCCACATTGGCTAAAC 2230
|||||
Db 20 AGGGCCACATTGGCTAAAC 1

RESULT 21

US-09-966-451-72/c
; Sequence 72, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 72
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-72

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 CATTGGCTAAACCTAAAGG 2237
|||||
Db 20 CATTGGCTAAACCTAAAGG 1

RESULT 22
US-09-966-451-73/c
; Sequence 73, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-73

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2223 GCTAAACCTAAAGGTGGCC 2242
|||||
Db 20 GCTAAACCTAAAGGTGGCC 1

RESULT 23
US-09-966-451-74/c
; Sequence 74, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-74

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2236 GGTGGCCTCTAGGATGAG 2255
|||||
Db 20 GGTGGCCTCTAGGATGAG 1

RESULT 24
US-09-966-451-75/c
```

```
; Sequence 75, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-75

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2256 ACCTACCTTCCAGTTGTCAG 2275
|||||
Db 20 ACCTACCTTCCAGTTGTCAG 1

RESULT 25
US-09-966-451-76/c
; Sequence 76, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-76

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2267 AGTTGTCAGCAAGCAGGAAA 2286
|||||
Db 20 AGTTGTCAGCAAGCAGGAAA 1

RESULT 26
US-09-966-451-77/c
; Sequence 77, Application US/09966451
; Patent No. 6692959
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-77

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2364 AGCTTCAGATGATACAC 2383
DB 20 AGCTTCAGATGATACAC 1

RESULT 27

US-09-966-451-78/c
; Sequence 78, Application US/09966451
; Patent No. 6692959

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 78

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-78

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2377 TAACACAGCTGGGTGAC 2396
DB 20 TAACACAGCTGGGTGAC 1

RESULT 28

US-09-966-451-79/c
; Sequence 79, Application US/09966451
; Patent No. 6692959

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 79

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-79

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2419 ATCCTCAGTATGAGATCTA 2438
DB 20 ATCCTCAGTATGAGATCTA 1

RESULT 29

US-09-418-640-80
; Sequence 80, Application US/09418640

; Patent No. 6140125
; GENERAL INFORMATION:
; APPLICANT: Jennifer K. Taylor
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF BCL-6 EXPRESSION
; FILE REFERENCE: RTS-0102
; CURRENT APPLICATION NUMBER: US/09/418,640
; CURRENT FILING DATE: 1999-10-15
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-418-640-80

Query Match 2.0%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1902 CACTTGTAAATTGTAAA 1919
DB 3 CACTTGTAAATTGTAAA 20

RESULT 30

US-09-422-978-11728
; Sequence 11728, Application US/09422978
; Patent No. 6537751

; GENERAL INFORMATION:

; APPLICANT: Cohen, Daniel

; APPLICANT: Blumenfeld, Marta

; APPLICANT: Chumakov, Ilya

; TITLE OF INVENTION: Biallelic markers for use in constructing a high density....

; FILE REFERENCE: GENESET-020CPI

; CURRENT APPLICATION NUMBER: US/09/422,978

; CURRENT FILING DATE: 1999-10-20

; EARLIER APPLICATION NUMBER: US 09/298,850

; EARLIER FILING DATE: 1999-04-21

; EARLIER APPLICATION NUMBER: US 60/109,732

; EARLIER FILING DATE: 1998-11-23

; EARLIER APPLICATION NUMBER: US 60/082,614

; EARLIER FILING DATE: 1998-04-21

; NUMBER OF SEQ ID NOS: 11796

; SEQ ID NO 11728

; LENGTH: 19

; TYPE: DNA

; ORGANISM: Homo Sapiens

; FEATURE:

; NAME/KEY: primer_bind

; LOCATION: 1..19

; OTHER INFORMATION: downstream amplification primer 99-3884 for SEQ 3863, in complemer

US-09-422-978-11728

Query Match 1.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 7.5;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2146 GACCTAATCCAAGTGAACC 2164
DB 1 GAACAAATCCAAGTGAACC 19

RESULT 31

US-09-371-772B-6036/c
; Sequence 6036, Application US/0937172B
; Patent No. 6566127

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; FILE REFERENCE: MBH900,876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: Patent in version 3.0
 ; SEQ ID NO 6036
 ; LENGTH: 16
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; US-09-371-772B-6036

Query Match 1.6%; Score 15; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 13;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1897 ACAAGCATTGTAA 1911
 DB 16 ACAAGCATTGTAA 2

RESULT 32
 US-08-584-040-4387/c
 ; Sequence 4387, Application US/08584040
 ; Patent No. 6346398
 ; GENERAL INFORMATION:
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: TREATMENT OF DISEASES OR
 ; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 ; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 ; NUMBER OF SEQUENCES: 8502
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/584,040
 ; FILING DATE: January 11, 1996
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/005,974
 ; FILING DATE: October 26, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/064
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 4387:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 16 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear

; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-584-040-4387
 Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 19;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAATG 1883
 DB 14 ATGAAATCAATG 1

RESULT 33
 US-08-584-040-5942/c
 ; Sequence 5942, Application US/08584040
 ; Patent No. 6346398
 ; GENERAL INFORMATION:
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Stinchcomb, Dan T.
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
 ; TITLE OF INVENTION: TREATMENT OF DISEASES OR
 ; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
 ; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
 ; NUMBER OF SEQUENCES: 8502
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/584,040
 ; FILING DATE: January 11, 1996
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/005,974
 ; FILING DATE: October 26, 1995
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 218/064
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 5942:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-584-040-5942

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 19;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAATG 1883

Db 14 ATGAAATCAAATG 1

RESULT 34

US-09-371-772B-2154/c
; Sequence 2154, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2154
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2154

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAATG 1883

Db 14 ATGAAATCAAATG 1

RESULT 35

US-09-371-772B-2779/c
; Sequence 2779, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2779
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2779

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAATG 1883

Db 14 ATGAAATCAAATG 1

RESULT 36

US-09-685-664B-2154/c
; Sequence 2154, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2154
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-2154

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAATG 1883

Db 14 ATGAAATCAAATG 1

RESULT 37

US-09-685-664B-2779/c
; Sequence 2779, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2779
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2779

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1870 ATGAAATCAATG 1883
Db 14 ATGAAATCAATG 1

RESULT 38
US-08-373-124A-1168/c
; Sequence 1168, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1168:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-373-124A-1170
; Query Match 1.5%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 88.2%; Pred. No. 21;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1573 GAATTCCTCAAAATATAA 1589
Db 17 GAATTCCTCAAAATATAA 1

RESULT 40
US-08-435-628-1168/c
; Sequence 1168, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; NUMBER OF SEQUENCES: 2627
```

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/435,628
;; FILING DATE: 05-MAY-1995
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/373,124
;; FILING DATE: January 13, 1995
;; APPLICATION NUMBER: 08/245,466
;; FILING DATE: May 18, 1994
;; APPLICATION NUMBER: 08/192,943
;; FILING DATE: February 7, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1168:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-435-628-1168

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1574 AACTTCCAAAATATAA 1590
DB 17 AACTTCCAAAATATAA 1

RESULT 41
US-08-435-628-1170/c
; Sequence 1170, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California

;; COUNTRY: U.S.A.
;; ZIP: 90071
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/435,628
;; FILING DATE: 05-MAY-1995
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/373,124
;; FILING DATE: January 13, 1995
;; APPLICATION NUMBER: 08/245,466
;; FILING DATE: May 18, 1994
;; APPLICATION NUMBER: 08/192,943
;; FILING DATE: February 7, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1170:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-435-628-1170

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1573 GAACTTCCAAAATATAA 1589
DB 17 GAACTTCCAAAATATAA 1

RESULT 42
US-08-896-116-2
; Sequence 2, Application US/08896116
; Patent No. 5869336
; GENERAL INFORMATION:
; APPLICANT: Meyer, Sheryl L.
; APPLICANT: Scott, Richard W.
; APPLICANT: Siman, Robert
; TITLE OF INVENTION: Recombinant Enzymatically Active Calpain
; TITLE OF INVENTION: Expressed in a Baculovirus System
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5869336ris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/896,116

```

; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/275,683
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: CEPH-013
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-896-116-2

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 CACTCTGATCTGAAGCC 1760
DB 1 CACCTTGATCTGAAGAC 17

RESULT 43
US-08-819-358-3/c
; Sequence 3, Application US/08819358
; Patent No. 5976799
; GENERAL INFORMATION:
; APPLICANT: O'BRIEN, TIMOTHY J.
; APPLICANT: SHIGEMASA, KAZUSHI
; TITLE OF INVENTION: EARLY DETECTION OF OVARIAN CARCINOMA
; TITLE OF INVENTION: USING p16 GENE PRODUCTS
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MARTIN L. MCGREGOR
; STREET: 5380 WEST 34TH STREET, #345
; CITY: HOUSTON
; STATE: TEXAS
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 77092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE 3.5 INCH 1.44 MB STORAGE
; COMPUTER: IBM COMPATIBLE
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/819,358
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/621,180
; FILING DATE: MARCH 21, 1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: MCGREGOR, MARTIN L.
; REGISTRATION NUMBER: 29,329
; REFERENCE/DOCKET NUMBER: 1-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713-682-1213
; TELEFAX: 713-682-5807
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 BASE PAIRS

```

```

; TYPE: NUCLEIC ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; MOLECULE TYPE: OTHER NUCLEIC ACID
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-819-358-3

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2315 AAGGAAGTCTGATCTGCG 2331
DB 17 AAGGAAGTCTGATCTGCG 1

RESULT 44
US-08-896-122-2
; Sequence 2, Application US/08896122
; Patent No. 6057143
; GENERAL INFORMATION:
; APPLICANT: Meyer, Sheryl L.
; APPLICANT: Scott, Richard W.
; APPLICANT: Siman, Robert
; TITLE OF INVENTION: Recombinant Enzymatically Active Calpain
; TITLE OF INVENTION: Expressed in a Baculovirus System
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 6057143rls
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/896,122
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/275,683
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: CEPH-013
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-896-122-2

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 CACTCTGATCTGAAGCC 1760
DB 1 CACCTTGATCTGAAGAC 17

```


Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATAATCAAAATGATGC 1887
DB 17 TGAATAATCAAAATGATGC 1

RESULT 48
US-09-371-772B-2153/c
; Sequence 2153, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2153
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2153

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATAATCAAAATGATGC 1887
DB 17 TGAATAATCAAAATGATGC 1

RESULT 49
US-09-371-772B-2778/c
; Sequence 2778, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2778

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATAATCAAAATGATGC 1887
DB 17 TGAATAATCAAAATGATGC 1

RESULT 50
US-09-371-772B-5483/c
; Sequence 5483, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 08/584,040
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5483
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5483

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1899 AAGCACTTTGTAAATTTG 1915
DB 17 AAGCACTTTGTAACTAG 1

RESULT 51
US-09-866-108A-2781
; Sequence 2781, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2781
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2781

Query Match          1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CTCCTTCAAGCACC 1682
DB 1 CACCTTCAAGCACC 17

RESULT 52
US-09-685-664B-2153/c
; Sequence 2153, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2153
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-2153

Query Match          1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAANAATCAATGATGC 1887
DB 17 TGAANAATCAATGCGGC 1

RESULT 53
US-09-685-664B-2778/c
; Sequence 2778, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
```

```
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH800-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-2778

Query Match          1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAANAATCAATGATGC 1887
DB 17 TGAANAATCAATGCGGC 1

RESULT 54
PCT-US95-08487-2
; Sequence 2, Application PC/TUS9508487
; GENERAL INFORMATION:
; APPLICANT: Meyer, Sheryl L.
; APPLICANT: Scott, Richard W.
; APPLICANT: Siman, Robert
; TITLE OF INVENTION: Recombinant Enzymatically Active
; TITLE OF INVENTION: Calpain Expressed IN A Baculovirus System
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz &
; ADDRESSEE: Norris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/08487
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: CEPH-013
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
PCT-US95-08487-2
```

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 21;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1744 CACTCTGATCTGAAGCC 1760
||| ||||| ||||| |||||
Db 1 CACCCGTGATCTGAAGAC 17

RESULT 55
US-07-971-978-22/c
; Sequence 22, Application US/07971978
; Patent No. 5614617
; GENERAL INFORMATION:
; APPLICANT: Cook and Sanghvi
; TITLE OF INVENTION: Nuclease Resistant, Pyrimidine
; TITLE OF INVENTION: Modified Oligonucleotides that Detect and Modulate
; TITLE OF INVENTION: Gene Expression
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESSEE: No. 5614617ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/971,978
; FILING DATE: February 18, 1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/558,806
; FILING DATE: July 27, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0333
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 13
; OTHER INFORMATION: 6-aza-cytidine substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 14
; OTHER INFORMATION: 6-aza-cytidine substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 15
; OTHER INFORMATION: 6-aza-cytidine substitution
; US-07-971-978-22

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 26;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2389 GGGCTGACACCTGGA 2403
||| ||||| ||||| |||||
Db 15 GGGCGGACACCTGGA 1

RESULT 57
US-07-971-978-52/c
; Sequence 52, Application US/07971978
; Patent No. 5614617
; GENERAL INFORMATION:
; APPLICANT: Cook and Sanghvi

Db 15 GGGCGGACACCTGGA 1
||| ||||| ||||| |||||

RESULT 56
US-07-971-978-23/c
; Sequence 23, Application US/07971978
; Patent No. 5614617
; GENERAL INFORMATION:
; APPLICANT: Cook and Sanghvi
; TITLE OF INVENTION: Nuclease Resistant, Pyrimidine
; TITLE OF INVENTION: Modified Oligonucleotides that Detect and Modulate
; TITLE OF INVENTION: Gene Expression
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
; ADDRESSEE: No. 5614617ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/971,978
; FILING DATE: February 18, 1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/558,806
; FILING DATE: July 27, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0333
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 14
; OTHER INFORMATION: 6-aza-cytidine substitution
; FEATURE:
; NAME/KEY: Modified-site
; LOCATION: 15
; OTHER INFORMATION: 6-aza-cytidine substitution
; US-07-971-978-23

Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 26;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2389 GGGCTGACACCTGGA 2403
||| ||||| ||||| |||||
Db 15 GGGCGGACACCTGGA 1

RESULT 57
US-07-971-978-52/c
; Sequence 52, Application US/07971978
; Patent No. 5614617
; GENERAL INFORMATION:
; APPLICANT: Cook and Sanghvi

;; TITLE OF INVENTION: Nuclease Resistant, Pyrimidine
;; TITLE OF INVENTION: Modified Oligonucleotides that Detect and Modulate
;; TITLE OF INVENTION: Gene Expression
;; NUMBER OF SEQUENCES: 65
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
;; ADDRESSEE: No. 5614617ris
;; STREET: One Liberty Place - 46th Floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: WordPerfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/971,978
;; FILING DATE: February 18, 1993
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/558,806
;; FILING DATE: July 27, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Joseph Lucci
;; REGISTRATION NUMBER: 33,307
;; REFERENCE/DOCKET NUMBER: ISIS-0333
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 52:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 16 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; FEATURE:
;; NAME/KEY: Modified-site
;; LOCATION: 13
;; OTHER INFORMATION: 5-bromo-2'-deoxycytidine
;; OTHER INFORMATION: substitution
;; FEATURE:
;; NAME/KEY: Modified-site
;; LOCATION: 14
;; OTHER INFORMATION: 5-bromo-2'-deoxycytidine
;; OTHER INFORMATION: substitution
;; FEATURE:
;; NAME/KEY: Modified-site
;; LOCATION: 15
;; OTHER INFORMATION: 5-bromo-2'-deoxycytidine
;; OTHER INFORMATION: substitution
;; US-07-971-978-52
Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 26;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2389 GGCTGACACCTGGA 2403
DB 15 GGCGGACACCTGGA 1
RESULT 58
US-07-971-978-58/c
; Sequence 58, Application US/07971978
; Patent No. 5614617
; GENERAL INFORMATION:
; APPLICANT: Cook and Sanghvi
; TITLE OF INVENTION: Nuclease Resistant, Pyrimidine
; TITLE OF INVENTION: Modified Oligonucleotides that Detect and Modulate
; TITLE OF INVENTION: Gene Expression

;; NUMBER OF SEQUENCES: 65
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and
;; ADDRESSEE: No. 5614617ris
;; STREET: One Liberty Place - 46th Floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: WordPerfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/971,978
;; FILING DATE: February 18, 1993
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/558,806
;; FILING DATE: July 27, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Joseph Lucci
;; REGISTRATION NUMBER: 33,307
;; REFERENCE/DOCKET NUMBER: ISIS-0333
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 58:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 16 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; FEATURE:
;; NAME/KEY: Modified-site
;; LOCATION: 13
;; OTHER INFORMATION: 5-methyl-2'-deoxycytidine
;; OTHER INFORMATION: substitution
;; FEATURE:
;; NAME/KEY: Modified-site
;; LOCATION: 14
;; OTHER INFORMATION: 5-methyl-2'-deoxycytidine
;; OTHER INFORMATION: substitution
;; FEATURE:
;; NAME/KEY: Modified-site
;; LOCATION: 15
;; OTHER INFORMATION: 5-methyl-2'-deoxycytidine
;; OTHER INFORMATION: substitution
;; US-07-971-978-58
Query Match 1.5%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 26;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2389 GGCTGACACCTGGA 2403
DB 15 GGCGGACACCTGGA 1
RESULT 59
US-08-311-486C-21/c
; Sequence 21, Application US/08311486C
; Patent No. 5811300
; GENERAL INFORMATION:
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth Draper
; APPLICANT: Kevin Kisich
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwigen
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS

```

; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: TNF-
; NUMBER OF SEQUENCES: 1157
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/311,486C
; FILING DATE: September 23, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION/DOCKET NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/166
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-311-486C-21

Query Match 1.4%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2201 AGTATGTGAGAGG 2213
Db 15 AGTATGTGAGAGG 3

RESULT 60
US-09-479-005A-70/c
; Sequence 70, Application US/09/479,005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MEH000-884-C
; CURRENT APPLICATION NUMBER: US/09/479,005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 70
; LENGTH: 16

; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-479-005A-70

Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 31;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2278 AGCAGGAAAAAA 2290
Db 13 AGCAGGAAAAAA 1

RESULT 61
US-08-207-547A-15/c
; Sequence 15, Application US/08207547A
; Patent No. 5624824
; GENERAL INFORMATION:
; APPLICANT: Yuan, Yan
; APPLICANT: Guerrier-Takada, Cecilia
; APPLICANT: Altman, Sidney
; APPLICANT: Liu, Fenyong
; TITLE OF INVENTION: Targeted Cleavage of RNA Using
; TITLE OF INVENTION: Eukaryotic Ribonuclease P and External Guide Sequence
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center
; STREET: 1201 West Peachtree Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/207,547A
; FILING DATE: 07-MAR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: US PCT/US93/03961
; FILING DATE: 28-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/054,892
; FILING DATE: 29-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/875,099
; FILING DATE: 28-APR-1992
; APPLICATION NUMBER: US 07/931,837
; FILING DATE: 18-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/328,368
; FILING DATE: 24-MAR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: YU100CIP(4)
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404)-873-8794
; TELEFAX: (404)-873-8795
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

```

```

; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-207-547A-15

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 34;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CCTTCAAGCATCACCA 1683
DB 16 CCTTCATGCTCACC A 1

RESULT 62
US-08-215-082-15/c
; Sequence 15, Application US/08215082
; Patent No. 5728521
; GENERAL INFORMATION:
; APPLICANT: Yuan, Yan
; APPLICANT: Guerrier-Takada, Cecilia
; APPLICANT: Altman, Sidney
; APPLICANT: Liu, Fenyong
; TITLE OF INVENTION: Targeted Cleavage of RNA Using
; TITLE OF INVENTION: Eukaryotic Ribonuclease P and External Guide Sequence
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 1100 Peachtree Street, Suite 2800
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30309-4530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/215,082
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: YU100CIP(4)
; FILING DATE: 07-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US PCT/US93/03961
; FILING DATE: 28-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/054,892
; FILING DATE: 29-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/931,837
; FILING DATE: 18-AUG-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/875,099
; FILING DATE: 28-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/568,834
; FILING DATE: 17-AUG-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/328,368
; FILING DATE: 24-MAR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: YU100CIP(5)
; TELEPHONE: (404)-815-6555
; TELEFAX: (404)-815-6508
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-702-652-15

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 34;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1668 CCTTCAAGCATCACCA 1683
DB 16 CCTTCATGCTCACC A 1

RESULT 63
US-08-702-652-15/c
; Sequence 15, Application US/08702652
; Patent No. 5869248
; GENERAL INFORMATION:
; APPLICANT: Yan Yuan, Cecilia Guerrier-Takada, and
; APPLICANT: Sidney Altman
; TITLE OF INVENTION: TARGETED CLEAVAGE OF RNA USING
; TITLE OF INVENTION: RIBONUCLEASE P TARGETING AND CLEAVAGE SEQUENCES
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Patrea L. Pabst
; STREET: 2800 One Atlantic Center
; STREET: 1201 West Peachtree Street
; CITY: Atlanta
; STATE: Georgia
; COUNTRY: USA
; ZIP: 30309-3450
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,652
; FILING DATE: NO. 5869248ember 6, 1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/02816
; FILING DATE: March 7, 1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/207,547
; FILING DATE: March 7, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Pabst, Patrea L.
; REGISTRATION NUMBER: 31,284
; REFERENCE/DOCKET NUMBER: YU112
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (404)-873-8794
; TELEFAX: (404)-873-8795
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-702-652-15

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 34;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 1668 CCTTCAAGCATCACCA 1683
Db 16 CCTTCATGCGCTCACCA 1

RESULT 64
US-09-371-772B-6037/c
; Sequence 6037, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6037
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6037

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 34;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1893 ATATCAAGCACTTGTG 1908
Db 16 ATGAACAGCACTTGTG 1

RESULT 65
US-09-371-772B-7113
; Sequence 7113, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 7113
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-7113

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 34;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1661 GAAATCTCCTTCAAGC 1676

Db 1 GAAAUUCUUGCAAGC 16

RESULT 66
US-09-479-005A-209/c
; Sequence 209, Application US/09479005A
; Patent No. 6656731
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
; FILE REFERENCE: MHB00-884-C
; CURRENT APPLICATION NUMBER: US/09/479.005A
; CURRENT FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 09/444,209
; PRIOR FILING DATE: 1999-11-19
; PRIOR APPLICATION NUMBER: US 09/159,274
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: US 60/059,473
; PRIOR FILING DATE: 1997-09-22
; NUMBER OF SEQ ID NOS: 1208
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 209
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-479-005A-209

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 34;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1974 ATTTATAGATTGTGTT 1989
Db 16 ATTACAGATTGTGCT 1

RESULT 67
PCT-US94-08023-24/c
; Sequence 24, Application PC/TUS9408023
; GENERAL INFORMATION:
; APPLICANT: de Kloet, Siwo R.
; TITLE OF INVENTION: Sex-Specific DNA Probe For Parrots,
; TITLE OF INVENTION: Methods And Kits
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Ruden, Barnett, McClosky, Smith, Schuster &
; ADDRESSER: Russell, P.A.
; STREET: 200 East Broward Boulevard
; CITY: Fort Lauderdale
; STATE: FL
; COUNTRY: USA
; ZIP: 33301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/08023
; FILING DATE: 15-JUL-1994
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/093,198
; FILING DATE: 15-JUL-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Manso, Peter J.
; REGISTRATION NUMBER: 32,264
; REFERENCE/DOCKET NUMBER: FL20979-34
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 305-527-2498
; TELEFAX: 305-764-4996
; INFORMATION FOR SEQ ID NO: 24:

SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US94-08023-24

Query Match 1.3%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 46;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1704 GGTTAGCAAAAG 1717
Db 14 GGTTAGCAAAAG 1

RESULT 68

US-08-182-968A-88/c
Sequence 88, Application US/08182968A
Patent No. 5610054
GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/182,968A
FILING DATE: 13-JANUARY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/882,888
FILING DATE: 14-MAY-1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 205/277
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 88:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-182-968A-88

Query Match 1.3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 43;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1597 GCCACCATATCAAC 1610
Db 15 GCCACCATATCCAC 2

RESULT 69

US-08-292-620A-214
Sequence 214, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (1-CAN-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435

PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 214:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-214

Query Match 1.3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 64.3%; Pred. No. 43;
Matches 9; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2019 ATCCCTTGATGATA 2032
Db 2 AACCCUUGAUGA 15

RESULT 70

US-08-774-306A-88/c
Sequence 88, Application US/08774306A
Patent No. 5869253
GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
INHIBITING HEPATITIS C

```

; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-774-306A-88

```

```

Query Match 1.3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 43;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1597 GCCACCATATCAAC 1610
DB 15 GCCACCATATCCAC 2

RESULT 71
US-09-064-156A-88/c
; Sequence 88, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-064-156A-88

```

```

Query Match 1.3%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 43;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1597 GCCACCATATCAAC 1610
DB 15 GCCACCATATCCAC 2

RESULT 72
US-09-071-845-214
; Sequence 214, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895

```

```

1 APPLICANT: Bogahn, Ulrich
2 TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
3 TITLE OF INVENTION: Immuno-suppressive effect of transferrin
4 NUMBER OF SEQUENCES: 137
5 CORRESPONDENCE ADDRESS:
6 ADDRESSEE: Jacobson, Price, Holman & Stern
7 STREET: 400 Seventh St. N.W.
8 CITY: Washington D.C
9 COUNTRY: U.S.A.
10 ZIP: 20004
11 COMPUTER READABLE FORM:
12 MEDIUM TYPE: Floppy disk
13 COMPUTER: IBM PC compatible
14 OPERATING SYSTEM: PC-DOS/MS-DOS
15 SOFTWARE: PatentIn Release #1.0, Version #1.25
16 CURRENT APPLICATION DATA:
17 APPLICATION NUMBER: US/08/535,249
18 FILING DATE:
19 CLASSIFICATION: 514
20 PRIOR APPLICATION DATA:
21 APPLICATION NUMBER: EP 93 107 089.0
22 FILING DATE: 30-APR-1993
23 PRIOR APPLICATION DATA:
24 APPLICATION NUMBER: EP 93 107 849.7
25 FILING DATE: 13-MAY-1993
26 ATTORNEY/AGENT INFORMATION:
27 NAME: Player, William E.
28 REGISTRATION NUMBER: 31,409
29 REFERENCE/DOCKET NUMBER: 10577/P58418
30 TELECOMMUNICATION INFORMATION:
31 TELEPHONE: (202)638-6666
32 TELEX: RCA 248593 IDEA UR
33 TELEFAX: (202) 393-5350
34 INFORMATION FOR SEQ ID NO: 120:
35 SEQUENCE CHARACTERISTICS:
36 LENGTH: 14 base pairs
37 TYPE: nucleic acid
38 STRANDEDNESS: unknown
39 TOPOLOGY: unknown
40 MOLECULE TYPE: DNA (genomic)
41 ANTI-SENSE: YES
42 US-08-535-249-120
43
44 Query Match 1.3%; Score 12; DB 1; Length 14;
45 Best Local Similarity 100.0%; Pred.No. 54;
46 Matches 12; Conservative 0; Mismatches 0; Indels
47
48 Qy 2443 TTCTGTGCTCGA 2454
49 |||||
50 |||||
51 Db 12 TTCTGTGCTCGA 1
52
53 RESULT 75
54 US-08-585-684B-630/c
55 Sequence 630, Application US/08585684B
56 Patent No. 5877021
57 GENERAL INFORMATION:
58 APPLICANT: Stinchcomb, Daniel T.
59 APPLICANT: Jarvis, Thale
60 APPLICANT: McSwigen, James
61 TITLE OF INVENTION: METHOD AND REAGENT FOR THE
62 TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
63 TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
64 NUMBER OF SEQUENCES: 2751
65 CORRESPONDENCE ADDRESS:
66 ADDRESSEE: Lyon & Lyon
67 STREET: 633 West Fifth Street
68 STREET: Suite 4700
69 CITY: Los Angeles
70 STATE: California
71 COUNTRY: U.S.A.
72 ZIP: 90071
73 COMPUTER READABLE FORM:

```

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 630:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-630

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1958 ATCCTATTAGTC 1969
DB 15 ATCCTATTAGTC 4

RESULT 76
US-08-585-684B-631/c
Sequence 631, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 631:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-631

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1958 ATCCTATTAGTC 1969
DB 15 ATCCTATTAGTC 4

RESULT 77
US-08-585-684B-632/c
Sequence 632, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 632:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-632

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1958 ATCCTATTAGTC 1969

Db 15 ATCCTATTAGTC 4

RESULT 78

US-08-585-684B-633/c

; Sequence 633, Application US/08585684B

; Patent No. 5877021

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

; NUMBER OF SEQUENCES: 2751

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FastSEQ Version 1.5

; CURRENT APPLICATION DATA:

; FILING DATE: January 16, 1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/000,951

; FILING DATE: July 7, 1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 218/078

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 633:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-585-684B-634

Query Match 1.3%; Score 12; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 50;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969

Db 12 ATCCTATTAGTC 1

RESULT 80

US-08-585-684B-2056/c

; Sequence 2056, Application US/08585684B

; Patent No. 5877021

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

; NUMBER OF SEQUENCES: 2751

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: IBM P.C. DOS 5.0

; SOFTWARE: FastSEQ Version 1.5

; CURRENT APPLICATION DATA:

; FILING DATE: January 16, 1996

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/000,951

; FILING DATE: July 7, 1995

; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327

; REFERENCE/DOCKET NUMBER: 218/078

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440

; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 633:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 15 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-585-684B-633

Query Match 1.3%; Score 12; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 50;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969

Db 12 ATCCTATTAGTC 1

RESULT 79

US-08-585-684B-634/c

; Sequence 634, Application US/08585684B

; Patent No. 5877021

; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.

; APPLICANT: Jarvis, Thale

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE

; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

; NUMBER OF SEQUENCES: 2751

```
;
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2056:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2056

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2271 GTCAGCAAGCAG 2282
Db 14 GTCAGCAAGCAG 3

RESULT 82
US-08-832-021-36/c
; Sequence 36, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Steinh, K.
; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832.021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; US-08-832-021-36

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2281 AGGAAAAAAAAA 2292
Db 15 AGGAAAAAAAAA 4

RESULT 83
US-09-038-073-630/c
; Sequence 630, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2330:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
```

```
/ APPLICATION NUMBER: US/09/038,073
/ FILING DATE:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/585,684
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 630:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-038-073-630

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 15 ATCCTATTAGTC 4

RESULT 84
US-09-038-073-631/c
/ Sequence 631, Application US/09038073
/ Patent No. 6194150
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Daniel T.
/ APPLICANT: Jarvis, Thale
/ TITLE OF INVENTION: METHOD AND REAGENT FOR THE
/ TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
/ TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
/ NUMBER OF SEQUENCES: 2751
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/038,073
/ FILING DATE:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/585,684
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 631:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-038-073-632/c

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 15 ATCCTATTAGTC 4

RESULT 85
US-09-038-073-632/c
/ Sequence 632, Application US/09038073
/ Patent No. 6194150
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Daniel T.
/ APPLICANT: Jarvis, Thale
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: METHOD AND REAGENT FOR THE
/ TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
/ TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
/ NUMBER OF SEQUENCES: 2751
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSEQ Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/038,073
/ FILING DATE:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/585,684
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 632:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-09-038-073-633/c

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
Db 15 ATCCTATTAGTC 4

RESULT 86
US-09-038-073-633/c
```

; Sequence 633, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 633:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-633

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
DB 12 ATCCTATTAGTC 1

RESULT 87
US-09-038-073-634/c
; Sequence 634, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 634:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-038-073-634

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1958 ATCCTATTAGTC 1969
DB 12 ATCCTATTAGTC 1

RESULT 88
US-09-038-073-2056/c
; Sequence 2056, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2056:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-2056

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2271 GTCAGCAAGCAG 2282
Db 14 GTCAGCAAGCAG 3

RESULT 89
US-09-038-073-2330/c
Sequence 2330, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2330:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-2330

Query Match 1.3%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 50;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2271 GTCAGCAAGCAG 2282
Db 14 GTCAGCAAGCAG 3
Search completed: April 7, 2005, 05:57:41
Job time : 1 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 7, 2005, 05:59:31 ; Search time 2 Seconds
(without alignments)
2.572 Million cell updates/sec

Title: US-10-630-399-3

Perfect score: 922

Sequence: 1 gacagtgggtattaaagcat.....ctggacttctaataataga 922

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 161 seqs, 2790 residues

Total number of hits satisfying chosen parameters: 322

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 162 summaries

Database : rnpb3.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	50	5.4	50	1	US-10-131-827-3266
2	20	2.2	20	1	US-09-966-451-52
3	20	2.2	20	1	US-09-966-451-53
4	20	2.2	20	1	US-09-966-451-54
5	20	2.2	20	1	US-09-966-451-55
6	20	2.2	20	1	US-09-966-451-56
7	20	2.2	20	1	US-09-966-451-57
8	20	2.2	20	1	US-09-966-451-58
9	20	2.2	20	1	US-09-966-451-59
10	20	2.2	20	1	US-09-966-451-60
11	20	2.2	20	1	US-09-966-451-61
12	20	2.2	20	1	US-09-966-451-62
13	20	2.2	20	1	US-09-966-451-63
14	20	2.2	20	1	US-09-966-451-64
15	20	2.2	20	1	US-09-966-451-65
16	20	2.2	20	1	US-09-966-451-66
17	20	2.2	20	1	US-09-966-451-67
18	20	2.2	20	1	US-09-966-451-68
19	20	2.2	20	1	US-09-966-451-69
20	20	2.2	20	1	US-09-966-451-70
21	20	2.2	20	1	US-09-966-451-71
22	20	2.2	20	1	US-09-966-451-72
23	20	2.2	20	1	US-09-966-451-73
24	20	2.2	20	1	US-09-966-451-74
25	20	2.2	20	1	US-09-966-451-75
26	20	2.2	20	1	US-09-966-451-76
27	20	2.2	20	1	US-09-966-451-77
28	20	2.2	20	1	US-09-966-451-78
29	20	2.2	20	1	US-09-966-451-79
30	20	2.2	20	1	US-10-630-399-52
31	20	2.2	20	1	US-10-630-399-53
32	20	2.2	20	1	US-10-630-399-54
33	20	2.2	20	1	US-10-630-399-55

Sequence 56, Appl	1	US-10-630-399-56	2.2	20	1	US-10-630-399-56	2.2	20	1	US-10-630-399-56
Sequence 57, Appl	20	US-10-630-399-57	2.2	20	1	US-10-630-399-57	2.2	20	1	US-10-630-399-57
Sequence 58, Appl	20	US-10-630-399-58	2.2	20	1	US-10-630-399-58	2.2	20	1	US-10-630-399-58
Sequence 59, Appl	20	US-10-630-399-59	2.2	20	1	US-10-630-399-59	2.2	20	1	US-10-630-399-59
Sequence 60, Appl	20	US-10-630-399-60	2.2	20	1	US-10-630-399-60	2.2	20	1	US-10-630-399-60
Sequence 61, Appl	20	US-10-630-399-61	2.2	20	1	US-10-630-399-61	2.2	20	1	US-10-630-399-61
Sequence 62, Appl	20	US-10-630-399-62	2.2	20	1	US-10-630-399-62	2.2	20	1	US-10-630-399-62
Sequence 63, Appl	20	US-10-630-399-63	2.2	20	1	US-10-630-399-63	2.2	20	1	US-10-630-399-63
Sequence 64, Appl	20	US-10-630-399-64	2.2	20	1	US-10-630-399-64	2.2	20	1	US-10-630-399-64
Sequence 65, Appl	20	US-10-630-399-65	2.2	20	1	US-10-630-399-65	2.2	20	1	US-10-630-399-65
Sequence 66, Appl	20	US-10-630-399-66	2.2	20	1	US-10-630-399-66	2.2	20	1	US-10-630-399-66
Sequence 67, Appl	20	US-10-630-399-67	2.2	20	1	US-10-630-399-67	2.2	20	1	US-10-630-399-67
Sequence 68, Appl	20	US-10-630-399-68	2.2	20	1	US-10-630-399-68	2.2	20	1	US-10-630-399-68
Sequence 69, Appl	20	US-10-630-399-69	2.2	20	1	US-10-630-399-69	2.2	20	1	US-10-630-399-69
Sequence 70, Appl	20	US-10-630-399-70	2.2	20	1	US-10-630-399-70	2.2	20	1	US-10-630-399-70
Sequence 71, Appl	20	US-10-630-399-71	2.2	20	1	US-10-630-399-71	2.2	20	1	US-10-630-399-71
Sequence 72, Appl	20	US-10-630-399-72	2.2	20	1	US-10-630-399-72	2.2	20	1	US-10-630-399-72
Sequence 73, Appl	20	US-10-630-399-73	2.2	20	1	US-10-630-399-73	2.2	20	1	US-10-630-399-73
Sequence 74, Appl	20	US-10-630-399-74	2.2	20	1	US-10-630-399-74	2.2	20	1	US-10-630-399-74
Sequence 75, Appl	20	US-10-630-399-75	2.2	20	1	US-10-630-399-75	2.2	20	1	US-10-630-399-75
Sequence 76, Appl	20	US-10-630-399-76	2.2	20	1	US-10-630-399-76	2.2	20	1	US-10-630-399-76
Sequence 77, Appl	20	US-10-630-399-77	2.2	20	1	US-10-630-399-77	2.2	20	1	US-10-630-399-77
Sequence 78, Appl	20	US-10-630-399-78	2.2	20	1	US-10-630-399-78	2.2	20	1	US-10-630-399-78
Sequence 79, Appl	20	US-10-630-399-79	2.2	20	1	US-10-630-399-79	2.2	20	1	US-10-630-399-79
Sequence 29540, A	21	US-10-751-736-29540	1.9	17.4	1	US-10-751-736-29540	1.9	17.4	1	US-10-751-736-29540
Sequence 1545, Ap	17	US-10-060-998-1545	1.7	16	1	US-10-060-998-1545	1.7	16	1	US-10-060-998-1545
Sequence 1546, Ap	17	US-10-060-998-1546	1.7	16	1	US-10-060-998-1546	1.7	16	1	US-10-060-998-1546
Sequence 11728, A	19	US-10-349-143-11728	1.7	15.8	1	US-10-349-143-11728	1.7	15.8	1	US-10-349-143-11728
Sequence 1679, App	19	US-10-665-951-1679	1.7	15.8	1	US-10-665-951-1679	1.7	15.8	1	US-10-665-951-1679
Sequence 796, App	19	US-10-665-951-796	1.7	15.8	1	US-10-665-951-796	1.7	15.8	1	US-10-665-951-796
Sequence 1544, Ap	17	US-10-060-998-1544	1.7	15.4	1	US-10-060-998-1544	1.7	15.4	1	US-10-060-998-1544
Sequence 6036, Ap	16	US-10-138-674-6036	1.6	15	1	US-10-138-674-6036	1.6	15	1	US-10-138-674-6036
Sequence 6036, Ap	16	US-10-287-949A-6036	1.6	15	1	US-10-287-949A-6036	1.6	15	1	US-10-287-949A-6036
Sequence 1547, Ap	17	US-10-060-998-1547	1.6	15	1	US-10-060-998-1547	1.6	15	1	US-10-060-998-1547
Sequence 8189, Ap	17	US-10-138-674-8189	1.6	15	1	US-10-138-674-8189	1.6	15	1	US-10-138-674-8189
Sequence 1450, Ap	17	US-10-712-633-1450	1.6	15	1	US-10-712-633-1450	1.6	15	1	US-10-712-633-1450
Sequence 74, Appl	18	US-10-455-552-74	1.6	14.8	1	US-10-455-552-74	1.6	14.8	1	US-10-455-552-74
Sequence 1033, Ap	17	US-09-730-2898-1033	1.6	14.4	1	US-09-730-2898-1033	1.6	14.4	1	US-09-730-2898-1033
Sequence 1122, Ap	17	US-09-730-2898-1122	1.6	14.4	1	US-09-730-2898-1122	1.6	14.4	1	US-09-730-2898-1122
Sequence 1542, Ap	17	US-10-060-998-1542	1.6	14.4	1	US-10-060-998-1542	1.6	14.4	1	US-10-060-998-1542
Sequence 1804, Ap	18	US-09-969-373-1804	1.6	14.4	1	US-09-969-373-1804	1.6	14.4	1	US-09-969-373-1804
Sequence 1548, Ap	17	US-10-060-998-1548	1.5	14	1	US-10-060-998-1548	1.5	14	1	US-10-060-998-1548
Sequence 71, Appl	17	US-10-156-306-71	1.5	14	1	US-10-156-306-71	1.5	14	1	US-10-156-306-71
Sequence 2713, Ap	17	US-10-156-306-2713	1.5	14	1	US-10-156-306-2713	1.5	14	1	US-10-156-306-2713
Sequence 2154, Ap	17	US-10-138-674-2154	1.5	14	1	US-10-138-674-2154	1.5	14	1	US-10-138-674-2154
Sequence 2779, Ap	17	US-10-138-674-2779	1.5	14	1	US-10-138-674-2779	1.5	14	1	US-10-138-674-2779
Sequence 8190, Ap	17	US-10-287-949A-8190	1.5	14	1	US-10-287-949A-8190	1.5	14	1	US-10-287-949A-8190
Sequence 9127, Ap	17	US-10-287-949A-9127	1.5	14	1	US-10-287-949A-9127	1.5	14	1	US-10-287-949A-9127
Sequence 1451, Ap	17	US-10-712-633-1451	1.5	14	1	US-10-712-633-1451	1.5	14	1	US-10-712-633-1451
Sequence 4397, Ap	17	US-10-712-633-4397	1.5	14	1	US-10-712-633-4397	1.5	14	1	US-10-712-633-4397
Sequence 2781, Ap	17	US-09-866-108-2781	1.5	13.8	1	US-09-866-108-2781	1.5	13.8	1	US-09-866-108-2781
Sequence 474, App	17	US-09-877-478-474	1.5	13.8	1	US-09-877-478-474	1.5	13.8	1	US-09-877-478-474
Sequence 2127, Ap	17	US-09-877-478-2127	1.5	13.8	1	US-09-877-478-2127	1.5	13.8	1	US-09-877-478-2127
Sequence 1182, Ap	17	US-09-848-754A-1182	1.5	13.8	1	US-09-848-754A-1182	1.5	13.8	1	US-09-848-754A-1182
Sequence 50, Appl	17	US-09-827-395A-50	1.5	13.8	1	US-09-827-395A-50	1.5	13.8	1	US-09-827-395A-50
Sequence 1033, Ap	17	US-10-060-998-1033	1.5	13.8	1	US-10-060-998-1033	1.5	13.8	1	US-10-060-998-1033
Sequence 2769, Ap	17	US-10-156-306-2769	1.5	13.8	1	US-10-156-306-2769	1.5	13.8	1	US-10-156-306-2769
Sequence 951, App	17	US-10-238-700-951	1.5	13.8	1	US-10-238-700-951	1.5	13.8	1	US-10-238-700-951
Sequence 697, App	17	US-10-061-201-697	1.5	13.8	1	US-10-061-201-697	1.5	13.8	1	US-10-061-201-697
Sequence 698, App	17	US-10-061-201-698	1.5	13.8	1	US-10-061-201-698	1.5	13.8	1	US-10-061-201-698
Sequence 50, Appl	17	US-10-430-882-50	1.5	13.8	1	US-10-430-882-50	1.5	13.8	1	US-10-430-882-50
Sequence 474, App	17	US-10-342-902-474	1.5	13.8	1	US-10-342-902-474	1.5	13.8	1	US-10-342-902-474
Sequence 2127, Ap	17	US-10-342-902-2127	1.5	13.8	1	US-10-342-902-2127	1.5	13.8	1	US-10-342-902-2127
Sequence 2153, Ap	17	US-10-138-674-2153	1.5	13.8	1	US-10-138-674-2153	1.5	13.8	1	US-10-138-674-2153
Sequence 2778, Ap	17	US-10-138-674-2778	1.5	13.8	1	US-10-138-674-2778	1.5	13.8	1	US-10-138-674-2778
Sequence 5483, Ap	17	US-10-138-674-5483	1.5	13.8	1	US-10-138-674-5483	1.5	13.8	1	US-10-138-674-5483
Sequence 9343, Ap	17	US-10-138-674-9343	1.5	13.8	1	US-10-138-674-9343	1.5	13.8	1	US-10-138-674-9343

107	13.8	1.5	17	1	US-10-138-674-9377	Sequence 9377, Ap
c 108	13.8	1.5	17	1	US-10-287-949A-2153	Sequence 2153, Ap
c 109	13.8	1.5	17	1	US-10-287-949A-2778	Sequence 2778, Ap
c 110	13.8	1.5	17	1	US-10-287-949A-5483	Sequence 5483, Ap
c 111	13.8	1.5	17	1	US-10-287-949A-9343	Sequence 9343, Ap
c 112	13.8	1.5	17	1	US-10-287-949A-9377	Sequence 9377, Ap
c 113	13.8	1.5	17	1	US-10-669-841-474	Sequence 474, App
c 114	13.8	1.5	17	1	US-10-669-841-1968	Sequence 1968, Ap
c 115	13.8	1.5	17	1	US-10-723-361-2781	Sequence 2781, Ap
c 116	13.8	1.5	17	1	US-10-712-633-4614	Sequence 4614, Ap
c 117	13.8	1.5	17	1	US-10-712-633-4648	Sequence 4648, Ap
c 118	13.4	1.5	16	1	US-10-043-875-177	Sequence 177, App
c 119	13.2	1.4	50	1	US-10-131-827-3266	Sequence 3266, Ap
c 120	13	1.4	13	1	US-10-257-017B-12919	Sequence 12919, A
c 121	13	1.4	13	1	US-10-257-017B-12920	Sequence 12920, A
c 122	13	1.4	13	1	US-10-257-017B-23771	Sequence 23771, A
c 123	13	1.4	13	1	US-10-257-017B-23772	Sequence 23772, A
c 124	13	1.4	13	1	US-10-257-017B-50497	Sequence 50497, A
c 125	13	1.4	13	1	US-10-257-017B-50498	Sequence 50498, A
c 126	13	1.4	13	1	US-10-257-017B-52315	Sequence 52315, A
c 127	13	1.4	13	1	US-10-257-017B-52316	Sequence 52316, A
c 128	13	1.4	13	1	US-10-257-017B-100801	Sequence 100801, A
c 129	13	1.4	13	1	US-10-257-017B-100802	Sequence 100802, A
c 130	13	1.4	13	1	US-10-257-017B-132137	Sequence 132137, A
c 131	13	1.4	13	1	US-10-257-017B-132138	Sequence 132138, A
c 132	13	1.4	13	1	US-10-257-017B-162297	Sequence 162297, A
c 133	13	1.4	13	1	US-10-257-017B-162298	Sequence 162298, A
c 134	13	1.4	13	1	US-10-257-017B-179793	Sequence 179793, A
c 135	13	1.4	13	1	US-10-257-017B-179794	Sequence 179794, A
c 136	13	1.4	13	1	US-10-257-017B-193759	Sequence 193759, A
c 137	13	1.4	13	1	US-10-257-017B-193760	Sequence 193760, A
c 138	13	1.4	13	1	US-10-257-017B-202391	Sequence 202391, A
c 139	13	1.4	13	1	US-10-257-017B-202392	Sequence 202392, A
c 140	13	1.4	13	1	US-10-257-017B-215295	Sequence 215295, A
c 141	13	1.4	13	1	US-10-257-017B-215296	Sequence 215296, A
c 142	13	1.4	13	1	US-10-257-017B-247011	Sequence 247011, A
c 143	13	1.4	13	1	US-10-257-017B-247012	Sequence 247012, A
c 144	13	1.4	13	1	US-10-257-017B-253051	Sequence 253051, A
c 145	13	1.4	13	1	US-10-257-017B-253052	Sequence 253052, A
c 146	12.8	1.4	16	1	US-10-140-293-6	Sequence 6, Appli
c 147	12.8	1.4	16	1	US-10-138-674-6037	Sequence 6037, Ap
c 148	12.8	1.4	16	1	US-10-138-674-7113	Sequence 7113, Ap
c 149	12.8	1.4	16	1	US-10-287-949A-6037	Sequence 6037, Ap
c 150	12.8	1.4	16	1	US-10-287-949A-7113	Sequence 7113, Ap
c 151	12.6	1.4	13	1	US-10-257-017B-4851	Sequence 4851, Ap
c 152	12.6	1.4	13	1	US-10-257-017B-4852	Sequence 4852, Ap
c 153	12.6	1.4	13	1	US-10-257-017B-14279	Sequence 14279, A
c 154	12.6	1.4	13	1	US-10-257-017B-14280	Sequence 14280, A
c 155	12.6	1.4	13	1	US-10-257-017B-31913	Sequence 31913, A
c 156	12.6	1.4	13	1	US-10-257-017B-31914	Sequence 31914, A
c 157	12.6	1.4	13	1	US-10-257-017B-38179	Sequence 38179, A
c 158	12.6	1.4	13	1	US-10-257-017B-38180	Sequence 38180, A
c 159	12.6	1.4	13	1	US-10-257-017B-59765	Sequence 59765, A
c 160	12.6	1.4	13	1	US-10-257-017B-59766	Sequence 59766, A
c 161	12.6	1.4	13	1	US-10-257-017B-111489	Sequence 111489, A
c 162	12.6	1.4	13	1	US-10-257-017B-111490	Sequence 111490, A

ALIGNMENTS

RESULT 1
US-09-966-451-53/c
; Sequence 3266, Application US/10131827
; Publication No. US20040009479A1
; GENERAL INFORMATION:
; APPLICANT: Wohlgemuth, Jay
; APPLICANT: Fry, Kirk
; APPLICANT: Woodward, Robert
; APPLICANT: Ly, Ngoc
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE
; TITLE OF INVENTION: CHRONIC INFLAMMATORY DISEASES
; FILE REFERENCE: 506612000120

; CURRENT APPLICATION NUMBER: US/10/131.827
; CURRENT FILING DATE: 2002-09-06
; PRIOR APPLICATION NUMBER: US 10/006,290
; PRIOR FILING DATE: 2001-10-22
; PRIOR APPLICATION NUMBER: US 60/296,764
; PRIOR FILING DATE: 2001-06-08
; NUMBER OF SEQ ID NOS: 9090
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3266
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-131-827-3266

Query Match 5.4%; Score 50; DB 1; Length 50;
Best Local Similarity 100.0%; Pred. No. 0.001;
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1819 GCCACTAATACATTGGGCTAATATCTGCTGTGCTTCTCTGACAGGTAGT 1868
DB 1 GCCACTAATACATTGGGCTAATATCTGCTGTGCTTCTCTGACAGGTAGT 50

RESULT 2
US-09-966-451-52/c
; Sequence 52, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-52

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 GACAGTGGTTATTAAAGCAT 1567
DB 20 GACAGTGGTTATTAAAGCAT 1

RESULT 3
US-09-966-451-53/c
; Sequence 53, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSI
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-53

Query Match 2.2%; Score 20; DB 1; Length 20;

```
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1560 TAAAGCATGGGTGAACCTTC 1579
Db 20 TAAAGCATGGGTGAACCTTC 1

RESULT 4
US-09-966-451-54/c
; Sequence 54, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-54

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1646 TACAGTAATCCCTGAGAAAT 1665
Db 20 TACAGTAATCCCTGAGAAAT 1

RESULT 5
US-09-966-451-55/c
; Sequence 55, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-55

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1674 AGCATCACCACCAACACAGTTT 1693
Db 20 AGCATCACCACCAACACAGTTT 1

RESULT 6
US-09-966-451-56/c
; Sequence 56, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-56
```

```
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 CAAAAGAGCGCTGGGCTGTA 1730
Db 20 CAAAAGAGCGCTGGGCTGTA 1

RESULT 7
US-09-966-451-57/c
; Sequence 57, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-57

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CCTGGGCTGTATGTAGGGTG 1739
Db 20 CCTGGGCTGTATGTAGGGTG 1

RESULT 8
US-09-966-451-58/c
; Sequence 58, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-58

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1730 CCTGGGCTGTATGTAGGGTG 1739
Db 20 CCTGGGCTGTATGTAGGGTG 1
```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1737 GTGGAACACTGTGACTGA 1756
|||||
DB 20 GTGGAACACTGTGACTGA 1

RESULT 9

US-09-966-451-59/c

; Sequence 59, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-59

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1756 AAGCCAGCTGACTCCACTA 1775
|||||
DB 20 AAGCCAGCTGACTCCACTA 1

RESULT 10

US-09-966-451-60/c

; Sequence 60, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-60

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1810 CTGCTGTGAGCCACTAATAA 1829
|||||
DB 20 CTGCTGTGAGCCACTAATAA 1

RESULT 11

US-09-966-451-61/c

; Sequence 61, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS

; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-61

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1829 ACATTGGGCTAATATCTGCT 1848
|||||
DB 20 ACATTGGGCTAATATCTGCT 1

RESULT 12

US-09-966-451-62/c

; Sequence 62, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-62

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1846 GCTGTGCTTCTCTGACAGGT 1865
|||||
DB 20 GCTGTGCTTCTCTGACAGGT 1

RESULT 13

US-09-966-451-63/c

; Sequence 63, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-63

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1854 TCTCTGACAGGTAGTCA 1873
|||||
Db 20 TCTCTGACAGGTAGTCA 1

RESULT 14

US-09-966-451-64/c
; Sequence 64, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-64

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1894 TATCAAGCATTGTAAAT 1913
|||||
Db 20 TATCAAGCATTGTAAAT 1

RESULT 15

US-09-966-451-65/c
; Sequence 65, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-65

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1951 TTACAAAATCCTATTAGTCA 1970
|||||
Db 20 TTACAAAATCCTATTAGTCA 1

RESULT 16

US-09-966-451-66/c
; Sequence 66, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-66

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1985 GTGTTACAGCAATCATTTA 2004
|||||
Db 20 GTGTTACAGCAATCATTTA 1

RESULT 17

US-09-966-451-67/c
; Sequence 67, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-67

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2066 TTACATGACAAAGTTGAAGG 2085
|||||
Db 20 TTACATGACAAAGTTGAAGG 1

RESULT 18

US-09-966-451-68/c
; Sequence 68, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-68

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2089 TTGGCAGATGCAGTTAAGT 2108
DB 20 TTGGCAGATGCAGTTAAGT 1

RESULT 19

US-09-966-451-69/c

; Sequence 69, Application US/09966451
; Publication No. US20030087856A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 69

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-69

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2137 AAAGGCCCTGACCTAATCCA 2156

DB 20 AAAGGCCCTGACCTAATCCA 1

RESULT 20

US-09-966-451-70/c

; Sequence 70, Application US/09966451

; Publication No. US20030087856A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 70

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-70

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2191 GCCTTGAAGAAGTATGTGAG 2210

DB 20 GCCTTGAAGAAGTATGTGAG 1

RESULT 21

US-09-966-451-71/c

; Sequence 71, Application US/09966451

; Publication No. US20030087856A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 71

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-71

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2211 AGGGCCACATTGGCTAAAC 2230

DB 20 AGGGCCACATTGGCTAAAC 1

RESULT 22

US-09-966-451-72/c

; Sequence 72, Application US/09966451

; Publication No. US20030087856A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 72

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-72

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 CATTCGCTAAACCTAAAGG 2237

DB 20 CATTCGCTAAACCTAAAGG 1

RESULT 23

US-09-966-451-73/c

; Sequence 73, Application US/09966451

; Publication No. US20030087856A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/09/966,451

; CURRENT FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 73

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-966-451-73

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2223 GCTAAACCTAAAGTGCC 2242

```
Db      20  GCTAAACCTAAAGTGGCC 1
|||||
RESULT 24
US-09-966-451-74/c
; Sequence 74, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-74
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2236  GGTGGCCTCTAGGAGTAG 2255
|||||
Db      20  GGTGGCCTCTAGGAGTAG 1

RESULT 25
US-09-966-451-75/c
; Sequence 75, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-75
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2256  ACCTACCTCCAGTTGTCAG 2275
|||||
Db      20  ACCTACCTCCAGTTGTCAG 1

RESULT 26
US-09-966-451-76/c
; Sequence 76, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
```

```
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-76
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2267  AGTTGTCAGCAAGCAGGAAA 2286
|||||
Db      20  AGTTGTCAGCAAGCAGGAAA 1

RESULT 27
US-09-966-451-77/c
; Sequence 77, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-77
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2364  AAGCTTCAGATGATAACCAC 2383
|||||
Db      20  AAGCTTCAGATGATAACCAC 1

RESULT 28
US-09-966-451-78/c
; Sequence 78, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-78
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2377  TAAACCACGCTGGCTGAC 2396
|||||
```

Db 20 TAACCACGCCTGGGCTGAC 1

RESULT 29

US-09-966-451-79/c
; Sequence 79, Application US/09966451
; Publication No. US20030087856A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/09/966,451
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-966-451-79

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2419 ATCTCAGTATGAGAACTCA 2438

Db 20 ATCTCAGTATGAGAACTCA 1

RESULT 30

US-10-630-399-52/c
; Sequence 52, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-52

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1548 GACAGTGGTTATTAAAGCAT 1567

Db 20 GACAGTGGTTATTAAAGCAT 1

RESULT 31

US-10-630-399-53/c
; Sequence 53, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399

; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-53

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1560 TAAAGCATGGTTGAATTC 1579

Db 20 TAAAGCATGGTTGAATTC 1

RESULT 32

US-10-630-399-54/c
; Sequence 54, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-54

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1646 TACAGTAATCCCTGAGAAAT 1665

Db 20 TACAGTAATCCCTGAGAAAT 1

RESULT 33

US-10-630-399-55/c
; Sequence 55, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-55

```
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1674 AGCATCACCAACACAGTTT 1693
    |||||
Db 20 AGCATCACCAACACAGTTT 1

RESULT 34
US-10-630-399-56/c
; Sequence 56, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-56

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 CAAAAGAGCGCTGGCTGTA 1730
    |||||
Db 20 CAAAAGAGCGCTGGCTGTA 1

RESULT 35
US-10-630-399-57/c
; Sequence 57, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 57
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-57

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1720 CCTGGCGCTGTATAGGGTG 1739
    |||||
Db 20 CCTGGCGCTGTATAGGGTG 1

RESULT 36
```

```
US-10-630-399-58/c
; Sequence 58, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 58
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-58

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1737 GTGGAACACTCTGATCTGA 1756
    |||||
Db 20 GTGGAACACTCTGATCTGA 1

RESULT 37
US-10-630-399-59/c
; Sequence 59, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 59
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-59

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1756 AAGCCGAGCTGACTCCACTA 1775
    |||||
Db 20 AAGCCGAGCTGACTCCACTA 1

RESULT 38
US-10-630-399-60/c
; Sequence 60, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
```

; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 60
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-60

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1810 CTGCTGTGAGCCACTAATAA 1829
DB 20 CTGCTGTGAGCCACTAATAA 1

RESULT 39
US-10-630-399-61/c
; Sequence 61, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 61
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-61

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1829 ACATTGGGCTAATATCTGCT 1848
DB 20 ACATTGGGCTAATATCTGCT 1

RESULT 40
US-10-630-399-62/c
; Sequence 62, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-62

Query Match 2.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1846 GCTGTGCTTCTCTGACAGGT 1865
DB 20 GCTGTGCTTCTCTGACAGGT 1

RESULT 41
US-10-630-399-63/c
; Sequence 63, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-63

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1854 TCTCTGACAGGTAGTCATGA 1873
DB 20 TCTCTGACAGGTAGTCATGA 1

RESULT 42
US-10-630-399-64/c
; Sequence 64, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-64

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1894 TATACAAGCACCTTTGTAAT 1913
DB 20 TATACAAGCACCTTTGTAAT 1

RESULT 43
US-10-630-399-65/c
; Sequence 65, Application US/10630399

```
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-65

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1951 TTACAAATCCTATTAGTCA 1970
Db 20 TTACAAATCCTATTAGTCA 1

RESULT 44
US-10-630-399-66/c
; Sequence 66, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-66

Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1985 GTGTTACAGCATCATTTA 2004
Db 20 GTGTTACAGCATCATTTA 1

RESULT 45
US-10-630-399-67/c
; Sequence 67, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; NUMBER OF SEQ ID NOS: 88
```

```
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-67
```

```
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2066 TTACATGACAAAGTTGAAGG 2085
Db 20 TTACATGACAAAGTTGAAGG 1
```

```
RESULT 46
US-10-630-399-68/c
; Sequence 68, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-68
```

```
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2089 TTGGCAGATGCAGTTAAGGT 2108
Db 20 TTGGCAGATGCAGTTAAGGT 1
```

```
RESULT 47
US-10-630-399-69/c
; Sequence 69, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESSION
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; PRIOR FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-69
```

```
Query Match      2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 2137 AAAGGCGCTGACCTAATCCA 2156
DB 20 AAAGGCGCTGACCTAATCCA 1

RESULT 48

US-10-630-399-70/c
; Sequence 70, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/10/630,399

; CURRENT FILING DATE: 2003-07-30

; PRIOR APPLICATION NUMBER: US/09/966,451

; PRIOR FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 70

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-630-399-70

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2191 GCCTTGAAGAAGTATGTGAG 2210
DB 20 GCCTTGAAGAAGTATGTGAG 1

RESULT 49

US-10-630-399-71/c
; Sequence 71, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/10/630,399

; CURRENT FILING DATE: 2003-07-30

; PRIOR APPLICATION NUMBER: US/09/966,451

; PRIOR FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 71

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-630-399-71

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2211 AGGCCACATTTGGCTAAAC 2230
DB 20 AGGCCACATTTGGCTAAAC 1

RESULT 50

US-10-630-399-72/c
; Sequence 72, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/10/630,399

; CURRENT FILING DATE: 2003-07-30

; PRIOR APPLICATION NUMBER: US/09/966,451

; PRIOR FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 72

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-630-399-72

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2218 CATTGGCTAAACCTAAAGG 2237
DB 20 CATTGGCTAAACCTAAAGG 1

RESULT 51

US-10-630-399-73/c
; Sequence 73, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/10/630,399

; CURRENT FILING DATE: 2003-07-30

; PRIOR APPLICATION NUMBER: US/09/966,451

; PRIOR FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 73

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-630-399-73

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2223 GCTAAACCTAAAGGTGGCC 2242
DB 20 GCTAAACCTAAAGGTGGCC 1

RESULT 52

US-10-630-399-74/c
; Sequence 74, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES

; FILE REFERENCE: RTS-0324

; CURRENT APPLICATION NUMBER: US/10/630,399

; CURRENT FILING DATE: 2003-07-30

; PRIOR APPLICATION NUMBER: US/09/966,451

; PRIOR FILING DATE: 2001-09-28

; NUMBER OF SEQ ID NOS: 88

; SEQ ID NO 74

; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-74

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2236 GGTCCTCTAGGAGATGAG 2255
Db 20 GGTCCTCTAGGAGATGAG 1

RESULT 53
US-10-630-399-75/c
; Sequence 75, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-75

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2256 ACCTACCTCCAGTTCTCAG 2275
Db 20 ACCTACCTCCAGTTCTCAG 1

RESULT 54
US-10-630-399-76/c
; Sequence 76, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-76

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2267 AGTTGTGACGACGAGAA 2286

Db 20 AGTTGTGACGACGAGAA 1

RESULT 55
US-10-630-399-77/c
; Sequence 77, Application US/10630399
; Publication No. US20040019009A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-77

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2364 AAGCTTCAGATGATACAC 2383
Db 20 AAGCTTCAGATGATACAC 1

RESULT 56
US-10-630-399-78/c
; Sequence 78, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-78

Query Match 2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2377 TAACCACAGCTGGGCTGAC 2396
Db 20 TAACCACAGCTGGGCTGAC 1

RESULT 57
US-10-630-399-79/c
; Sequence 79, Application US/10630399
; Publication No. US20040019009A1

; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRESS
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-79

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-4 EXPRES
; FILE REFERENCE: RTS-0324
; CURRENT APPLICATION NUMBER: US/10/630,399
; CURRENT FILING DATE: 2003-07-30
; PRIOR APPLICATION NUMBER: US/09/966,451
; PRIOR FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-630-399-79

Query Match          2.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2419 ATCCTCAGTATGAGATCTA 2438
DB 20 ATCCTCAGTATGAGATCTA 1
|||||

RESULT 58
US-10-751-736-29540
; Sequence 29540, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29540
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-29540

Query Match          1.9%; Score 17.4; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 30;
Matches 11; Conservative 7; Mismatches 1; Indels 0; Gaps 0;

QY 1984 TGTGTTACAGCAATCAATT 2002
DB 3 UGUGUUCACAGCAAUUUU 21
|||||

RESULT 59
US-10-060-998-1545/c
; Sequence 1545, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
```

```
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1545
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1545
```

```
Query Match          1.7%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1745 ACTCTGATCTGAAGCC 1760
DB 17 ACTCTGATCTGAAGCC 2
|||||
```

```
RESULT 60
US-10-060-998-1546/c
; Sequence 1546, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1546
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1546
```

```
Query Match          1.7%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 54;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1745 ACTCTGATCTGAAGCC 1760
DB 16 ACTCTGATCTGAAGCC 1
|||||
```

```
RESULT 61
US-10-349-143-11728
; Sequence 11728, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/10/349,143
; CURRENT FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11728
; LENGTH: 19
```



```

; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1543

Query Match      1.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 64;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1747 TCTGATCTGAAGCCGAG 1763
DB 17 TCTGATCTGAAGCCGAG 1

RESULT 65
US-10-060-998-1544/c
; Sequence 1544, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gl, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1544
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1544

Query Match      1.7%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 64;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1746 CTCTGATCTGAAGCCCA 1762
DB 17 CTCTGATCTGAAGCCCA 1

RESULT 66
US-10-138-674-6036/c
; Sequence 6036, Application US/10138674
; Publication No. US2004007565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6036
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-6036

Query Match      1.6%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1897 ACAAGCACTTTGTAA 1911
DB 16 ACAAGCACTTTGTAA 2

RESULT 67
US-10-287-949A-6036/c
; Sequence 6036, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6036
; LENGTH: 16
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-6036

Query Match      1.6%; Score 15; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1897 ACAAGCACTTTGTAA 1911
DB 16 ACAAGCACTTTGTAA 2

RESULT 68
US-10-060-998-1547/c
; Sequence 1547, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gl, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1547
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1547

Query Match      1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1745 ACTCTGATCTGAAGC 1759
DB 15 ACTCTGATCTGAAGC 1

RESULT 69
US-10-138-674-8189/c

```

```

; Sequence 8189, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHE900-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8189
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-8189

Query Match          1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1897 ACAAGCAGCTTTGTAA 1911
DB 16 ACAAGCAGCTTTGTAA 2

RESULT 70
US-10-287-949A-8189/c
; Sequence 8189, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHE900-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8189
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-8189

Query Match          1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1897 ACAAGCAGCTTTGTAA 1911
DB 16 ACAAGCAGCTTTGTAA 2

RESULT 71
US-10-712-633-1450/c
; Sequence 1450, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan

```

```

; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; FILE REFERENCE: MHE02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1450
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-1450

Query Match          1.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1897 ACAAGCAGCTTTGTAA 1911
DB 16 ACAAGCAGCTTTGTAA 2

RESULT 72
US-10-455-552-74/c
; Sequence 74, Application US/10455552
; Publication No. US2004001853A1
; GENERAL INFORMATION:
; APPLICANT: Adam, Gail Isabel
; APPLICANT: Langdown, Maria
; APPLICANT: Roth, Richard
; APPLICANT: Denissenko, Mikhail
; APPLICANT: Smvlie, Kevin
; TITLE OF INVENTION: DIAGNOSING PREDISPOSITION TO FAT
; TITLE OF INVENTION: DEPOSITION AND THERAPEUTIC METHODS FOR REDUCING FAT
; FILE REFERENCE: 52459-20030.00
; CURRENT APPLICATION NUMBER: US/10/455,552
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: US 60/386,012
; PRIOR FILING DATE: 2002-06-04
; NUMBER OF SEQ ID NOS: 98
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-455-552-74

Query Match          1.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 70;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2374 TGATAACCAACAGCTGGG 2391
DB 18 TTAATAACCAACAGCTGGG 1

```

RESULT 73
US-09-730-289B-1033
; Sequence 1033, Application US/09730289B
; Publication No. US2003050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCE: MBH800-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1033
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-1033

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 82;
Matches 6; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 2052 ATTATTAGATTATGTT 2067

DB 1 AUUAUAGAUUAUU 16

RESULT 74
US-09-730-289B-1122
; Sequence 1122, Application US/09730289B
; Publication No. US2003050259A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for Treatment of Cardiac Disease
; FILE REFERENCE: MBH800-864-A (400/006)
; CURRENT APPLICATION NUMBER: US/09/730,289B
; CURRENT FILING DATE: 2000-12-05
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1122
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-730-289B-1122

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 37.5%; Pred. No. 82;
Matches 6; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 2052 ATTATTAGATTATGTT 2067

DB 2 AUUAUAGAUUAUU 17

RESULT 75
US-10-060-998-1542/c
; Sequence 1542, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: US 60/169,100
; PRIOR FILING DATE: 1999-12-06
; NUMBER OF SEQ ID NOS: 3897
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1542
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-060-998-1542/c

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 1542
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1542

Query Match 1.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1748 CTGATCTGAAGCCAG 1763

DB 17 CTGATCTGAAGCCAG 2

RESULT 76
US-09-969-373-1804
; Sequence 1804, Application US/09969373
; Patent No. US2002013852A1
; GENERAL INFORMATION:
; APPLICANT: Hoffert, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1804
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1804

Query Match 1.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 78;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1597 GCCACCATATCAACAC 1612

DB 3 GCCACCATCTCAACAC 18

RESULT 77
US-10-060-998-1548/c
; Sequence 1548, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Acomica Sequence Listing Engine

; SEQ ID NO 1548
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1548

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1745 ACTCTGATCTGAAG 1758
Db 14 ACTCTGATCTGAAG 1

RESULT 78

US-10-156-306-71
; Sequence 71, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 71
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-71

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 91;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1905 TTGTGTAATTGTAA 1918
Db 4 UUUGUAAAUUGUAA 17

RESULT 79

US-10-156-306-2713
; Sequence 2713, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2713
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2713

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 91;
Matches 7; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1905 TTGTGTAATTGTAA 1918
Db 2 UUUGUAAAUUGUAA 15

RESULT 80

US-10-138-674-2154/c
; Sequence 2154, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2154
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2154

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAAATCAAATG 1883
Db 14 ATGAAAATCAAATG 1

RESULT 81

US-10-138-674-2779/c
; Sequence 2779, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to
; FILE REFERENCE: MH800-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2779
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2779

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAAATCAAATG 1883
Db 14 ATGAAAATCAAATG 1

RESULT 82

US-10-138-674-8190/c
; Sequence 8190, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674
 ; CURRENT FILING DATE: 2002-05-03
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 8190
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-138-674-8190

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 91;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1897 ACAAGCAGCTTTGTA 1910
 DB 14 ACAAGCAGCTTTGTA 1

RESULT 83
 US-10-138-674-9127/c
 ; Sequence 9127, Application US/10138674
 ; Publication No. US2004007565A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/138,674
 ; CURRENT FILING DATE: 2002-05-03
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 9127
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-138-674-9127

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 91;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAAATG 1883
 DB 16 ATGAAATCAAAATG 3

RESULT 84
 US-10-287-949A-2154/c
 ; Sequence 2154, Application US/10287949A
 ; Publication No. US20040102389A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/287,949A
 ; CURRENT FILING DATE: 2003-04-11
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2154

; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-287-949A-2154

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 91;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAAATG 1883
 DB 14 ATGAAATCAAAATG 1

RESULT 85
 US-10-287-949A-2779/c
 ; Sequence 2779, Application US/10287949A
 ; Publication No. US20040102389A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/287,949A
 ; CURRENT FILING DATE: 2003-04-11
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 2779
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Mus musculus
 US-10-287-949A-2779

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 91;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAAATG 1883
 DB 14 ATGAAATCAAAATG 1

RESULT 86
 US-10-287-949A-8190/c
 ; Sequence 8190, Application US/10287949A
 ; Publication No. US20040102389A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00-876-N (400/049)
 ; CURRENT APPLICATION NUMBER: US/10/287,949A
 ; CURRENT FILING DATE: 2003-04-11
 ; NUMBER OF SEQ ID NOS: 20822
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 8190
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-10-287-949A-8190

Query Match 1.5%; Score 14; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 91;
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1897 ACAAGCACTTTGTA 1910
Db 14 ACAAGCACTTTGTA 1

RESULT 87
US-10-287-949A-9127/c
; Sequence 9127, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9127
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9127

Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAATG 1883
Db 16 ATGAAATCAAATG 3

RESULT 88
US-10-712-633-1451/c
; Sequence 1451, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1451
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens

US-10-712-633-1451/c
Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1870 ATGAAATCAAATG 1883
Db 16 ATGAAATCAAATG 3

RESULT 90
US-09-866-108-2781
; Sequence 2781, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

US-10-712-633-1451

```
Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1897 ACAAGCACTTTGTA 1910
Db 14 ACAAGCACTTTGTA 1
```

```
RESULT 89
US-10-712-633-4397/c
; Sequence 4397, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4397
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-10-712-633-4397
```

```
Query Match 1.5%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 91;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1870 ATGAAATCAAATG 1883
Db 16 ATGAAATCAAATG 3
```

```
RESULT 90
US-09-866-108-2781
; Sequence 2781, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

Query Match
Best Local Similarity 1.5%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CTCCTTCAAGCATCACC 1682
DB 1 CACCTTCAAGCATCACC 17

RESULT 91
US-09-877-478-474
; Sequence 474, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2781
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2781

Query Match
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CTCCTTCAAGCATCACC 1682
DB 1 CACCTTCAAGCATCACC 17

RESULT 91
US-09-877-478-474
; Sequence 474, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993

Query Match
Best Local Similarity 1.5%; Score 13.8; DB 1; Length 17;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2081 GAAGGAATTGGCAGAT 2097
DB 1 GAAGGAATTGGCAGAU 17

RESULT 92
US-09-877-478-2127/c
; Sequence 2127, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 474
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-474

Query Match
Best Local Similarity 64.7%; Pred. No. 96;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2081 GAAGGAATTGGCAGAT 2097
DB 1 GAAGGAATTGGCAGAU 17

RESULT 92
US-09-877-478-2127/c
; Sequence 2127, Application US/09877478
; Publication No. US20030068301A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: MBH00-845-H (400/029)
; CURRENT APPLICATION NUMBER: US/09/877,478
; PRIOR FILING DATE: 2001-12-31
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 08/433,993
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 08/434,504
; PRIOR FILING DATE: 1995-05-04
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2127
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-09-877-478-2127

Query Match
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1824 TAATAACATTGGCTAA 1840
DB 17 TAGTAACATTGGCTAA 1

RESULT 93
US-09-848-754A-1182
; Sequence 1182, Application US/09848754A
; Publication No. US20030073207A1

```
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH00-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1182
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-1182

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 96;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 2280 CAGGAAAAAAATTCG 2296
Db 1 CAGGAAACAAAAAUUG 17

RESULT 94
US-09-827-395A-50
; Sequence 50, Application US/09827395A
; Publication No. US20030113891A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor
; FILE REFERENCE: MBH00-878-C (400/017)
; CURRENT APPLICATION NUMBER: US/09/827,395A
; CURRENT FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 50
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-827-395A-50

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 96;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 2428 ATGAGAAATCTACTGTT 2444
Db 1 AUGACACUUAUCUGUU 17

RESULT 95
US-10-060-998-1033/c
; Sequence 1033, Application US/10060998
; Publication No. US20030104530A1
; GENERAL INFORMATION:
; APPLICANT: Gu, Yizhong
; TITLE OF INVENTION: HUMAN SODIUM-HYDROGEN EXCHANGER LIKE PROTEIN 1
; FILE REFERENCE: PB01108
; CURRENT APPLICATION NUMBER: US/10/060,998
; CURRENT FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/343,331
```

```
; PRIOR FILING DATE: 2001-12-21
; NUMBER OF SEQ ID NOS: 3056
; SOFTWARE: Aemica Sequence Listing Engine
; SEQ ID NO 1033
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-060-998-1033

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2274 AGCAAGCAGGAAAAAA 2290
Db 17 AGAAAGCAGGAAAAACA 1

RESULT 96
US-10-156-306-2769/c
; Sequence 2769, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Growth Factor Receptors
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2769
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2769

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1657 CTGAGAAATCTCTTCA 1673
Db 17 CTGAGAAATCTCTTCA 1

RESULT 97
US-10-238-700-951/c
; Sequence 951, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Levels of Growth Factor Receptors
; FILE REFERENCE: 400/057 (MBH01-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 951
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-951

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```

QY 1877 TCAATGATGCAATA 1893
DB 17 TCAATGATGCAATA 1

RESULT 98
US-10-061-201-697/c
; Sequence 697, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 697
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-697

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2042 TGATATGTCCTATTATTA 2058
DB 17 TGATATGTCCTATTATTA 1

RESULT 99
US-10-061-201-698/c
; Sequence 698, Application US/10061201
; Publication No. US20030166229A1
; GENERAL INFORMATION:
; APPLICANT: Shannon, Mark
; TITLE OF INVENTION: HUMAN POSH-LIKE PROTEIN 1
; FILE REFERENCE: PB0178
; CURRENT APPLICATION NUMBER: US/10/061,201
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30

```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/328,205
; PRIOR FILING DATE: 2001-10-10
; NUMBER OF SEQ ID NOS: 4162
; SOFTWARE: Acomica Sequence Listing Engine
; SEQ ID NO 698
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-061-201-698

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2041 ATGATATGTCCTATTATTA 2057
DB 17 ATGATATGTCCTATTATTA 1

RESULT 100
US-10-430-882-50
; Sequence 50, Application US/10430882
; Publication No. US20030203870A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Lawrence Blatt
; APPLICANT: James McSwiggen
; APPLICANT: Bharat Chowrira
; APPLICANT: Peter Haeberli
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor G
; FILE REFERENCE: MBH00-878-H (400/112)
; CURRENT APPLICATION NUMBER: US/10/430,882
; CURRENT FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 09/827,395
; PRIOR FILING DATE: 2001-04-05
; PRIOR APPLICATION NUMBER: 09/780,533
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: PCT/US01/04273
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/181,797
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/10512
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 2617
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 50
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-430-882-50

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 96;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 2428 ATGAGATCTATCTCTT 2444
DB 1 AUGACACUCUACUCUU 17

RESULT 101
US-10-342-902-474
; Sequence 474, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:

```

; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; PRIOR FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 474
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B virus
US-10-342-902-474

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 96;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2081 GAAGGAATTGGCAGAT 2097
DB 1 GAAGUAAUUUGGAAGAU 17

RESULT 102
US-10-342-902-2127/c
; Sequence 2127, Application US/10342902
; Publication No. US20040054156A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Draper, Kenneth
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; APPLICANT: Morrissey, Dave
; TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
; FILE REFERENCE: 400/075 (MBHB00-845-I)
; CURRENT APPLICATION NUMBER: US/10/342,902
; CURRENT FILING DATE: 2003-01-15
; PRIOR APPLICATION NUMBER: US 09/877,478
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 09/531,025
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/636,385
; PRIOR FILING DATE: 2000-08-09
; PRIOR APPLICATION NUMBER: US 09/696,347
; PRIOR FILING DATE: 2000-10-24
; PRIOR APPLICATION NUMBER: US 08/193,627
; PRIOR FILING DATE: 1994-02-07
; PRIOR APPLICATION NUMBER: US 07/882,712
; PRIOR FILING DATE: 1992-05-14
; PRIOR APPLICATION NUMBER: US 09/436,430
; PRIOR FILING DATE: 1999-11-08
; NUMBER OF SEQ ID NOS: 6592
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2127
; LENGTH: 17
; TYPE: RNA

; ORGANISM: Hepatitis B virus
US-10-342-902-2127
Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1824 TAATAACATTGGGCTAA 1840
DB 17 TAGTAACATTGGGATAA 1

RESULT 103

US-10-138-674-2153/c
; Sequence 2153, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2153
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-138-674-2153

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATAATCAATGATGC 1887
DB 17 TGAATAATCAATGCGGC 1

RESULT 104

US-10-138-674-2778/c
; Sequence 2778, Application US/10138674
; Publication No. US20040077565A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Rel
; FILE REFERENCE: MBHB00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/138,674
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-138-674-2778

Query Match 1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATAATCAATGATGC 1887
|||||

Db 17 TGAATAATCAATGTGGC 1

RESULT 105

US-10-138-674-5483/c

; Sequence 5483, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 5483

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-5483

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 96;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1899 AAGCACTTTGTAATG 1915

Db 17 AAGCACTTTGTAAGTAG 1

RESULT 106

US-10-138-674-9343

; Sequence 9343, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 9343

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-9343

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 96;

Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2453 GACTCTCAATATAG 2469

Db 1 GACUUUACAUAGA 17

RESULT 107

US-10-138-674-9377

; Sequence 9377, Application US/10138674

; Publication No. US20040077565A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/138,674

; CURRENT FILING DATE: 2002-05-03

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 9377

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-138-674-9377

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 41.2%; Pred. No. 96;

Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1970 ATATATTTATAGTTGT 1986

Db 1 AUAUAUUUAAGUCUGU 17

RESULT 108

US-10-287-949A-2153/c

; Sequence 2153, Application US/10287949A

; Publication No. US20040102389A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/287,949A

; CURRENT FILING DATE: 2003-04-11

; NUMBER OF SEQ ID NOS: 20822

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 2153

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-287-949A-2153

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 96;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATAATCAATGTGC 1887

Db 17 TGAATAATCAATGTGCGC 1

RESULT 109

US-10-287-949A-2778/c

; Sequence 2778, Application US/10287949A

; Publication No. US20040102389A1

; GENERAL INFORMATION:

; APPLICANT: Ribozyme Pharmaceuticals, Inc.

; APPLICANT: Pavco, Pam

; APPLICANT: McSwiggen, Jim

; APPLICANT: Stinchcomb, Dan

; APPLICANT: Escobedo, Jaime

; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor

; FILE REFERENCE: MBH00-876-N (400/049)

; CURRENT APPLICATION NUMBER: US/10/287,949A

; CURRENT FILING DATE: 2003-04-11

; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2778
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-10-287-949A-2778

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 TGAATCAATGATGC 1887
DB 17 TGAATCAATGATGC 1

RESULT 110

US-10-287-949A-5483/c
; Sequence 5483, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5483
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-5483

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1899 AAGCACTTGTAAATG 1915
DB 17 AAGCACTTGTAACTAG 1

RESULT 111

US-10-287-949A-9343
; Sequence 9343, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9343
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9343

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 58.8%; Pred. No. 96;
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2453 GACTCTTAATATAGA 2469
DB 1 GACUUUUAAUAUAGA 17

RESULT 112

US-10-287-949A-9377
; Sequence 9377, Application US/10287949A
; Publication No. US20040102389A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-N (400/049)
; CURRENT APPLICATION NUMBER: US/10/287,949A
; CURRENT FILING DATE: 2003-04-11
; NUMBER OF SEQ ID NOS: 20822
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9377
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-287-949A-9377

Query Match 1.5%; Score 13.8; DB 1; Length 17;

Best Local Similarity 41.2%; Pred. No. 96;
Matches 7; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY 1970 ATATATTTATAGATTGT 1986
DB 1 AUAUAUUUAUGUCUGU 17

RESULT 113

US-10-669-841-474
; Sequence 474, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26

```

; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 474
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-474

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 96;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 2081 GAAGGAAUUGGAGAU 2097
DB 1 GAAGGAAUUGGAGAU 17

RESULT 114
US-10-669-841-1968/C
; Sequence 1968, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blatt
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggan
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 1968
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Hepatitis B Virus
US-10-669-841-1968

Query Match      1.5%; Score 13.8; DB 1; Length 17;

```

```

Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1824 TAATAACATTTGGGCTAA 1840
DB 17 TAGTAACATTTGGGATAA 1

RESULT 115
US-10-723-361-2781
; Sequence 2781, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANI
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/006666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/006668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 2781
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2781

Query Match      1.5%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 96;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1666 CTCCTTCAAGCATCACC 1682
DB 1 CACCTTCAAGCACCACC 17

RESULT 116
US-10-712-633-4614
; Sequence 4614, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Gilad
; APPLICANT: McSwiggan, James
; APPLICANT: Stinchcomb, Dan

```

Query Match	1.4%	Score 13.2;	DB 1;	Length 50;
Best Local Similarity	61.8%	Pred. No. 38;		


```
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 50497
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014187
US-10-257-017B-50497

Query Match          1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1888 AAAATATATACAA 1900
Db 13 AAAATATATACAA 1

RESULT 125
US-10-257-017B-50498
; Sequence 50498, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 50498
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014187
US-10-257-017B-50498

Query Match          1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1888 AAAATATATACAA 1900
Db 1 AAAATATATACAA 13

RESULT 126
US-10-257-017B-52315/c
; Sequence 52315, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
```

```
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 52315
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014536
US-10-257-017B-52315

Query Match          1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2008 ACAAAATAAATAT 2020
Db 13 ACAAAATAAATAT 1

RESULT 127
US-10-257-017B-52316
; Sequence 52316, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 52316
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0014536
US-10-257-017B-52316

Query Match          1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2008 ACAAAATAAATAT 2020
Db 1 ACAAAATAAATAT 13

RESULT 128
US-10-257-017B-100801
; Sequence 100801, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 100801
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0025074
US-10-257-017B-100801

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1972 ATATTATTAGATT 1984
|||||
Db 1 ATATTATTAGATT 13

RESULT 129

US-10-257-017B-100802/c
; Sequence 100802, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 100802
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0025074
US-10-257-017B-100802

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1972 ATATTATTAGATT 1984
|||||
Db 13 ATATTATTAGATT 1

RESULT 130

US-10-257-017B-132137/c
; Sequence 132137, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 132137
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032979
US-10-257-017B-132137

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1580 CAAATATATAAAAA 1592
|||||
Db 13 CAAATATATAAAAA 1

RESULT 131

US-10-257-017B-132138
; Sequence 132138, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 132138
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0032979
US-10-257-017B-132138

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1580 CAAATATATAAAAA 1592
|||||
Db 1 CAAATATATAAAAA 13

RESULT 132

US-10-257-017B-162297/c
; Sequence 162297, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 162297
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009377
US-10-257-017B-162297

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1770 CCACTACTAATTT 1782
|||||
Db 13 CCACTACTAATTT 1

RESULT 133

US-10-257-017B-162298

```
; Sequence 162298, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 162298
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009377
US-10-257-017B-162298

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1770 CCACTACTAATTT 1782
Db 1 CCACTACTAATTT 13

RESULT 134
US-10-257-017B-179793
; Sequence 179793, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 179793
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0044520
US-10-257-017B-179793

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1585 TATAAAATAGAG 1597
Db 1 TATAAAATAGAG 13

RESULT 135
US-10-257-017B-179794/c
; Sequence 179794, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
```

```
; TITLE OF INVENTION: methylations
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 179794
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0044520
US-10-257-017B-179794

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1585 TATAAAATAGAG 1597
Db 13 TATAAAATAGAG 1

RESULT 136
US-10-257-017B-193759/c
; Sequence 193759, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 193759
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0047657
US-10-257-017B-193759

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1951 TTACAAATCCTA 1963
Db 13 TTACAAATCCTA 1

RESULT 137
US-10-257-017B-193760
; Sequence 193760, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
```

; SEQ ID NO 193760
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0047657
US-10-257-017B-193760

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1951 TTACAAATCCTA 1963
|||||
Db 1 TTACAAATCCTA 13

RESULT 138

US-10-257-017B-202391/c
; Sequence 202391, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 202391
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0008339
US-10-257-017B-202391

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1887 CAAATATATACA 1899
|||||
Db 13 CAAATATATACA 1

RESULT 139

US-10-257-017B-202392
; Sequence 202392, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 202392
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0008339
US-10-257-017B-202392

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1887 CAAATATATACA 1899
|||||
Db 1 CAAATATATACA 13

RESULT 140

US-10-257-017B-215295/c
; Sequence 215295, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 215295
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006400
US-10-257-017B-215295

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1821 CACTAATAACATT 1833
|||||
Db 13 CACTAATAACATT 1

RESULT 141

US-10-257-017B-215296
; Sequence 215296, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 215296
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006400
US-10-257-017B-215296

Query Match 1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1821 CACTAATAACATT 1833
|||||

```
Db      1 CACTAATACATT 13

RESULT 142
US-10-257-017B-247011
; Sequence 247011, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 247011
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0060369
US-10-257-017B-247011

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1974 ATTTATAGATTGT 1986
Db      1 ATTTATAGATTGT 13

RESULT 143
US-10-257-017B-247012/c
; Sequence 247012, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 247012
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0060369
US-10-257-017B-247012

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1974 ATTTATAGATTGT 1986
Db      1 ATTTATAGATTGT 13

RESULT 144
US-10-257-017B-253051
; Sequence 253051, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 253051
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006570
US-10-257-017B-253051

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1908 GTAAATTGTAAAA 1920
Db      1 GTAAATTGTAAAA 13

RESULT 145
US-10-257-017B-253052/c
; Sequence 253052, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 253052
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006570
US-10-257-017B-253052

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1908 GTAAATTGTAAAA 1920
Db      13 GTAAATTGTAAAA 1

RESULT 146
US-10-140-293-6
; Sequence 6, Application US/10140293
; Publication No. US20030022833A1
; GENERAL INFORMATION:
; APPLICANT: CHEN, WEN Y.
; APPLICANT: WAGNER, THOMAS E.
; TITLE OF INVENTION: USE OF ANTI-PROLACTIN AGENTS TO TREAT PORLIFERATIVE
; TITLE OF INVENTION: CONDITIONS
; FILE REFERENCE: 035879/0109
; CURRENT APPLICATION NUMBER: US/10/140,293
```

```
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 253051
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006570
US-10-257-017B-253051

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1908 GTAAATTGTAAAA 1920
Db      1 GTAAATTGTAAAA 13

RESULT 145
US-10-257-017B-253052/c
; Sequence 253052, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 253052
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0006570
US-10-257-017B-253052

Query Match      1.4%; Score 13; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1908 GTAAATTGTAAAA 1920
Db      13 GTAAATTGTAAAA 1

RESULT 146
US-10-140-293-6
; Sequence 6, Application US/10140293
; Publication No. US20030022833A1
; GENERAL INFORMATION:
; APPLICANT: CHEN, WEN Y.
; APPLICANT: WAGNER, THOMAS E.
; TITLE OF INVENTION: USE OF ANTI-PROLACTIN AGENTS TO TREAT PORLIFERATIVE
; TITLE OF INVENTION: CONDITIONS
; FILE REFERENCE: 035879/0109
; CURRENT APPLICATION NUMBER: US/10/140,293
```

/ CURRENT FILING DATE: 2002-05-08
/ PRIOR APPLICATION NUMBER: US/09/246,041
/ PRIOR FILING DATE: 1999-02-05
/ NUMBER OF SEQ ID NOS: 42
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 6
/ LENGTH: 16
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-140-293-6

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1870 ATGAAATCAATGAT 1885
|||||
Db 1 ATGAACATCAAGGAT 16

RESULT 147

US-10-138-674-6037/c
/ Sequence 6037, Application US/10138674
/ Publication No. US20040077565A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ FILE REFERENCE: MBH00-876-N (400/049)
/ CURRENT APPLICATION NUMBER: US/10/138,674
/ CURRENT FILING DATE: 2002-05-03
/ NUMBER OF SEQ ID NOS: 20822
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 6037
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-138-674-6037

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1893 ATATACAGCACTTTG 1908
|||||
Db 16 ATGAACAAGCACTTTG 1

RESULT 148

US-10-138-674-7113
/ Sequence 7113, Application US/10138674
/ Publication No. US20040077565A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ FILE REFERENCE: MBH00-876-N (400/049)
/ CURRENT APPLICATION NUMBER: US/10/138,674
/ CURRENT FILING DATE: 2002-05-03
/ NUMBER OF SEQ ID NOS: 20822
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 7113
/ LENGTH: 16

/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-138-674-7113

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1661 GAAATCTCTTCAAGC 1676
|||||
Db 1 GAAUCUCUUGCAAGC 16

RESULT 149

US-10-287-949A-6037/c
/ Sequence 6037, Application US/10287949A
/ Publication No. US20040102389A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ FILE REFERENCE: MBH00-876-N (400/049)
/ CURRENT APPLICATION NUMBER: US/10/287,949A
/ CURRENT FILING DATE: 2003-04-11
/ NUMBER OF SEQ ID NOS: 20822
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 6037
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-287-949A-6037

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1893 ATATACAGCACTTTG 1908
|||||
Db 16 ATGAACAAGCACTTTG 1

RESULT 150

US-10-287-949A-7113
/ Sequence 7113, Application US/10287949A
/ Publication No. US20040102389A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ FILE REFERENCE: MBH00-876-N (400/049)
/ CURRENT APPLICATION NUMBER: US/10/287,949A
/ CURRENT FILING DATE: 2003-04-11
/ NUMBER OF SEQ ID NOS: 20822
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 7113
/ LENGTH: 16
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-287-949A-7113

Query Match 1.4%; Score 12.8; DB 1; Length 16;
Best Local Similarity 68.8%; Pred. No. 1.3e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 1661 GAAATCTCTTCAAGC 1676

; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 31913
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009939
US-10-257-017B-31913

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1997 ATCATTTAACCCAC 2009
Db 13 RTCATTTAACCCAC 1

RESULT 156
US-10-257-017B-31914
; Sequence 31914, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 31914
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0009939
US-10-257-017B-31914

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1997 ATCATTTAACCCAC 2009
Db 1 RTCATTTAACCCAC 13

RESULT 157
US-10-257-017B-38179/c
; Sequence 38179, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 38179

; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0011829
US-10-257-017B-38179

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1581 AAAATATATAAAAT 1593
Db 13 RAAATATATAAAAT 1

RESULT 158
US-10-257-017B-38180
; Sequence 38180, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 38180
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0011829
US-10-257-017B-38180

Query Match 1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1581 AAAATATATAAAAT 1593
Db 1 RAAATATATAAAAT 13

RESULT 159
US-10-257-017B-59765/c
; Sequence 59765, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 59765
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0015985
US-10-257-017B-59765

```
Query Match      1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1582 AAATATAAAATA 1594
Db 13 RAATATAAAATA 1

RESULT 160
US-10-257-017B-59766
; Sequence 59766, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 59766
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0015985
US-10-257-017B-59766

Query Match      1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1582 AAATATAAAATA 1594
Db 1 RAATATAAAATA 13

RESULT 161
US-10-257-017B-111489
; Sequence 111489, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 111489
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0027841
US-10-257-017B-111489

Query Match      1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2282 GGAAAAAAATTT 2294
Db 1 GGAAAAAAATTT 13
```

```
RESULT 162
US-10-257-017B-111490/c
; Sequence 111490, Application US/10257017B
; Publication No. US20040241651A1
; GENERAL INFORMATION:
; APPLICANT: Alexander Olek
; APPLICANT: Christian Piepenbrock
; APPLICANT: Kurt Berlin
; TITLE OF INVENTION: Detection of single nucleotide polymorphisms [SNPs] and cytosine
; FILE REFERENCE: E01/1193/WO
; CURRENT APPLICATION NUMBER: US/10/257,017B
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: DE 10019173.8
; PRIOR FILING DATE: 2000-04-07
; NUMBER OF SEQ ID NOS: 382046
; SEQ ID NO 111490
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide for detection of SNP TSC0027841
US-10-257-017B-111490
```

```
Query Match      1.4%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.7e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2282 GGAAAAAAATTT 2294
Db 13 GGAAAAAAATTT 1
```

```
Search completed: April 7, 2005, 05:59:34
Job time : 3 secs
```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: April 7, 2005, 06:01:58 ; Search time 1 Seconds
(without alignments)
0.192 Million cell updates/sec

Title: US-10-630-399-3
Perfect score: 922
Sequence: 1 gacagtgggtattaaagcat.....ctggacttctaataatagata 922

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 8 seqs, 104 residues
Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 8
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 9 summaries

Database : rst3.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	13	1.4	16	1 AW250981	ACCESSION:AW250981
2	12	1.3	12	1 CF331951	ACCESSION:CF331951
3	10.4	1.1	12	1 CF302060	ACCESSION:CF302060
4	10.4	1.1	12	1 CF330680	ACCESSION:CF330680
5	10.4	1.1	13	1 CF291168	ACCESSION:CF291168
6	10.4	1.1	13	1 CF299609	ACCESSION:CF299609
7	10.4	1.1	13	1 CF300659	ACCESSION:CF300659
8	10.4	1.1	13	1 AJ599990	ACCESSION:AJ599990
9	10.4	1.1	13	1 AJ599990	ACCESSION:AJ599990

ALIGNMENTS

RESULT 1
AW250981/c 16 bp mRNA linear EST 07-JAN-2000
LOCUS 2822267.3prime NIH_MGC_7 Homo sapiens cDNA clone IMAGE:2822267 3', mRNA sequence.
DEFINITION
ACCESSION AW250981
VERSION AW250981.1 GI:6594070
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 16)
AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished (1999)
COMMENT Other ESTs: 2822267.5prime
Contact: Robert Strausberg, Ph.D.
Email: cgabbs-r@mail.nih.gov

Tissue Procurement: DCTD/DTP cDNA Library Preparation: Ling Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL) DNA Sequencing by: Berkeley MGC sequencing project Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www.bio.llnl.gov/bbrp/image/image.html Base Calling / Quality Scores: PHRED from University of Washington Genome Center. Vector Trimming: cross match from University of Washington Genome Center PHRAP suite. Poly-T Identification: patMatch.pl from Berkeley Drosophila Genome Project. University of Washington Genome Center: <http://www.genome.washington.edu/LowQualitySequence>. Very Low PHRED high quality bases following vector sequence. 9 contiguous Quality Sequence: Trace file contained 16 contiguous distinct peaks following vector sequence. Polyadenylation: Based upon the presence of a XhoI site followed by a run of 14 or more T residues at the beginning of the sequence, this cDNA insert was polyadenylated. Plate: LICM8 row: P column: 12
High quality sequence stop: 9.

FEATURES

Location/Qualifiers
1..16
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:2822267"
/tissue_type="small cell carcinoma"
/cell_line="MGC3"
/lab_host="DH10B (phage-resistant)"
/clone_lib="NIH MGC 7"
/note="Organ: lung; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)."

Query Match 1.4%; Score 13; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 0.63;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2280 CAGGAAAAAAAAA 2292

Db 14 CAGGAAAAAAAAA 2

RESULT 2

CF331951
LOCUS
DEFINITION
CF331951 12 bp mRNA linear EST 18-AUG-2003
NACL--08-E07-g1 Rice callus plasmid cDNA library (NACL) Oryza sativa (japonica cultivar-group) cDNA clone NACL--08-E07, mRNA sequence.

ACCESSION CF331951

VERSION CF331951.1 GI:33812123

KEYWORDS EST.

SOURCE

ORGANISM

Oryza sativa (japonica cultivar-group)
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.

REFERENCE 1 (bases 1 to 12)

AUTHORS

Kim, J.S., Jun, K.M., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nahm, B.H.

TITLE

JOURNAL

COMMENT

Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division of Bioscience and Bioinformatics, Myongji University
Yongin, Gyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnaheggbio.com, bhnaheggbio@myongji.ac.kr.

FEATURES

Location/Qualifiers

```

source
1. .12
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--08-E07"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match
Best Local Similarity 100.0%; Pred. No. 1.6; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 0;

QY 1581 AAAATATAAAAA 1592
Db 1 AAAATATAAAAA 12

RESULT 3
CF302060
LOCUS
DEFINITION
Oryza sativa (japonica cultivar-group) cDNA clone 7LEAF--07-E01, mRNA
sequence.
CF302060
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 12)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.
Location/Qualifiers
1. .12
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--06-H22"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match
Best Local Similarity 91.7%; Pred. No. 4.4;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2268 GTTGTGACGCAAG 2279
Db 1 GTTGACGCAAG 12

FEATURES
source
1. .12
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="NACL--06-H22"
/tissue_type="callus"
/dev_stage="proliferated callus on 2N6 media for 30 days"
/lab_host="E.coli DH10B"
/clone_lib="Rice callus plasmid cDNA library (NACL)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match
Best Local Similarity 1.1%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2268 GTTGTGACGCAAG 2279
Db 1 GTTGACGCAAG 12

RESULT 5
CF291168
LOCUS
DEFINITION
Oryza sativa (japonica cultivar-group) cDNA clone 14ROOT--01-H20, mRNA
sequence.
CF291168
VERSION
KEYWORDS
SOURCE
ORGANISM
Oryza sativa (japonica cultivar-group)
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Ehrhartoideae; Oryzaceae; Oryza.
1 (bases 1 to 13)
Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,
Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.
Large-scale Sequencing Analysis of Rice ESTs
Unpublished (2003)
Contact: Nahm B.H.
Genomics and Genetics Institute, GreenGene Biotech Inc.; Division
of Bioscience and Bioinformatics, Myongji University
Yongin, Kyeonggi, Korea
Tel: 82 31 330 6193
Fax: 82 31 321 6355
Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.
Location/Qualifiers
1. .12
/organism="Oryza sativa (japonica cultivar-group)"
/mol_type="mRNA"
/cultivar="Nackdong"
/db_xref="taxon:39947"
/clone="7LEAF--07-E01"
/tissue_type="leaf"
/dev_stage="7 days after germination"
/lab_host="E.coli DH10B"
/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"
/note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped
with oligoribonucleotides and then used as templates for
RT-PCR."

Query Match
Best Local Similarity 91.7%; Pred. No. 4.4;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2268 GTTGTGACGCAAG 2279
Db 1 GTTGACGCAAG 12

```

Tel: 82 31 330 6193
 Fax: 82 31 321 6355
 Email: bhnam@bio.com, bhnam@bio.myongji.ac.kr.

FEATURES

source

1. .13
 /organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:39947"

/clone="14ROOT--01-H20"

/tissue_type="root"

/dev_stage="14 days after germination"

/lab_host="E.coli DH10B"

/clone_lib="Rice root plasmid cDNA library (14ROOT)"

/notes="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 1.1%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 4.1;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 AAAATATAAAAA 1592

Db 2 AAAATATAAAAA 13

RESULT 6

CF299609

LOCUS

DEFINITION CF299609 13 bp mRNA linear EST 15-AUG-2003
 7LEAF--03-L04.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
 sativa (japonica cultivar-group) cDNA clone 7LEAF--03-L04, mRNA
 sequence.

ACCESSION

VERSION CF299609.1 GI:33671370

KEYWORDS

EST.

SOURCE

Oryza sativa (japonica cultivar-group)

Oryza sativa (japonica cultivar-group)

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Ehrhartoideae; Oryzaceae; Oryza.

1 (bases 1 to 13)

Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,

Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division

of Bioscience and Bioinformatics, Myongji University

Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnam@bio.com, bhnam@bio.myongji.ac.kr.

FEATURES

source

1. .13
 /organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:39947"

/clone="7LEAF--03-L04"

/tissue_type="leaf"

/dev_stage="7 days after germination"

/lab_host="E.coli DH10B"

/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"

/notes="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 1.1%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 4.1;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 AAAATATAAAAA 1592

Db 1 AAAATATAAAAA 12

RESULT 7

CF300659

LOCUS

DEFINITION CF300659 13 bp mRNA linear EST 15-AUG-2003
 7LEAF--05-D14.g1 Rice leaf plasmid cDNA library II (7LEAF) Oryza
 sativa (japonica cultivar-group) cDNA clone 7LEAF--05-D14, mRNA
 sequence.

ACCESSION

VERSION CF300659.1 GI:33672420

KEYWORDS

EST.

SOURCE

Oryza sativa (japonica cultivar-group)

Oryza sativa (japonica cultivar-group)

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;

Ehrhartoideae; Oryzaceae; Oryza.

1 (bases 1 to 13)

Kim,J.S., Jun,K.M., Cheong,P.J., Kim,M.J., Lee,T.H., Shin,Y.C.,

Song,S.I., Kim,J.K., Kim,Y.-K. and Nahm,B.H.

Large-scale Sequencing Analysis of Rice ESTs

Unpublished (2003)

Contact: Nahm B.H.

Genomics and Genetics Institute, GreenGene Biotech Inc.; Division

of Bioscience and Bioinformatics, Myongji University

Yongin, Kyeonggi, Korea

Tel: 82 31 330 6193

Fax: 82 31 321 6355

Email: bhnam@bio.com, bhnam@bio.myongji.ac.kr.

FEATURES

source

1. .13
 /organism="Oryza sativa (japonica cultivar-group)"

/mol_type="mRNA"

/cultivar="Nackdong"

/db_xref="taxon:39947"

/clone="7LEAF--05-D14"

/tissue_type="leaf"

/dev_stage="7 days after germination"

/lab_host="E.coli DH10B"

/clone_lib="Rice leaf plasmid cDNA library II (7LEAF)"

/notes="Vector: PCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 1.1%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 4.1;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1581 AAAATATAAAAA 1592

Db 2 AAAATATAAAAA 13

RESULT 8

AJ599990

LOCUS

DEFINITION AJ599990 13 bp DNA linear GSS 15-JAN-2004
 Arabidopsis thaliana T-DNA flanking sequence, left border, clone
 497H02 genomic survey sequence.

ACCESSION

VERSION AJ599990.1 GI:37949618

KEYWORDS

GSS; left border; T-DNA flanking sequence.

Arabidopsis thaliana (thale cress)

Arabidopsis thaliana

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi

1

Brunaud,V., Balzerque,S., Dubreucq,B., Aubourg,S., Samson,F.,

Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G.,

Lepiniec,L., Caboche,M. and Lecharny,A.

T-DNA integration into the Arabidopsis genome depends on sequences

of pre-insertion sites

JOURNAL
 MEDLINE 22363535
 PUBMED 12446565
 REFERENCE 2 (bases 1 to 13)
 AUTHORS Balzergue,S.
 TITLE Direct Submission
 JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE

COMMENT
 PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
 source 1..13
 Location/Qualifiers
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Wassillewskija"
 /db_xref="taxon:3702"
 /clone="497H02"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 misc_feature 1..13
 /note="T-DNA flanking sequence
 left border"

Query Match 1.1%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 4.1;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2051 CATTATTAGATT 2062
 |||||
 Db 1 CATTTTTAGATT 12

RESULT 9
 AJ599990/c
 LOCUS
 DEFINITION Arabidopsis thaliana T-DNA flanking sequence, left border, clone 497H02, genomic survey sequence.
 ACCESSION AJ599990
 VERSION AJ599990.1 GI:37949618
 KEYWORDS GSS; left border; T-DNA flanking sequence.
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE
 AUTHORS 1
 Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F., Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pelletier,G., Lepiniec,L., Caboche,M. and Lecharny,A.
 TITLE T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites
 JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)
 MEDLINE 22363535
 PUBMED 12446565
 REFERENCE 2 (bases 1 to 13)
 AUTHORS Balzergue,S.
 TITLE Direct Submission
 JOURNAL Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 91057 Evry cedex, FRANCE

COMMENT
 PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a

graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
 source 1..13
 Location/Qualifiers
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /cultivar="Wassillewskija"
 /db_xref="taxon:3702"
 /clone="497H02"
 /clone_lib="Arabidopsis thaliana T-DNA insertion lines"
 misc_feature 1..13
 /note="T-DNA flanking sequence
 left border"

Query Match 1.1%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 4.1;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1582 AAATATATAAAT 1593
 |||||
 Db 13 AAATCTAAAAAT 2

Search completed: April 7, 2005, 06:01:59
 Job time : 1 secs